
    
<!DOCTYPE html>




<html lang="en" >
<head >
    <meta charset="UTF-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">

    <!-- Mobile properties -->
    <meta name="HandheldFriendly" content="True">
    <meta name="MobileOptimized" content="320">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">

  
    <!-- Stylesheets -->
    <link rel="stylesheet" href="/pmc/static/CACHE/css/output.cc84172e9e16.css" type="text/css">
  
  <link rel="stylesheet" href="/pmc/static/CACHE/css/output.b634933a977d.css" type="text/css"><link rel="stylesheet" href="/pmc/static/CACHE/css/output.913c7dcab8ff.css" type="text/css"><link rel="stylesheet" href="/pmc/static/CACHE/css/output.3766d7ad0d2d.css" type="text/css"><link rel="stylesheet" href="/pmc/static/CACHE/css/output.e3c3c2c84eb3.css" type="text/css">

  
    <link rel="stylesheet" href="https://maxcdn.bootstrapcdn.com/font-awesome/4.7.0/css/font-awesome.min.css"/>
  
<link type="text/css" href="/pmc/static/bundles/base/base.a2ef7ca69e4b20dff539.css" rel="stylesheet" />


    <link rel="stylesheet" href="/corehtml/pmc/css/fonts/stix/stixfonts.css" type="text/css" /><link rel="stylesheet" href="/corehtml/pmc/css/3.18/pmcrefs1.min.css" type="text/css" /><link rel="stylesheet" href="/corehtml/pmc/css/pmc2020_1.1/ncbi_web.min.css?_=a" type="text/css" /><style type="text/css">.pmc-wm {background:transparent repeat-y top left;background-image:url(/corehtml/pmc/pmcgifs/wm-journal.gif);background-size: auto, contain}</style><style type="text/css">.print-view{display:block}</style>

    <link type="text/css" href="/pmc/static/bundles/article/article.3c5d12ff2e4beea20136.css" rel="stylesheet" />
    <link type="text/css" href="/pmc/static/django_pmc_cite_box/lib/cite-box.css" rel="stylesheet" />


    <title>Empagliflozin Induced Ketosis, Upregulated IGF-1/Insulin Receptors and the Canonical Insulin Signaling Pathway in Neurons, and Decreased the Excitatory Neurotransmitter Glutamate in the Brain of Non-Diabetics - PMC</title>

  
  <!-- Favicons -->
  <link rel="shortcut icon" type="image/ico" href="https://www.ncbi.nlm.nih.gov/coreutils/nwds/img/favicons/favicon.ico" />
  <link rel="icon" type="image/png" href="https://www.ncbi.nlm.nih.gov/coreutils/nwds/img/favicons/favicon.png" />

  <!-- 192x192, as recommended for Android
  http://updates.html5rocks.com/2014/11/Support-for-theme-color-in-Chrome-39-for-Android
  -->
  <link rel="icon" type="image/png" sizes="192x192" href="https://www.ncbi.nlm.nih.gov/coreutils/nwds/img/favicons/favicon-192.png" />

  <!-- 57x57 (precomposed) for iPhone 3GS, pre-2011 iPod Touch and older Android devices -->
  <link rel="apple-touch-icon-precomposed" href="https://www.ncbi.nlm.nih.gov/coreutils/nwds/img/favicons/favicon-57.png">
  <!-- 72x72 (precomposed) for 1st generation iPad, iPad 2 and iPad mini -->
  <link rel="apple-touch-icon-precomposed" sizes="72x72" href="https://www.ncbi.nlm.nih.gov/coreutils/nwds/img/favicons/favicon-72.png">
  <!-- 114x114 (precomposed) for iPhone 4, 4S, 5 and post-2011 iPod Touch -->
  <link rel="apple-touch-icon-precomposed" sizes="114x114" href="https://www.ncbi.nlm.nih.gov/coreutils/nwds/img/favicons/favicon-114.png">
  <!-- 144x144 (precomposed) for iPad 3rd and 4th generation -->
  <link rel="apple-touch-icon-precomposed" sizes="144x144" href="https://www.ncbi.nlm.nih.gov/coreutils/nwds/img/favicons/favicon-144.png">



    
        <!-- Logging params: Pinger defaults -->

<meta name="ncbi_app" content="pmc-frontend" />

<meta name="ncbi_db" content="pmc" />

<meta name="ncbi_phid" content="D0BD41E4AC192A4500004A8785524579.1.m_2" />


        <!-- Logging params: Pinger custom -->

<meta name="ncbi_pdid" content="article" />

<meta name="ncbi_op" content="retrieved" />

<meta name="ncbi_app_version" content="0.0" />

<meta name="ncbi_domain" content="cells" />

<meta name="ncbi_type" content="fulltext" />

<meta name="ncbi_pcid" content="/articles/PMC9657243/" />


    


    <script>
        
            var ncbiBaseUrl = "https://www.ncbi.nlm.nih.gov";
        
        var useOfficialGovtHeader = true;
    </script>


    <meta name="robots" content="INDEX,NOFOLLOW,NOARCHIVE" /><link rel="canonical" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9657243/" /><link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /><meta name="citation_journal_title" content="Cells" /><meta name="citation_title" content="Empagliflozin Induced Ketosis, Upregulated IGF-1/Insulin Receptors and the Canonical Insulin Signaling Pathway in Neurons, and Decreased the Excitatory Neurotransmitter Glutamate in the Brain of Non-Diabetics" /><meta name="citation_author" content="Konstantinos I. Avgerinos" /><meta name="citation_author" content="Roger J. Mullins" /><meta name="citation_author" content="Michael Vreones" /><meta name="citation_author" content="Maja Mustapic" /><meta name="citation_author" content="Qinghua Chen" /><meta name="citation_author" content="Denise Melvin" /><meta name="citation_author" content="Dimitrios Kapogiannis" /><meta name="citation_author" content="Josephine M. Egan" /><meta name="citation_publication_date" content="2022/11" /><meta name="citation_issue" content="21" /><meta name="citation_volume" content="11" /><meta name="citation_doi" content="10.3390/cells11213372" /><meta name="citation_abstract_html_url" content="/pmc/articles/PMC9657243/?report=abstract" /><meta name="citation_fulltext_html_url" content="/pmc/articles/PMC9657243/" /><meta name="citation_pmid" content="36359767" /><meta name="DC.Title" content="Empagliflozin Induced Ketosis, Upregulated IGF-1/Insulin Receptors and the Canonical Insulin Signaling Pathway in Neurons, and Decreased the Excitatory Neurotransmitter Glutamate in the Brain of Non-Diabetics" /><meta name="DC.Type" content="Text" /><meta name="DC.Publisher" content="Multidisciplinary Digital Publishing Institute  (MDPI)" /><meta name="DC.Contributor" content="Konstantinos I. Avgerinos" /><meta name="DC.Contributor" content="Roger J. Mullins" /><meta name="DC.Contributor" content="Michael Vreones" /><meta name="DC.Contributor" content="Maja Mustapic" /><meta name="DC.Contributor" content="Qinghua Chen" /><meta name="DC.Contributor" content="Denise Melvin" /><meta name="DC.Contributor" content="Dimitrios Kapogiannis" /><meta name="DC.Contributor" content="Josephine M. Egan" /><meta name="DC.Date" content="2022 Nov" /><meta name="DC.Identifier" content="10.3390/cells11213372" /><meta name="DC.Language" content="en" /><meta property="og:title" content="Empagliflozin Induced Ketosis, Upregulated IGF-1/Insulin Receptors and the Canonical Insulin Signaling Pathway in Neurons, and Decreased the Excitatory Neurotransmitter Glutamate in the Brain of Non-Diabetics" /><meta property="og:type" content="article" /><meta property="og:description" content="Sodium-glucose cotransporter-2 inhibitors (SGLT2is), such as empagliflozin, lower blood glucose in type 2 diabetes mellitus and improve cardiorenal outcomes regardless of diabetes presence. Whether SGLT2is exert any effects on the brain&#x02019;s metabolism ..." /><meta property="og:url" content="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9657243/" /><meta property="og:site_name" content="PubMed Central (PMC)" /><meta property="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/pmc-card-share.jpg?_=0" /><meta name="twitter:card" content="summary_large_image" /><meta name="twitter:site" content="@ncbi" /><meta name="ncbi_feature" content="associated_data" />


</head>
<body >

   
    
        <button
          class="back-to-top back-to-top--bottom"
          data-ga-category="pagination"
          data-ga-action="back_to_top">
          Back to Top
        </button>
    

    <a class="usa-skipnav" href="#main-content">Skip to main content</a>
    <!-- ========== BEGIN HEADER ========== -->
<section class="usa-banner" style="display: none;">
  <div class="usa-accordion">
    <header class="usa-banner-header">
      <div class="usa-grid usa-banner-inner">
        <img src="https://www.ncbi.nlm.nih.gov/coreutils/uswds/img/favicons/favicon-57.png" alt="U.S. flag" />
        <p>An official website of the United States government</p>
        <button
          class="usa-accordion-button usa-banner-button"
          aria-expanded="false"
          aria-controls="gov-banner-top"
        >
          <span class="usa-banner-button-text">Here's how you know</span>
        </button>
      </div>
    </header>
    <div
      class="usa-banner-content usa-grid usa-accordion-content"
      id="gov-banner-top"
    >
      <div class="usa-banner-guidance-gov usa-width-one-half">
        <img
          class="usa-banner-icon usa-media_block-img"
          src="https://www.ncbi.nlm.nih.gov/coreutils/uswds/img/icon-dot-gov.svg"
          alt="Dot gov"
        />
        <div class="usa-media_block-body">
          <p>
            <strong>The .gov means it’s official.</strong>
            <br />
            Federal government websites often end in .gov or .mil. Before
            sharing sensitive information, make sure you’re on a federal
            government site.
          </p>
        </div>
      </div>
      <div class="usa-banner-guidance-ssl usa-width-one-half">
        <img
          class="usa-banner-icon usa-media_block-img"
          src="https://www.ncbi.nlm.nih.gov/coreutils/uswds/img/icon-https.svg"
          alt="Https"
        />
        <div class="usa-media_block-body">
          <p>
            <strong>The site is secure.</strong>
            <br />
            The <strong>https://</strong> ensures that you are connecting to the
            official website and that any information you provide is encrypted
            and transmitted securely.
          </p>
        </div>
      </div>
    </div>
  </div>
</section>
<div class="usa-overlay"></div>
<header class="ncbi-header" role="banner" data-section="Header">

	<div class="usa-grid">
		<div class="usa-width-one-whole">

            <div class="ncbi-header__logo">
                <a href="https://www.ncbi.nlm.nih.gov/" class="logo" aria-label="NCBI Logo" data-ga-action="click_image" data-ga-label="NIH NLM Logo">
                  <img src="https://www.ncbi.nlm.nih.gov/coreutils/nwds/img/logos/AgencyLogo.svg" alt="NIH NLM Logo" />
                </a>
            </div>

			<div class="ncbi-header__account">
				<a id="account_login" href="https://account.ncbi.nlm.nih.gov" class="usa-button header-button" style="display:none" data-ga-action="open_menu" data-ga-label="account_menu">Log in</a>
				<button id="account_info" class="header-button" style="display:none"
						aria-controls="account_popup">
					<span class="fa fa-user" aria-hidden="true"></span>
					<span class="username desktop-only" aria-hidden="true" id="uname_short"></span>
					<span class="sr-only">Show account info</span>
				</button>
			</div>

			<div class="ncbi-popup-anchor">
				<div class="ncbi-popup account-popup" id="account_popup" aria-hidden="true">
					<div class="ncbi-popup-head">
						<button class="ncbi-close-button" data-ga-action="close_menu" data-ga-label="account_menu"><span class="fa fa-times"></span><span class="usa-sr-only">Close</span></button>
						<h4>Account</h4>
					</div>
					<div class="account-user-info">
						Logged in as:<br/>
						<b><span class="username" id="uname_long">username</span></b>
					</div>
					<div class="account-links">
						<ul class="usa-unstyled-list">
							<li><a id="account_myncbi" href="/myncbi/" class="set-base-url" data-ga-action="click_menu_item" data-ga-label="account_myncbi">Dashboard</a></li>
							<li><a id="account_pubs" href="/myncbi/collections/bibliography/" class="set-base-url" data-ga-action="click_menu_item" data-ga-label="account_pubs">Publications</a></li>
							<li><a id="account_settings" href="/account/settings/" class="set-base-url" data-ga-action="click_menu_item" data-ga-label="account_settings">Account settings</a></li>
							<li><a id="account_logout" href="/account/signout/" class="set-base-url" data-ga-action="click_menu_item" data-ga-label="account_logout">Log out</a></li>
						</ul>
					</div>
				</div>
			</div>

		</div>
	</div>
</header>
<div role="navigation" aria-label="access keys">
<a id="nws_header_accesskey_0" href="https://www.ncbi.nlm.nih.gov/guide/browsers/#ncbi_accesskeys" class="usa-sr-only" accesskey="0" tabindex="-1">Access keys</a>
<a id="nws_header_accesskey_1" href="https://www.ncbi.nlm.nih.gov" class="usa-sr-only" accesskey="1" tabindex="-1">NCBI Homepage</a>
<a id="nws_header_accesskey_2" href="/myncbi/" class="set-base-url usa-sr-only" accesskey="2" tabindex="-1">MyNCBI Homepage</a>
<a id="nws_header_accesskey_3" href="#maincontent" class="usa-sr-only" accesskey="3" tabindex="-1">Main Content</a>
<a id="nws_header_accesskey_4" href="#" class="usa-sr-only" accesskey="4" tabindex="-1">Main Navigation</a>
</div>
<section data-section="Alerts">
	<div class="ncbi-alerts-placeholder"></div>
</section>
<!-- ========== END HEADER ========== -->

    
    


    
        

<section class="pmc-alerts">
    
    <div role="alert" class="pmc-alert pmc-alert--info" role="region" aria-label="Alert" aria-hidden="false"  data-key="pmc-alert-welcome">
        <div class="pmc-alert__body pmc-alert--ncbi-icon">
            <div class="pmc-alert__content">
                <p>
                    <strong>
                        Preview improvements coming to the PMC website in October 2024.
                        <a href="https://ncbiinsights.ncbi.nlm.nih.gov/2024/03/14/preview-pmc-improvements/" data-ga-category="cloud_beta_banner" data-ga-label="learn_more" data-ga-action="on_pmc2020">Learn More</a> or
                        <a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC9657243/" data-ga-category="cloud_beta_banner" data-ga-action="on_pmc2020" data-ga-label="go_to_cloud">Try it out now</a>.
                    </strong>
                </p>
            </div>
        </div>
    </div>
    
</section>
    

    
    
        
        <header class="pmc-header usa-header-extended" role="banner">
    <div class="pmc-header__bar">
        <div class="pmc-header__control usa-accordion">
            
                <button class="usa-menu-btn pmc-header--button pmc-header--left">
                    <i class="fa fa-ellipsis-v" aria-hidden="true"></i>
                </button>
            

            <div class="usa-logo pmc-header__logo pmc-header--stretch
                
               " id="extended-mega-logo">
                <div class="usa-logo-text">
                    <a href="/pmc/" title="Home" aria-label="Home" ></a>
                </div>
            </div>
            <button class="usa-accordion-button pmc-header--right pmc-header--button pmc-header__search--control pmc-header--right" aria-expanded="false" aria-controls="a1">
                <i class="fa fa-search" aria-hidden="true"></i>
                <i class="fa fa-times" aria-hidden="true"></i>
            </button>
        </div>
        <div class="pmc-header__search usa-accordion-content" id="a1">
            <div role="search"  class="pmc-header--stretch"  >
    <form class="usa-search " autocomplete="off">
        <div>
              <label class="usa-sr-only" for="pmc-search">Search PMC Full-Text Archive</label>
              <span class="clearable">
                <input
                  required="required"
                  autocomplete-url="/pmc/autocomplete/pmc/"
                  placeholder="Search PMC Full-Text Archive"
                  id="pmc-search" type="search" name="term"/>
                  <i class="clear-btn" ></i>
              </span>
              <button type="submit" formaction="/pmc/">
                <span class="usa-search-submit-text">Search in PMC</span>
              </button>
        </div>
    </form>
</div>


            <ul class="usa-unstyled-list usa-nav-secondary-links pmc-header--offset-two">
                    <li>
                        <a href="https://www.ncbi.nlm.nih.gov/pmc/advanced" data-ga-action="featured_link" data-ga-label="advanced_search">
                            Advanced Search
                        </a>
                    </li>
                    <li>
                        <a  href="/pmc/about/userguide/" data-ga-action="featured_link"
                        data-ga-label="user guide">
                            User Guide
                        </a>
                    </li>
            </ul>
        </div>
    </div>
     <nav role="navigation" class="usa-nav ">
        <button class="usa-nav-close">
            <i class="fa fa-times" aria-hidden="true"></i>
        </button>
        <div class="usa-breadcrumb usa-breadcrumb--wrap usa-breadcrumb--hack">
             
    <ul class="usa-breadcrumb__list">
            
                <li class="usa-breadcrumb__list-item"
                    >
                    <a href="/pmc/journals/" class="navlink">Journal List</a>
                </li>
            
                <li class="usa-breadcrumb__list-item"
                    >
                    <a href="/pmc/?term=%22Cells%22[journal]" class="navlink">Cells</a>
                </li>
            
                <li class="usa-breadcrumb__list-item"
                     aria-current="page" >
                    PMC9657243
                </li>
            
    </ul>
 

        </div>
        
        
            <div class="pmc-sidebar pmc-sidebar-hack">
                

<div class="scroller">

    
        <section>
                <h6>Other Formats</h6>
                <ul class="pmc-sidebar__formats">
                  <li class="pdf-link other_item"><a href="/pmc/articles/PMC9657243/pdf/cells-11-03372.pdf" class="int-view">PDF (3.2M)</a></li>
                </ul>
        </section>
    
    <section>
        <h6>Actions</h6>
        <ul class="pmc-sidebar__actions">
            <li>
                <button role="button" class="citation-button citation-dialog-trigger ctxp"
                        aria-label="Open dialog with citation text in different styles" data-ga-category="save_share" data-ga-action="cite" data-ga-label="open"
                        data-all-citations-url="/pmc/resources/citations/9657243/"
                        data-citation-style="nlm"
                        data-download-format-link="/pmc/resources/citations/9657243/export/"
                >
                    <span class="button-label">Cite</span>
                </button>
            </li>
            <li>
                
                    

<link type="text/css" href="ncbi-overlay-block/src/overlay-block.css">
<div class="collections-button-container" data-article-id="9657243" data-article-db="pmc">
  <button class="collections-button collections-dialog-trigger"
          aria-label="Save article in MyNCBI collections."
          data-ga-category="collections_button"
          data-ga-action="click"
          data-ga-label="collections_button"
          data-collections-open-dialog-enabled="false"
          data-collections-open-dialog-url="https://www.ncbi.nlm.nih.gov/account?back_url=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC9657243%2F%23open-collections-dialog"
          data-in-collections="false">
      <span class="button-label">Collections</span>
  </button>
  <div class="overlay" role="dialog">
  <div id="collections-action-dialog"
       class="dialog collections-dialog"
       aria-hidden="true">
    <div class="title">Add to Collections</div>
    <div class="collections-action-panel action-panel">
      


<form id="collections-action-dialog-form"
      class="collections-action-panel-form action-panel-content action-form action-panel-smaller-selectors"
      data-existing-collections-url="/pmc/list-existing-collections/"
      data-add-to-existing-collection-url="/pmc/add-to-existing-collection/"
      data-create-and-add-to-new-collection-url="/pmc/create-and-add-to-new-collection/"
      data-myncbi-max-collection-name-length="100"
      data-collections-root-url="https://www.ncbi.nlm.nih.gov/myncbi/collections/">

  <input type="hidden" name="csrfmiddlewaretoken" value="mWzWnwbOACVdPxPnDywVlQqoLqyYan1R3aEWXQkb8n1TRqtpTJdjovMgOXLgSRHA">

  

  <div class="choice-group" role="radiogroup">
    <ul class="radio-group-items">
      <li>
        <input type="radio"
               id="collections-action-dialog-new-header "
               class="collections-new"
               name="collections"
               value="new"
               data-ga-category="collections_button"
               data-ga-action="click"
               data-ga-label="collections_radio_new">
        <label for="collections-action-dialog-new-header ">Create a new collection</label>
      </li>
      <li>
        <input type="radio"
               id="collections-action-dialog-existing-header "
               class="collections-existing"
               name="collections"
               value="existing"
               checked="true"
               data-ga-category="collections_button"
               data-ga-action="click"
               data-ga-label="collections_radio_existing">
        <label for="collections-action-dialog-existing-header ">Add to an existing collection</label>
      </li>
    </ul>
  </div>

  <div class="controls-wrapper">
    <div class="action-panel-control-wrap new-collections-controls">
      <label for="collections-action-dialog-add-to-new" class="action-panel-label required-field-asterisk">
        Name your collection:
      </label>
      <input
        type="text"
        name="add-to-new-collection"
        id="collections-action-dialog-add-to-new"
        class="collections-action-add-to-new"
        pattern="[^&quot;&amp;=&lt;&gt;/]*" title="The following characters are not allowed in the Name field: &quot;&amp;=&lt;&gt;/"
        maxlength=""
        data-ga-category="collections_button"
        data-ga-action="create_collection"
        data-ga-label="non_favorties_collection">
      <div class="collections-new-name-too-long usa-input-error-message selection-validation-message">
        Name must be less than  characters
      </div>
    </div>
    <div class="action-panel-control-wrap existing-collections-controls">
      <label for="collections-action-dialog-add-to-existing" class="action-panel-label">
        Choose a collection:
      </label>
      <select id="collections-action-dialog-add-to-existing"
              class="action-panel-selector collections-action-add-to-existing"
              data-ga-category="collections_button"
              data-ga-action="select_collection"
              data-ga-label="($('.collections-action-add-to-existing').val() === 'Favorites') ? 'Favorites' : 'non_favorites_collection'">
      </select>
      <div class="collections-retry-load-on-error usa-input-error-message selection-validation-message">
        Unable to load your collection due to an error<br>
        <a href="#">Please try again</a>
      </div>
    </div>
  </div>

  <div class="action-panel-actions">
    <button class="action-panel-submit"
            type="submit"
            data-loading-label="Adding..."
            data-pinger-ignore
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="add">
      Add
    </button>
    <button class="action-panel-cancel"
            aria-label="Close 'Add to Collections' panel"
            ref="linksrc=close_collections_panel"
            aria-controls="collections-action-panel"
            aria-expanded="false"
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="cancel">
      Cancel
    </button>
  </div>
</form>
    </div>
  </div>
</div>
</div>
                
            </li>

        </ul>
    </section>
    
        <section class="social-sharing">
            <h6>Share</h6>
            <ul class="pmc-sidebar__share">
                <li><a class="fa-stack fa-lg" target="_blank" rel="noopener noreferrer" role="button" href="https://twitter.com/intent/tweet?url=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC9657243%2F&amp;text=Empagliflozin%20Induced%20Ketosis%2C%20Upregulated%20IGF-1%2FInsulin%20Receptors%20and%20the%20Canonical%20Insulin%20Signaling%20Pathway%20in%20..." alt="Share on Twitter"><i class="fa fa-twitter fa-stack-1x">&#160;</i></a></li> 
<li><a class="fa-stack fa-lg" target="_blank" rel="noopener noreferrer" role="button" href="https://www.facebook.com/sharer/sharer.php?u=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC9657243%2F" alt="Share on Facebook"><i class="fa fa-facebook fa-stack-1x">&#160;</i></a></li>
                <li>
                    <div class="share-permalink">
                        <button class="trigger"  alt="Show article permalink" aria-expanded="false" aria-haspopup="true">
                            <i class="fa-stack fa-lg" >
                                <i class="fa fa-link fa-stack-1x">&nbsp;</i>
                            </i>
                        </button>
                        <div class="dropdown dropdown-container" hidden>
                              <div class="title">
                                Permalink
                              </div>
                              <div class="content">
                                  <input type="text" class="permalink-text" value="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9657243/" aria-label="Article permalink"><button class="permalink-copy-button usa-button-primary" title="Copy article permalink" data-ga-category="save_share" data-ga-action="link" data-ga-label="copy_link">
                                      <span class="button-title">Copy</span>
                                  </button>
                              </div>
                        </div>
                    </div>
                </li>
            </ul>
        </section>
    
    <section>
        <h6>RESOURCES</h6>
        <ul class="pmc-sidebar__resources">
        
            <li>
                <div class="usa-accordion">
                    <button
                            data-ga-category="resources_accordion"
                            data-ga-action="open_similar_articles"
                            data-ga-label="/pmc/articles/PMC9657243/"
                            class="usa-accordion-button"
                            aria-controls="similar-articles-accordion-header"
                            aria-expanded="false"
                            data-action-open="open_similar_articles"
                            data-action-close="close_similar_articles"
                    >
                        Similar articles
                    </button>
                    <div
                            
                                data-source-url="/pmc/resources/similar-article-links/36359767/"
                            

                         class="usa-accordion-content pmc-sidebar__resources--citations" id="similar-articles-accordion-header" aria-hidden="true">
                        
                    </div>
                </div>
            </li>
            <li>
                <div class="usa-accordion">
                    <button
                            data-ga-category="resources_accordion"
                            data-ga-action="open_cited_by"
                            data-ga-label="/pmc/articles/PMC9657243/"
                            class="usa-accordion-button"
                            aria-controls="cited-by-accordion-header"
                            aria-expanded="false"
                            data-action-open="open_cited_by"
                            data-action-close="close_cited_by"
                    >
                        Cited by other articles
                    </button>
                    <div
                            
                                data-source-url="/pmc/resources/cited-by-links/36359767/"
                            
                            class="usa-accordion-content pmc-sidebar__resources--citations"
                            id="cited-by-accordion-header"
                            aria-hidden="true"
                    >
                        
                    </div>
                </div>
            </li>
            <li>
                <div class="usa-accordion">
                    <button
                            data-ga-category="resources_accordion"
                            data-ga-action="open_NCBI_links"
                            data-ga-label="/pmc/articles/PMC9657243/"
                            class="usa-accordion-button"
                            aria-controls="links-accordion-header"
                            aria-expanded="false"
                            data-action-open="open_NCBI_links"
                            data-action-close="close_NCBI_link"
                    >
                        Links to NCBI Databases
                    </button>
                    <div data-source-url="/pmc/resources/db-links/9657243/" class="usa-accordion-content" id="links-accordion-header" aria-hidden="true"></div>
                </div>
            </li>

            
        
        </ul>
    </section>

 </div>
            </div>
        

    </nav>

</header>

    
    

    <div class="usa-overlay"></div>
    
<main id="main-content" class="usa-grid usa-layout-docs pmc-main">
    <article class="usa-width-three-fourths usa-layout-docs-main_content pmc-article">
        <section class="usa-breadcrumb usa-breadcrumb--wrap">
         
    <ul class="usa-breadcrumb__list">
            
                <li class="usa-breadcrumb__list-item"
                    >
                    <a href="/pmc/journals/" class="navlink">Journal List</a>
                </li>
            
                <li class="usa-breadcrumb__list-item"
                    >
                    <a href="/pmc/?term=%22Cells%22[journal]" class="navlink">Cells</a>
                </li>
            
                <li class="usa-breadcrumb__list-item"
                     aria-current="page" >
                    PMC9657243
                </li>
            
    </ul>
 

        </section>
        
  <div class="pmc-article__disclaimer" role="complementary" aria-label="Disclaimer note">
    As a library, NLM provides access to scientific literature. Inclusion in an NLM database does not imply endorsement of, or agreement with,
    the contents by NLM or the National Institutes of Health.<br/>
    Learn more:
    <a data-ga-category="Link click" data-ga-action="Disclaimer" data-ga-label="New disclaimer box" href="/pmc/about/disclaimer/">PMC Disclaimer</a>
    |
    <a data-ga-category="Link click" data-ga-action="PMC Copyright Notice" data-ga-label="New disclaimer box" href="/pmc/about/copyright/">
        PMC Copyright Notice
    </a>
</div>

        <section class="pmc-page-banner" role="banner">
            
                
                    <div><img src="/corehtml/pmc/pmcgifs/logo-cells.png" alt="Logo of cells" usemap="#logo-imagemap" /><map id="logo-imagemap" name="logo-imagemap"><area alt="Link to Publisher's site" title="Link to Publisher's site" shape="default" coords="0,0,499,74" href="http://www.mdpi.com/journal/cells" target="_blank" rel="noopener noreferrer" ref="reftype=publisher&amp;article-id=9657243&amp;issue-id=421422&amp;journal-id=2106&amp;FROM=Article%7CBanner&amp;TO=Publisher%7COther%7CN/A" /></map></div> 
                
            
        </section>
        <section  role="document">
            
                <div id="mc" class=" article lit-style content pmc-wm slang-all page-box"><!--main-content--><div class="jig-ncbiinpagenav" data-jigconfig="smoothScroll: false, allHeadingLevels: ['h2'], headingExclude: ':hidden,.nomenu'"><div class="fm-sec half_rhythm no_top_margin"><div class="fm-flexbox"><div class="fm-citation"><div class="citation-default"><div class="part1"><span id="pmcmata">Cells.</span> 2022 Nov; 11(21): 3372. </div><div class="part2"><span class="fm-vol-iss-date">Published online 2022 Oct 25. </span>  <span class="doi"><span>doi: </span><a href="//doi.org/10.3390%2Fcells11213372" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9657243&amp;issue-id=421422&amp;journal-id=2106&amp;FROM=Article%7CFront%20Matter&amp;TO=Content%20Provider%7CCrosslink%7CDOI">10.3390/cells11213372</a></span></div></div></div><div class="fm-ids"><div class="fm-citation-pmcid"><span class="fm-citation-ids-label">PMCID: </span><span>PMC9657243</span></div><div class="fm-citation-pmid">PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/36359767">36359767</a></div></div></div><h1 class="content-title">Empagliflozin Induced Ketosis, Upregulated IGF-1/Insulin Receptors and the Canonical Insulin Signaling Pathway in Neurons, and Decreased the Excitatory Neurotransmitter Glutamate in the Brain of Non-Diabetics</h1><div class="half_rhythm"><div class="contrib-group fm-author"><a href="https://pubmed.ncbi.nlm.nih.gov/?term=Avgerinos%20KI%5BAuthor%5D">Konstantinos I. Avgerinos</a>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Mullins%20RJ%5BAuthor%5D">Roger J. Mullins</a>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Vreones%20M%5BAuthor%5D">Michael Vreones</a>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Mustapic%20M%5BAuthor%5D">Maja Mustapic</a>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Chen%20Q%5BAuthor%5D">Qinghua Chen</a>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Melvin%20D%5BAuthor%5D">Denise Melvin</a>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Kapogiannis%20D%5BAuthor%5D">Dimitrios Kapogiannis</a>,<sup>*</sup> and  <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Egan%20JM%5BAuthor%5D">Josephine M. Egan</a><sup>*</sup></div><div style="display:none" class="contrib-group aff-tip"></div></div><div class="contrib-group half_rhythm fm-editor">Carlos Guill&#x000e9;n Viejo, <span class="fm-role">Academic Editor</span></div><div class="half_rhythm"><div class="togglers fm-copyright-license"><a href="#" class="pmctoggle" rid="idm140106936045472_ai idm140106911833536_ai idm140106925688848_ai">Author information</a> <a href="#" class="pmctoggle" rid="idm140106936045472_an">Article notes</a> <a href="#" class="pmctoggle" rid="idm140106936045472_cpl">Copyright and License information</a> <a href="/pmc/about/disclaimer/" style="margin-left: 1em">PMC Disclaimer</a></div><div class="fm-authors-info hide half_rhythm" id="idm140106936045472_ai" style="display:none"><div class="fm-affl" id="af1-cells-11-03372">Laboratory of Clinical Investigation, Intramural Program, National Institute on Aging, NIH, Baltimore, MD 21224, USA</div><div id="c1-cells-11-03372"><sup>*</sup>Correspondence: <a href="mailto:dev@null" data-email="vog.hin.liam@dsinnaigopak" class="oemail">vog.hin.liam@dsinnaigopak</a> (D.K.); <a href="mailto:dev@null" data-email="vog.hin.ain.crg@jnage" class="oemail">vog.hin.ain.crg@jnage</a> (J.M.E.)</div></div><div class="fm-article-notes hide half_rhythm" id="idm140106936045472_an" style="display:none"><div class="fm-pubdate half_rhythm">Received 2022 Sep 10; Accepted 2022 Oct 21.</div></div><div class="permissions half_rhythm hide" id="idm140106936045472_cpl" style="display:none"><div class="fm-copyright half_rhythm"><a href="/pmc/about/copyright/">Copyright</a> &#x000a9; 2022 by the authors.</div><div class="license half_rhythm">Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<a href="https://creativecommons.org/licenses/by/4.0/" data-ga-action="click_feat_suppl" ref="reftype=extlink&amp;article-id=9657243&amp;issue-id=421422&amp;journal-id=2106&amp;FROM=Article%7CFront%20Matter&amp;TO=External%7CLink%7CURI" target="_blank">https://creativecommons.org/licenses/by/4.0/</a>).</div></div></div><div id="pmclinksbox" class="links-box whole_rhythm hidden" role="complementary" aria-label="Related or updated information about this article."></div></div><div class="sec"></div><div id="ass-data" class="tsec fm-sec whole_rhythm" data-section="Featured_PMC_Datacitation"><h2 class="nomenu">Associated Data</h2><dl data-count="1" class="box-data-suppmats whole_rhythm no_bottom_margin"><dt><a href="#" rid="data-suppmats" data-ga-action="click_feat_toggler" data-ga-label="Supplementary Materials" class="pmctoggle">Supplementary Materials</a></dt><dd id="data-suppmats" style="display: none;"><div class="half_rhythm"><div><a href="/pmc/articles/PMC9657243/bin/cells-11-03372-s001.zip" data-ga-action="click_feat_suppl">cells-11-03372-s001.zip</a><span style="color:gray"> (1.7M)</span></div><div class="small guid">GUID: B2326523-8B3F-4A94-9910-5F20498E9D9D</div></div></dd></dl><dl data-length="157" class="box-data-avail whole_rhythm no_bottom_margin"><dt><a href="#" rid="data-avl-stmnt" data-ga-action="click_feat_toggler" data-ga-label="Data Availability Statement" class="pmctoggle">Data Availability Statement</a></dt><dd id="data-avl-stmnt" style="display: none;"><p>Datasets generated and/or analyzed during the current study are not publicly available but are available from the corresponding author on reasonable request.</p></dd></dl></div><div id="abstract-a.p.b.p" lang="en" class="tsec sec"><h2 class="head no_bottom_margin" id="abstract-a.p.b.ptitle">Abstract</h2><!--article-meta--><div><p class="p p-first-last">Sodium-glucose cotransporter-2 inhibitors (SGLT2is), such as empagliflozin, lower blood glucose in type 2 diabetes mellitus and improve cardiorenal outcomes regardless of diabetes presence. Whether SGLT2is exert any effects on the brain&#x02019;s metabolism has not been studied. We conducted a single-arm clinical trial to investigate the effects of once daily administration of oral empagliflozin (25 mg) for 14 days on systemic and brain metabolism in 21 non-diabetics aged 55 years old or older. Empagliflozin lowered circulating insulin and elevated &#x003b2;-hydroxybutyrate over 34-h periods, both following its first administration and after 14 days of daily administration, with minor alterations in glucose homeostasis. Levels of phosphorylated insulin-like growth factor-1 receptor (pIGF-1R), phosphorylated insulin receptor (pIR), phosphorylated-in-tyrosine insulin receptor substrate-1 (pY-IRS-1), and phosphorylated protein kinase B or AKT (pAKT) were increased in extracellular vesicles enriched for neuronal origin (NEVs) following the first empagliflozin administration, but not after 14 days. Our finding of IGF-1R upregulation in NEVs is promising because several post-mortem and epidemiological studies support the idea that upregulation of IGF signaling may protect against Alzheimer&#x02019;s disease (AD). Moreover, our finding showing activation of insulin signaling and, in particular, the canonical pathway (pIR, pY-IRS-1, pAKT) in NEVs is important because such changes have been repeatedly associated with neuronal survival. Using brain magnetic resonance spectroscopy (MRS), we detected decreased concentrations of the excitatory neurotransmitter glutamate and its precursor glutamine after empagliflozin administration. This finding is also encouraging since glutamatergic excitotoxicity has long been implicated in AD pathology. Overall, our findings may motivate the repurposing of SGLT2is for use in AD and other, related diseases that are characterized by downregulation of IGF-1/insulin signaling in neurons and excitotoxicity.</p></div><div class="sec"><strong class="kwd-title">Keywords: </strong><span class="kwd-text">empagliflozin, &#x003b2;-hydroxybutyrate, neuronal-origin extracellular vesicles, insulin signaling, magnetic resonance spectroscopy, glutamate, glutamine</span></div></div><div id="sec1-cells-11-03372" class="tsec sec"><h2 class="head no_bottom_margin" id="sec1-cells-11-03372title">1. Introduction</h2><p class="p p-first">Sodium-glucose cotransporter-2 inhibitors (SGLT2is) were originally approved for treating type 2 diabetes mellitus (T2DM) because they lower blood glucose and HbA1c levels. These effects result from the inhibition of sodium and glucose reabsorption at the proximal tubules of the kidneys leading to their spillage in the urine [<a href="#B1-cells-11-03372" rid="B1-cells-11-03372" class=" bibr popnode">1</a>]. The SGLT2i empagliflozin has also recently been approved for the treatment of adults suffering from heart failure with reduced ejection fraction (HFrEF). This approval came after a large multicenter trial reported a reduction in cardiovascular mortality or hospitalization due to heart failure and a reduction in kidney function decline, regardless of the presence of T2DM [<a href="#B2-cells-11-03372" rid="B2-cells-11-03372" class=" bibr popnode">2</a>]. The mortality and cardiorenal benefits of SGLTIs may be partially explained by an induction of a state that mimics the adaptive cellular response to starvation or fasting, which involves low insulin levels, ketosis, downregulation of glycolysis, upregulation of Krebs cycle, decrease in inflammation and an increase in autophagy markers [<a href="#B2-cells-11-03372" rid="B2-cells-11-03372" class=" bibr popnode">2</a>,<a href="#B3-cells-11-03372" rid="B3-cells-11-03372" class=" bibr popnode">3</a>,<a href="#B4-cells-11-03372" rid="B4-cells-11-03372" class=" bibr popnode">4</a>,<a href="#B5-cells-11-03372" rid="B5-cells-11-03372" class=" bibr popnode">5</a>,<a href="#B6-cells-11-03372" rid="B6-cells-11-03372" class=" bibr popnode">6</a>].</p><p>Although the fasting-like metabolic switch induced by empagliflozin could theoretically benefit any organ system, it could be particularly advantageous for the brain. Preclinical evidence shows that forms of energy restriction ameliorate common brain pathologies and are protective of cognitive function [<a href="#B7-cells-11-03372" rid="B7-cells-11-03372" class=" bibr popnode">7</a>,<a href="#B8-cells-11-03372" rid="B8-cells-11-03372" class=" bibr popnode">8</a>]. By potentially reducing brain exposure to chronic hyperinsulinemia that occurs even in non-diabetic states of insulin resistance [<a href="#B9-cells-11-03372" rid="B9-cells-11-03372" class=" bibr popnode">9</a>], empagliflozin could inhibit the aggregation of pathogenic proteins such as amyloid-beta (A&#x003b2;) and Tau that underlie the pathogenesis of Alzheimer&#x02019;s disease (AD) [<a href="#B10-cells-11-03372" rid="B10-cells-11-03372" class=" bibr popnode">10</a>,<a href="#B11-cells-11-03372" rid="B11-cells-11-03372" class=" bibr popnode">11</a>,<a href="#B12-cells-11-03372" rid="B12-cells-11-03372" class=" bibr popnode">12</a>,<a href="#B13-cells-11-03372" rid="B13-cells-11-03372" class=" bibr popnode">13</a>]. Additionally, inducing ketosis with empagliflozin may also have the benefit of providing the brain with ketone bodies, which are considered a more efficient energy substrate than glucose [<a href="#B14-cells-11-03372" rid="B14-cells-11-03372" class=" bibr popnode">14</a>,<a href="#B15-cells-11-03372" rid="B15-cells-11-03372" class=" bibr popnode">15</a>].</p><p class="p p-last">This study sought to investigate the metabolic changes induced in the periphery by oral empagliflozin administration to people aged 55 or older who did not have T2DM. To that end, we measured serum metabolites and plasma hormones likely to be impacted by acute and chronic empagliflozin treatment, and insulin-like growth factor-1 (IGF-1)/insulin signaling cascade mediators in plasma total extracellular vesicles (TEVs). In addition, we sought evidence that could help motivate the potential repurposing of empagliflozin for brain disorders. To that end, we investigated the brain&#x02019;s metabolism by magnetic resonance spectroscopy (MRS) and interrogated the IGF-1/insulin signaling cascade in a subpopulation of plasma EVs enriched for neuronal origin (NEVs). To our knowledge, this is the first human study to explore the effects of empagliflozin on the brain&#x02019;s metabolism by means of brain MRS and NEVs/TEVs isolated from plasma.</p></div><div id="sec2-cells-11-03372" class="tsec sec"><h2 class="head no_bottom_margin" id="sec2-cells-11-03372title">2. Methods</h2><div id="sec2dot1-cells-11-03372" class="sec sec-first"><h3 id="sec2dot1-cells-11-03372title">2.1. Trial Design and Regulatory Framework</h3><p class="p p-first-last">This was a single-arm clinical trial that involved a baseline assessment (visit 1), and assessment of empagliflozin&#x02019;s effects, both acutely (visit 2; first dose) and chronically (visit 3; last/14th dose). The study protocol was approved by the NIH IRB and registered in ClinicalTrials.gov (<a id="__tag_1125338680" class="tag_hotlink" href="https://clinicaltrials.gov/ct2/show/NCT03852901" ref="reftype=extlink-clinical-trial&amp;issue-id=421422&amp;journal-id=2106&amp;FROM=Article%7CBody&amp;TO=External%7CResource%7CClinical%20Trials%7CClinicalTrials.gov"><span class="tag-json" style="display:none">{"type":"clinical-trial","attrs":{"text":"NCT03852901","term_id":"NCT03852901"}}</span>NCT03852901</a>) before enrollment began. Subjects were recruited using multiple strategies, including, but not limited to, advertising in newspapers, flyers, the internet, NIH and NIA websites, expos and health fairs and volunteers who had expressed interest in NIA studies. All study procedures took place at the NIA Clinical Unit in Baltimore, MD, between March 2019 and November 2020. The clinical trial was conducted in compliance with the Good Clinical Practices (GCP) protocol, and all applicable regulatory requirements. Informed consent was obtained from all participants during the screening visit.</p></div><div id="sec2dot2-cells-11-03372" class="sec"><h3 id="sec2dot2-cells-11-03372title">2.2. Participants</h3><p class="p p-first-last">Included participants were non-diabetic men or women of age 55 years or older. We excluded individuals who had hypoglycemia or glucosuria in the screening labs. Individuals with significant medical conditions including class 2 obesity or more (BMI &#x0003e; 35 kg/m<sup>2</sup>), impaired kidney function (GFR &#x0003c; 60 mL/min/1.73 m<sup>2</sup>) were also excluded. For a full list of inclusion/exclusion criteria see the &#x0201c;study protocol&#x0201d; in <a href="#app1-cells-11-03372" rid="app1-cells-11-03372" class=" app">Supplemental Othor Materials S1</a>. We studied participants 55 years old or older since our ultimate goal is to repurpose empagliflozin (and potentially other SGLTis) as a treatment for aging-associated cognitive impairment as well as for AD and related dementias.</p></div><div id="sec2dot3-cells-11-03372" class="sec"><h3 id="sec2dot3-cells-11-03372title">2.3. Intervention and Outcomes</h3><p class="p p-first-last">Oral empagliflozin (25 mg every morning prior to breakfast) was ingested for 14 days. The primary outcome was change of serum &#x003b2;-hydroxybutyrate (BHB). Secondary outcomes included changes of metabolites/hormones such as plasma glucose, serum non-esterified fatty acids (NEFAs), serum acetoacetate (AcAc), plasma insulin and HOMA-IR calculated in fasting state with the formula ((insulin &#x000d7; glucose)/405), IGF-1, and glucagon. Additional secondary outcomes were changes of IGF-1/insulin signaling cascade molecules such as phosphorylated insulin-like growth 1 receptor (pIGF-1R), phosphorylated insulin receptor (pIR), phosphorylated-in-serine insulin receptor substrate-1 (pSer-IRS-1), phosphorylated-in-tyrosine insulin receptor substrate-1 (pY-IRS-1), (pSer-IRS-1)/(pY-IRS-1) ratio, phosphorylated extracellular signal-regulated kinase-1 (pERK-1), phosphorylated c-Jun N-terminal kinases (pJNK), phosphorylated protein kinase B (also known as AKT) (pAKT), total AKT (tAKT), and phosphorylated p38 mitogen-activated protein kinases (pp38) measured in plasma-derived total (TEVs) (to probe whole-body cell signaling) and in neuronal-origin extracellular vesicles (NEVs) (to probe neuronal-specific signaling). Other secondary outcomes included changes of brain MRS metabolites such as alanine (Ala), aspartate (Asp), creatine (Cr), phosphocreatine (PCr), gamma-aminobutyric acid (GABA), glucose (Glc), glutamine (Gln), glutamate (Glu), glycerophosphocholine (GPC), glutathione (GSH), myo-inositol (Ins), lactate (Lac), N-acetyl aspartate (NAA), N-acetylaspartylglutamate (NAAG), scyllo-inositol (Scy), taurine (Tau) phosphocholine (PCh), alanine (Ala), BHB, AcAc, and acetone (Ace). </p></div><div id="sec2dot4-cells-11-03372" class="sec"><h3 id="sec2dot4-cells-11-03372title">2.4. Study Procedures during Visits </h3><p class="p p-first">Study procedures are shown in <a href="/pmc/articles/PMC9657243/figure/cells-11-03372-f001/" target="figure" class="fig-table-link figpopup" rid-figpopup="cells-11-03372-f001" rid-ob="ob-cells-11-03372-f001" co-legend-rid="lgnd_cells-11-03372-f001"><span>Figure 1</span></a>b. Subjects were admitted for 34 h during visits 1 (baseline), 2 (first dose) and 3 (last/14th dose). Participants were admitted the evening before each visit to facilitate study procedures. After a 12-h overnight fast, participants underwent intravenous (IV) placement for a fasting blood draw (t<sub>o</sub>), followed by drug ingestion (visits 2 and 3) and repeated blood draws (all visits) over a 34-h window (initially every 1.5 h &#x000d7; 2 times, then every 1 h &#x000d7; 1 time, then every 1.5 h &#x000d7; 8 times, then every 2 h &#x000d7; 4 times, then every 1.5 h &#x000d7; 2 times, then every 1 h &#x000d7; 1 time, and finally every 1.5 h &#x000d7; 4 times). For serum collection, blood was collected into BD Vacutainer serum separation tubes (gold top, SKU: 367983). For plasma collection, blood was collected into BD Vacutainer EDTA tubes (purple top, SKU: 367856). All blood samples were immediately centrifuged at 4 &#x000b0;C on site and plasma and serum were stored in frozen aliquots at &#x02212;80 &#x000b0;C in less than 1 h. Each aliquot was thawed only once. Serum metabolites and plasma hormones were measured from each blood draw (t<sub>0</sub> to t<sub>34</sub>). TEV and NEV biomarkers were measured at fasting timepoints only (visit 1 t<sub>o</sub>, visit 2 t<sub>24,</sub> visit 3 t<sub>24</sub>) to limit variation in lipoprotein concentrations that interfere with EV isolation. The standardization of the timing of blood draws, the fact that these were performed in the fasting condition, and the processing of plasma samples in &#x0003c; 1 h with immediate storage at &#x02212;80 &#x000b0;C are steps that satisfy key recommendations regarding pre-analytical factors affecting EV isolation [<a href="#B16-cells-11-03372" rid="B16-cells-11-03372" class=" bibr popnode">16</a>]. Participants had breakfast around 8.30 am (30 min after drug ingestion), lunch around 12.30 pm and dinner around 5.30 pm. MRS was performed around 4 pm on each visit. Timings of blood draws, meals and MRS were similar across all visits.</p><!--fig ft0--><!--fig mode=article f1--><div class="fig iconblock whole_rhythm" id="cells-11-03372-f001" co-legend-rid="lgnd_cells-11-03372-f001"><a href="/pmc/articles/PMC9657243/figure/cells-11-03372-f001/" target="figure" rid-figpopup="cells-11-03372-f001" rid-ob="ob-cells-11-03372-f001"><!--fig/graphic|fig/alternatives/graphic mode="anchored" m1--><div class="figure" data-largeobj="" data-largeobj-link-rid="largeobj_idm140106927765504"><a class="inline_block ts_canvas" href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=9657243_cells-11-03372-g001.jpg" target="tileshopwindow" rel="noopener"><div class="ts_bar small" title="Click on image to zoom"></div><img loading="lazy" alt="An external file that holds a picture, illustration, etc.&#10;Object name is cells-11-03372-g001.jpg" title="Click on image to zoom" class="tileshop" src="/pmc/articles/PMC9657243/bin/cells-11-03372-g001.jpg" /></a></div><div class="largeobj-link align_right" id="largeobj_idm140106927765504"><a target="object" rel="noopener" href="/pmc/articles/PMC9657243/figure/cells-11-03372-f001/?report=objectonly">Open in a separate window</a></div></a><div class="icnblk_cntnt" id="lgnd_cells-11-03372-f001"><div><a class="figpopup" href="/pmc/articles/PMC9657243/figure/cells-11-03372-f001/" target="figure" rid-figpopup="cells-11-03372-f001" rid-ob="ob-cells-11-03372-f001">Figure 1</a></div><!--caption a7--><div class="caption"><p>(<strong>a</strong>)<strong>.</strong> Flowchart of study population; (<strong>b</strong>)<strong>.</strong> Study procedures include: fasting blood draws for isolation of EVs (visit 1 t<sub>o</sub>, visit 2 t<sub>24</sub> and visit 3 t<sub>24</sub>); empagliflozin administration from visit 2 to visit 3; breakfast, lunch and dinner; brain magnetic resonance spectroscopy (MRS); repeated blood draws for serum metabolites and plasma hormones throughout every visit [<a href="#B17-cells-11-03372" rid="B17-cells-11-03372" class=" bibr popnode">17</a>].</p></div></div></div><p class="p p-last">For 13 days after visit 2 (first day on medication), the participants ingested empagliflozin every morning at home about 30 min before breakfast. The participants had a continuous glucose monitoring system (FreeStyle Libre Pro 1.1.1) placed between visits to further safeguard against hypoglycemia. The end of visit 3 concluded all study procedures. </p></div><div id="sec2dot5-cells-11-03372" class="sec"><h3 id="sec2dot5-cells-11-03372title">2.5. Laboratory Assays</h3><p class="p p-first-last">Plasma insulin was measured using an ELISA kit (Mercordia; Catalog No. 10-1113-01) [<a href="#B18-cells-11-03372" rid="B18-cells-11-03372" class=" bibr popnode">18</a>]. Both serum BHB and AcAc were measured using colorimetric assay kits (Cayman Chemicals; Catalog No. 700190 and Sigma-Aldrich; Catalog No. MAK199, respectively), according to manufacturer&#x02019;s instructions. Non-esterified fatty acids were measured by an enzymatic colorimetric method (FUJIFILM Wako Chemicals; Catalog No. 999-34691 and 995-34791) [<a href="#B19-cells-11-03372" rid="B19-cells-11-03372" class=" bibr popnode">19</a>]. Plasma glucagon was measured using a radioimmune assay (Millipore; Catalog No. GL-32K) [<a href="#B18-cells-11-03372" rid="B18-cells-11-03372" class=" bibr popnode">18</a>]. </p></div><div id="sec2dot6-cells-11-03372" class="sec"><h3 id="sec2dot6-cells-11-03372title">2.6. Isolation of Total and Neuronal Extracellular Vesicles from Blood Plasma </h3><p class="p p-first">An extensive description of the methodology used to isolate NEVs from plasma has been previously reported by our group [<a href="#B20-cells-11-03372" rid="B20-cells-11-03372" class=" bibr popnode">20</a>]. Plasma aliquots (0.5 mL) were defibrinated using Thrombin (System Biosciences, Inc., Palo Alto, CA, USA). Plasma was then treated with particle precipitation solution, Exoquick (System Biosciences, Inc., Palo Alto, CA, USA). The resulting pellet containing crude EVs was resuspended in 0.7 mL of distilled water supplemented with protease and phosphatase inhibitors and was centrifuged at 400&#x000d7; <em>g</em> for 5 min at +4 &#x000b0;C to remove insoluble contaminants. After transfer to a clean tube, the supernatant was incubated with 4 &#x000b5;g of mouse anti-human CD171 (L1CAM; clone 5G3) biotinylated antibody (Thermo Scientific, Inc., Waltham, MA, USA) for 2 h at +4 &#x000b0;C, followed by incubation with 25 &#x003bc;L of Pierce Streptavidin Plus UltraLink Resin (Thermo Scientific, Inc., Waltham, MA, USA) for 1 h at +4 &#x000b0;C. After centrifugation at 800&#x000d7; <em>g</em> for 10 min at +4 &#x000b0;C, the supernatant was removed, and the pellet containing NEV-bead conjugates was further purified of soluble material by adding 500 &#x000b5;L of distilled water (with inhibitors) and centrifugation at 800&#x000d7; <em>g</em> for 10 min at +4 &#x000b0;C. Following removal of the supernatant, NEVs were eluted with 200 &#x000b5;L of 0.1 M glycine and beads were separated by centrifugation at 4500&#x000d7; <em>g</em> for 5 min at +4 &#x000b0;C. The resulting supernatant containing NEVs was transferred to a clean tube and the pH was immediately neutralized using 1 M tris-HCl. NEVs were lysed and protein was extracted using M-PER (Thermo Scientific, Inc., Waltham, MA, USA) and two freeze&#x02013;thaw cycles. The NEV lysate was stored at &#x02212;80 &#x000b0;C. A variation of the same methodology was used to capture TEVs utilizing 4 &#x000b5;g of a mix of antibodies against three canonical EV markers: CD9 (clone KMC8; BD Pharmingen, Inc., San Diego, CA, USA), CD63 (clone TEA3/18; Abnova, Taipei City, Taipei, Taiwan), and CD81 (clone 1.3.3.22; Ancell, Inc. Bayport, MN, USA).</p><p>To demonstrate the ultrastructural properties of NEVs, cryogenic transmission electron microscopy (Cryo-TEM) of intact NEV was performed at the Nanoscale and Microscale Research Centre of the University of Nottingham, UK. We used Holey carbon TEM grids (EM resolutions, Sheffield, UK). NEV samples were left to adsorb onto the grids (5 &#x003bc;L/grid) for 2 min, and then excess solution was removed using filters. The NEV samples were blotted for 1 s and were frozen in liquid ethane using a Gatan CP3 plunge freezing unit (Ametek, Leicester, UK). The frozen samples were loaded to a Tecnai G2 Spirit BioTWIN, a 20&#x02013;120 kV/LaB6 Transmission Electron Microscope, with Cryo-TEM carried out with an accelerating voltage of 100 kV. We obtained the images using an inbuilt Gatan SIS Megaview IV digital camera.</p><p class="p p-last">Recently, we published additional evidence on the characterization of NEVs, demonstrating by WBs that L1CAM+ NEVs display the full length 220 kD characteristic band for L1CAM, which is present in brain lysate. This is unlike other sub-populations of plasma EVs that display solely the 200 kD band, a band which corresponds to soluble L1CAM [<a href="#B21-cells-11-03372" rid="B21-cells-11-03372" class=" bibr popnode">21</a>]. Moreover, L1CAM+ NEVs contain many-fold higher L1CAM (normalized to canonical EV marker CD9) compared to other plasma EV sub-populations, suggesting the specificity of the anti-L1CAM immunoprecipitation [<a href="#B21-cells-11-03372" rid="B21-cells-11-03372" class=" bibr popnode">21</a>]. Finally, using confocal fluorescence microscopy after double immunolabeling with L1CAM and neuronal marker VAMP2, we demonstrated the co-existence of L1CAM and VAMP2 on particles at the size range of single EVs [<a href="#B21-cells-11-03372" rid="B21-cells-11-03372" class=" bibr popnode">21</a>]. </p></div><div id="sec2dot7-cells-11-03372" class="sec"><h3 id="sec2dot7-cells-11-03372title">2.7. Quantification of NEV Proteins</h3><p class="p p-first-last">We quantified phosphorylated insulin signaling pathway proteins in NEV and TEV lysates using Meso Scale Discovery (MSD) electrochemiluminescence assays. pIGF-1R (Tyr1316), pIR (Tyr1150/1151), pIRS-1 (Tyr612) (Cat. # K15151C), pIRS-1 (Ser312) (Cat. # K150HLD), pJNK (Thr183/Tyr185), pp38 (Thr180/Tyr182), pERK-1/2 (Thr/Tyr: 202/204; 185/187) (Cat. # K15101D), pAkt (Ser473), and total Akt (Cat. # K15100D) were measured using the Meso QuickPlex SQ120 imager and the workbench Software 4.0 (Meso Scale Discovery, Rockville, MD, USA). Due to the absence of standards in these phospho-protein assays, we analyzed the electrochemiluminescence signal. All assays were conducted in duplicate and the mean coefficients of variation for each assay were 7.31% (IGF-1R), 7.76% (pIR), 8.79% (pTyr-IRS-1), 11.16% (pSer-IRS-1), 5.58% (pJNK), 4.69% (pp38), 12.82% (pERK1/2), 7.84% (pAKT), and 9.14% (tAKT). To assess inter-plate variability, duplicate NEV isolates from a healthy control subject were included as an internal control on each plate. The CVs for the internal control were 9.76% (IGF-1R), 5.31% (pIR), 6.86% (pTyr-IRS-1), 5.05% (pSer-IRS-1), 6.31% (pJNK), 6.37% (pp38), 3.98% (pERK1/2), 25.0% (pAKT), and 12.3% (tAKT). A correction factor was applied to the raw signal intensities of each assay to normalize inter-plate variability (internal control signal for a given plate divided by the average internal control signal of all plates). </p></div><div id="sec2dot8-cells-11-03372" class="sec"><h3 id="sec2dot8-cells-11-03372title">2.8. Magnetic Resonance Spectroscopy</h3><p class="p p-first">To measure in vivo brain metabolite concentrations, single-voxel <sup>1</sup>H MRS data were acquired on a Philips Achieva 3T whole-body MR scanner equipped with an 8-channel SENSE head coil. A 25 &#x000d7; 18 &#x000d7; 20 mm<sup>3</sup> MRS voxel was placed within the posteromedial cortex, centered to ensure maximal coverage of bilateral precuneus, as previously undertaken [<a href="#B22-cells-11-03372" rid="B22-cells-11-03372" class=" bibr popnode">22</a>]. Point-Resolved Spectroscopy (PRESS) with non-suppressed water reference was used to acquire metabolite concentrations, including standard water-scaled metabolites Ala, Asp, Cr, PCr, GABA, Glc, Gln, Glu, GPC, GSH, Ins, Lac, NAA, NAAG Scy, Tau, Pch, as well as the combined signals for Glu &#x00026; Gln (Glx), GPC &#x00026; PCh, and NAA &#x00026; NAAG [<a href="#B23-cells-11-03372" rid="B23-cells-11-03372" class=" bibr popnode">23</a>,<a href="#B24-cells-11-03372" rid="B24-cells-11-03372" class=" bibr popnode">24</a>]. The ketone-related metabolites BHB, AcAc, and Acetone (Ace) were detected via a modified basis set provided in July of 2019 by LCModel&#x02019;s developer, Dr. Stephen Provencher. This modification consisted of a supplemental scanner specific LCModel &#x0201c;control.txt&#x0201d; file that allowed us to measure BHB, AcAc, and Ace in addition to the standard set of metabolites in the basis set (<a href="#app1-cells-11-03372" rid="app1-cells-11-03372" class=" app">Supplemental Othor Materials S2</a>). PRESS parameters were TE = 35 msec, TR = 2000 msec, 256 averages, direct dimension bandwidth = 2 kHz, and 2048 sample points. Reliability of the measurements and fitting procedure for each metabolite was assessed using Cramer&#x02013;Rao lower bounds (CRLB) [<a href="#B25-cells-11-03372" rid="B25-cells-11-03372" class=" bibr popnode">25</a>], and line widths for water resonance were monitored for intra-subject scan reliability and were previously observed at a stable (mean &#x000b1; SD) 7.3 &#x000b1; 1.7 Hz.</p><p class="p p-last">To provide volumes of parenchymal and CSF segments within the MRS voxel, T1-weighted magnetization-prepared rapid gradient-echo (MPRAGE) images were acquired during the same session. A Turbo Field Echo acquisition sequence was used with the following parameters: TR = 6.803 ms, TE = 3.19 ms, number of excitations = 1, flip angle = 8&#x000b0;, acquisition matrix = 256 &#x000d7; 256 &#x000d7; 170, resolution = 1 &#x000d7; 1 &#x000d7; 1.2 mm.</p></div><div id="sec2dot9-cells-11-03372" class="sec sec-last"><h3 id="sec2dot9-cells-11-03372title">2.9. Statistical Methods</h3><p class="p p-first">Biofluid biomarkers were analyzed using linear mixed models with repeated measures in SPSS (Build 1.0.0.1508). For circulating metabolites/hormones assessed repeatedly over the course of 34 h during each visit, the models included participant ID as a random effect, &#x0201c;Visit&#x0201d; and &#x0201c;Timepoint&#x0201d; as repeated-measures variables, and the factors &#x0201c;Visit&#x0201d;, &#x0201c;Timepoint&#x0201d;, &#x0201c;Sex&#x0201d;, and the interaction &#x0201c;Visit*Sex&#x0201d; as terms for fixed effects. For NEV/TEV biomarkers and calculated HOMA-IR, the models included &#x0201c;Visit&#x0201d; as the repeated-measures variable. The terms for fixed effects included the factors &#x0201c;Visit&#x0201d;, &#x0201c;Sex&#x0201d;, the covariate &#x0201c;BMI&#x0201d;, and the interactions &#x0201c;Visit*Sex&#x0201d; and &#x0201c;Visit*BMI&#x0201d;. We included the interactions &#x0201c;Visit*Sex&#x0201d; and &#x0201c;Visit*BMI&#x0201d; in our models because of evidence that SGLT2 inhibitors may have different clinical effects depending on sex and BMI [<a href="#B26-cells-11-03372" rid="B26-cells-11-03372" class=" bibr popnode">26</a>,<a href="#B27-cells-11-03372" rid="B27-cells-11-03372" class=" bibr popnode">27</a>,<a href="#B28-cells-11-03372" rid="B28-cells-11-03372" class=" bibr popnode">28</a>]. To correct skewness, EV biomarker measures were natural logarithm (ln)-transformed before being implemented into models.</p><p class="p p-last"><sup>1</sup> H MRS data was processed in LCModel, an automated fitting routine that quantifies the concentration of select metabolite resonances within the MRS voxel [<a href="#B29-cells-11-03372" rid="B29-cells-11-03372" class=" bibr popnode">29</a>]. Water-scaled metabolite concentrations (mmol/L) obtained via LCModel were then analyzed using R v.3.6.3. To minimize unreliable measurements, metabolites were censored using a strict CRLB% of &#x0003c;20 for the standard metabolites and a lenient exploratory &#x0003c; 100 for ketone metabolites (BHB, AcAc, Ace). Ala, Asp, GABA, Glc, PCh, Lac, NAAG, Scyllo, and Tau were excluded from the analysis set due to having 50% or more CRLB-censored values. Additionally, a set of weights was derived from the inverse of the CRLB for each measurement to reduce the influence of less reliable (i.e., high CRLB) measurements [<a href="#B30-cells-11-03372" rid="B30-cells-11-03372" class=" bibr popnode">30</a>]. This ensured that more reliable (i.e., low-CRLB) measures had more impact on the statistical model than less reliable ones. We then derived the fraction of CSF (fCSF) in the MRS voxel to correct for the potential confounding effects of varying CSF volume in the precuneal voxel. To do this, we used the T<sub>1</sub>-weighted anatomical images (MP-RAGE) and a custom MATLAB script adapted from Partial Volume Code for Philips MRS data provided by Dr. Nia Goulden and Dr. Paul Mullins of Bangor University [<a href="#B31-cells-11-03372" rid="B31-cells-11-03372" class=" bibr popnode">31</a>]. This script output the gray matter (GM), white matter (WM) and CSF volumes used to calculate the fractional volume of cerebrospinal fluid (fCSF = CSF<sub>vol/</sub>(GM<sub>vol</sub> + WM<sub>vol</sub> + CSF<sub>vol</sub>)) within the MRS voxel. Finally, we used a linear mixed effects model (nlme v.3.1) with participant ID as the random effect, MRS &#x0201c;Visit&#x0201d; (1&#x02013;3) as repeated measure, each metabolite as the dependent variable, and &#x0201c;Visit&#x0201d;, &#x0201c;Age&#x0201d;, &#x0201c;Sex&#x0201d;, and &#x0201c;fCSF&#x0201d; as factors or covariates. &#x0201c;Age&#x0201d; was included in the model given strong evidence that it affects MRS metabolites [<a href="#B32-cells-11-03372" rid="B32-cells-11-03372" class=" bibr popnode">32</a>]. This model included the aforementioned weighting term for the inverse CRLB for each metabolite, restricted maximum likelihood (REML) as the variance estimator, and first order autoregression (AR(1)) for autocorrelation.</p></div></div><div id="sec3-cells-11-03372" class="tsec sec"><h2 class="head no_bottom_margin" id="sec3-cells-11-03372title">3. Results</h2><div id="sec3dot1-cells-11-03372" class="sec sec-first"><h3 id="sec3dot1-cells-11-03372title">3.1. Participant Flow and Baseline Characteristics</h3><p class="p p-first-last">Of the 39 participants that underwent screening, 18 were excluded prior to drug administration for eligibility reasons, 21 took at least one drug dose, and 20 took all drug doses completing all study visits (<a href="/pmc/articles/PMC9657243/figure/cells-11-03372-f001/" target="figure" class="fig-table-link figpopup" rid-figpopup="cells-11-03372-f001" rid-ob="ob-cells-11-03372-f001" co-legend-rid="lgnd_cells-11-03372-f001"><span>Figure 1</span></a>a). Baseline characteristics are presented in <a href="/pmc/articles/PMC9657243/table/cells-11-03372-t001/" target="table" class="fig-table-link figpopup" rid-figpopup="cells-11-03372-t001" rid-ob="ob-cells-11-03372-t001" co-legend-rid=""><span>Table 1</span></a>.</p><!--table ft1--><!--table-wrap mode="anchored" t5--><div class="table-wrap anchored whole_rhythm" id="cells-11-03372-t001"><h3>Table 1</h3><!--caption a7--><div class="caption"><p>Baseline demographic and laboratory characteristics.</p></div><div class="xtable"><table frame="hsides" rules="groups" class="rendered small default_table"><tbody><tr><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Sample Size (n)</td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">21</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Sex (F/M)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">11/10</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Age (years)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">62.14 (6.91)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">BMI (kg/m<sup>2</sup>)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">27.15 (2.97)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Fasting glucose (mg/dL)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">95.19 (8.79)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Fasting Insulin (mIU/L)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6.32 (4.76)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HOMA-IR</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.54 (1.30)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Glucagon (ng/L)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">120.04 (63.03)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NEFAs (mEq/L)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.41 (0.17)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">BHB (&#x000b5;M)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">202.38 (72.86)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">AcAc (&#x000b5;M)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">39.40 (16.65)</td></tr><tr><td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">Continuous variables are reported as means (SDs)</td></tr></tbody></table></div><div class="largeobj-link align_right" id="largeobj_idm140106938635168"><a target="object" rel="noopener" href="/pmc/articles/PMC9657243/table/cells-11-03372-t001/?report=objectonly">Open in a separate window</a></div></div></div><div id="sec3dot2-cells-11-03372" class="sec"><h3 id="sec3dot2-cells-11-03372title">3.2. Outcomes</h3><p class="p p-first">In this study, we implemented repeated-measures analyses as appropriate for each outcome. Biomarkers directly assayed in plasma or serum (glucose, insulin, NEFAs, glucagon, ketone bodies) were measured multiple times over 34 h to determine their diurnal variation and relationship to meals. To demonstrate the effects of empagliflozin both acutely and after chronic administration, all outcomes were assessed at three timepoints (baseline, following the first dose, following 14 days of daily administration). We provide three different metrics (% change from baseline, F test, mean difference) for each outcome. For outcomes repeated over 34-h periods we report results for the overall pattern of repeated measurements rather than a single timepoint.</p><div id="sec3dot2dot1-cells-11-03372" class="sec"><p></p><h4 id="sec3dot2dot1-cells-11-03372title" class="inline">3.2.1. Empagliflozin Shifted Metabolism towards a Low-Insulin, High-Glucagon State Elevating Fatty Acids, and &#x003b2;-hydroxybutyrate Levels </h4><p class="p p-first"><a href="/pmc/articles/PMC9657243/figure/cells-11-03372-f002/" target="figure" class="fig-table-link figpopup" rid-figpopup="cells-11-03372-f002" rid-ob="ob-cells-11-03372-f002" co-legend-rid="lgnd_cells-11-03372-f002"><span>Figure 2</span></a> and <a href="/pmc/articles/PMC9657243/table/cells-11-03372-t002/" target="table" class="fig-table-link figpopup" rid-figpopup="cells-11-03372-t002" rid-ob="ob-cells-11-03372-t002" co-legend-rid=""><span>Table 2</span></a> show metabolites and hormone levels throughout 34-h periods for all three visits. Across all participants, BHB increased by 15% (on average over 34 h) compared with baseline after the first empagliflozin dose (F<sub>1, 921.000</sub> = 54.310, <em>p</em> &#x0003c; 0.001; mean difference (MD) = 33.955 &#x000b5;M, 95% CI = 24.912, 42.997); and by 21% compared with baseline after the last dose (F<sub>1, 902.758</sub> = 70.003, <em>p</em> &#x0003c; 0.001; MD = 40.717 &#x000b5;M, 95% CI = 31.166, 50.268).</p><!--fig ft0--><!--fig mode=article f1--><div class="fig iconblock whole_rhythm" id="cells-11-03372-f002" co-legend-rid="lgnd_cells-11-03372-f002"><a href="/pmc/articles/PMC9657243/figure/cells-11-03372-f002/" target="figure" rid-figpopup="cells-11-03372-f002" rid-ob="ob-cells-11-03372-f002"><!--fig/graphic|fig/alternatives/graphic mode="anchored" m1--><div class="figure" data-largeobj="" data-largeobj-link-rid="largeobj_idm140106937028448"><a class="inline_block ts_canvas" href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=9657243_cells-11-03372-g002.jpg" target="tileshopwindow" rel="noopener"><div class="ts_bar small" title="Click on image to zoom"></div><img loading="lazy" alt="An external file that holds a picture, illustration, etc.&#10;Object name is cells-11-03372-g002.jpg" title="Click on image to zoom" class="tileshop" src="/pmc/articles/PMC9657243/bin/cells-11-03372-g002.jpg" /></a></div><div class="largeobj-link align_right" id="largeobj_idm140106937028448"><a target="object" rel="noopener" href="/pmc/articles/PMC9657243/figure/cells-11-03372-f002/?report=objectonly">Open in a separate window</a></div></a><div class="icnblk_cntnt" id="lgnd_cells-11-03372-f002"><div><a class="figpopup" href="/pmc/articles/PMC9657243/figure/cells-11-03372-f002/" target="figure" rid-figpopup="cells-11-03372-f002" rid-ob="ob-cells-11-03372-f002">Figure 2</a></div><!--caption a7--><div class="caption"><p>Means (SEs) of circulating metabolites and hormones ((<strong>a</strong>&#x02013;<strong>f</strong>): glucose, insulin, non-esterified fatty acids (NEFAs), glucagon, acetoacetate (AcAc), &#x003b2;-hydroxybutyrate (BHB)) measured from blood draws over a 34-h window (22 timepoints) starting at 8 am in the morning and finishing at 6 pm the next afternoon (i.e., every 1.5 h &#x000d7; 2, 1 h &#x000d7; 1, 1.5 h &#x000d7; 8, 2 h &#x000d7; 4, 1.5 h &#x000d7; 2, 1 h &#x000d7; 1, and finally 1.5 h &#x000d7; 4), at baseline (visit 1 (V1)), immediately before and after the first empagliflozin dose (visit 2 (V2)), and immediately before and after the last empagliflozin dose (visit 3 (V3)). Statistical analysis involved repeated-measures linear mixed models with &#x0201c;Visit&#x0201d; as the repeated-measures variable and additional variables as factors and covariates (see <a href="#sec2dot9-cells-11-03372" rid="sec2dot9-cells-11-03372" class=" sec">Section 2.9</a> for details). Significance is indicated in the graphs when type III tests of fixed effects for &#x0201c;Visit&#x0201d; and pairwise comparisons between &#x0201c;Visits&#x0201d; were significant. Significance symbols ns, *, **, *** correspond to <em>p</em> &#x0003e; 0.05, <em>p</em> &#x02264; 0.05, <em>p</em> &#x02264; 0.01 and <em>p</em> &#x02264; 0.001, respectively.</p></div></div></div><!--table ft1--><!--table-wrap mode="anchored" t5--><div class="table-wrap anchored whole_rhythm" id="cells-11-03372-t002"><h3>Table 2</h3><!--caption a7--><div class="caption"><p>Serum metabolites and plasma hormones measured in 34-h periods at baseline (V1), after one dose (V2), and after multiple (V3) empagliflozin doses.</p></div><div class="xtable"><table frame="hsides" rules="groups" class="rendered small default_table"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Circulating<br />Metabolite/<br />Hormone/<br />Other</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Visits Compared</th><th colspan="4" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">Type III Tests of Fixed Effects</th><th colspan="6" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">Pairwise Comparisons (Least Significant Difference)</th></tr><tr><th rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
</th><th rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
</th><th rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Num df</th><th rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Den <br />df</th><th rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">F</th><th rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Sig.</th><th rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Mean Difference </th><th rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Std. Error </th><th rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">df</th><th rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Sig.</th><th colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">95% Confidence Interval</th></tr><tr><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Lower Bound</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Upper Bound</th></tr></thead><tbody><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Glucose</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">V2 vs. V1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">902.217</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.940</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<strong>0.047</strong>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;2.011</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.013</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">902.217</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<strong>0.047</strong>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;4.000</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;0.023</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">V3 vs. V1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">884.229</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.367</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.545</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;0.637</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.051</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">884.229</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.545</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;2.699</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.426</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Insulin</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">V2 vs. V1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">902.122</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6.530</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<strong>0.011</strong>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;3.307</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.294</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">902.122</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<strong>0.011</strong>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;5.846</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;0.767</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">V3 vs. V1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">880.870</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.970</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<strong>0.047</strong>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;2.647</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.329</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">880.870</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<strong>0.047</strong>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;5.255</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;0.040</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">IGF-1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">V2 vs. V1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">18.000</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.000</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.993</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;0.001</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.059</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">18.000</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.993</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;0.124</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.123</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">V3 vs. V1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">18.000</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.212</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.651</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;0.023</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.051</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">18.000</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.651</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;0.131</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.084</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">HOMA-IR</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">V2 vs. V1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">19.000</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.520</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.480</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.077</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.107</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">19.000</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.480</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;0.147</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.302</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">V3 vs. V1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">18.224</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.588</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.125</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;0.242</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.151</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">18.224</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.125</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;0.559</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.074</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Glucagon</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">V2 vs. V1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">381.000</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7.900</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<strong>0.005</strong>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">19.572</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6.963</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">381.000</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<strong>0.005</strong>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5.880</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">33.263</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">V3 vs. V1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">374.045</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10.636</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<strong>0.001</strong>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">25.416</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7.793</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.001</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<strong>0.001</strong>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10.092</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">40.741</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">NEFAs</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">V2 vs. V1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">902.094</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">15.986</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<strong>&#x0003c;0.001</strong>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.035</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.009</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">902.094</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<strong>&#x0003c;0.001</strong>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.018</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.053</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">V3 vs. V1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">880.629</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">8.782</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<strong>0.003</strong>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.027</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.009</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">880.629</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<strong>0.003</strong>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.009</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.044</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">AcAc</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">V2 vs. V1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">921.000</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.439</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.508</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;1.281</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.933</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">921.000</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.508</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;5.074</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.512</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">V3 vs. V1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">902.181</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">9.049</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<strong>0.003</strong>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;5.573</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.853</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">902.181</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<strong>0.003</strong>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;9.210</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;1.937</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">BHB</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">V2 vs. V1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">921.000</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">54.310</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<strong>&#x0003c;0.001</strong>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">33.955</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4.607</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">921.000</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<strong>&#x0003c;0.001</strong>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">24.912</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">42.997</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">V3 vs. V1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">902.758</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">70.003</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<strong>&#x0003c;0.001</strong>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">40.717</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4.866</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">902.758</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<strong>&#x0003c;0.001</strong>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">31.166</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">50.268</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">AcAc/BHB</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">V2 vs. V1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">901.067</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">62.430</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<strong>&#x0003c;0.001</strong>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;0.036</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.005</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">901.067</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<strong>&#x0003c;0.001</strong>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;0.045</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;0.027</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">V3 vs. V1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">878.674</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">133.526</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<strong>&#x0003c;0.001</strong>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;0.054</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.005</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">878.674</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<strong>&#x0003c;0.001</strong>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;0.063</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;0.045</td></tr></tbody></table></div><div class="largeobj-link align_right" id="largeobj_idm140106935499952"><a target="object" rel="noopener" href="/pmc/articles/PMC9657243/table/cells-11-03372-t002/?report=objectonly">Open in a separate window</a></div></div><p>The first empagliflozin dose did not change AcAc (on average over 34 h) compared with baseline (F<sub>1, 921.000</sub> = 0.439, <em>p</em> = 0.508; MD = &#x02212;1.281 &#x000b5;M; 95% CI = &#x02212;5.074, 2.512), but there was an AcAc decrease by 11% compared with baseline after the last dose (F<sub>1, 902.181</sub> = 9.049, <em>p</em> = 0.003; MD = &#x02212;5.573 &#x000b5;M; 95% CI = &#x02212;9.210, &#x02212;1.937). Moreover, the first empagliflozin dose reduced the ratio AcAc/BHB by 16% (on average over 34 h) compared with baseline (F<sub>1, 901.067</sub> = 62.430, <em>p</em> &#x0003c; 0.001; MD = &#x02212;0.036, 95% CI = &#x02212;0.045, &#x02212;0.027), and the last dose reduced it by 23% compared with baseline (F<sub>1, 878.674</sub> = 133.526, <em>p</em> &#x0003c; 0.001; MD = &#x02212;0.054, 95% CI = &#x02212;0.063, &#x02212;0.045).</p><p>The first empagliflozin dose decreased plasma glucose by 2% (on average over 34 h) compared with baseline (F<sub>1, 902.217</sub> = 3.940, <em>p</em> = 0.047; MD = &#x02212;2.011 mg/dL, 95% CI = &#x02212;4.000, &#x02212;0.023). A significant interaction between Visit and Sex (F<sub>1, 902.217</sub> = 6.704, <em>p</em> = 0.010) revealed that glucose decreased in men (F<sub>1, 902</sub> = 10.461, <em>p</em> &#x0003c; 0.001), but remained unchanged in women (F<sub>1, 902</sub> = 0.188, <em>p</em> = 0.664). Glucose values following the last drug administration were not different (on average over 34 h) compared with baseline (F<sub>1, 884.229</sub> = 0.367, <em>p</em> = 0.545; MD = &#x02212;0.637 mg/dL, 95% CI = &#x02212;2.699, 1.426). In addition, continuous glucose monitoring confirmed that glucose levels while participants were taking empagliflozin at home were similar to baseline levels (F<sub>1, 404</sub> = 0.148, <em>p</em> = 0.700). Sensitivity analysis after excluding participants with missing data yielded a similar result (F<sub>1, 345</sub> = 0.485, <em>p</em> = 0.486).</p><p>Regarding insulin, the first empagliflozin dose induced a 15% decrease (on average over 34 h) compared with baseline (F<sub>1, 902.122</sub> = 6.530, <em>p</em> = 0.011; MD = &#x02212;3.307 mIU/L, 95% CI = &#x02212;5.846, &#x02212;0.767). The last dose decreased insulin by 12% (on average over 34 h) compared with baseline (F<sub>1, 880.870</sub> = 3.970, <em>p</em> = 0.047; MD = &#x02212;2.647 mIU/L; 95% CI = &#x02212;5.255, &#x02212;0.040).</p><p>The first empagliflozin dose increased glucagon levels by 12% (on average over 34 h) compared with baseline (F<sub>1, 381</sub> = 7.900, <em>p</em> = 0.005; MD = 19.572 ng/L, 95% CI = 5.880, 33.263). There was an interaction between Visit and Sex (F<sub>1, 381</sub> = 4.542, <em>p</em> = 0.034) showing a significant elevation in men (F<sub>1, 381</sub> = 27.476, <em>p</em> &#x0003c; 0.001), but not women (F<sub>1, 381</sub> = 0.148, <em>p</em> = 0.700). Similarly, the last dose increased glucagon by 16% (on average over 34 h) compared with baseline (F<sub>1, 374.045</sub> = 10.636, <em>p</em> = 0.001; MD = 25.416 ng/L; 95% CI = 10.092, 40.741). An interaction between Visit and Sex was also found after the last dose (F<sub>1, 374.045</sub> = 14.925, <em>p</em> &#x0003c; 0.001), showing that glucagon increased in men (F<sub>1, 374</sub> = 61.711, <em>p</em> &#x0003c; 0.001), but did not change in women (F<sub>1, 374</sub> = 0.114, <em>p</em> = 0.736).</p><p class="p p-last">The first empagliflozin dose resulted in increased NEFAs by 12% (on average over 34 h) compared with baseline (F<sub>1, 902.094</sub> = 15.986, <em>p</em> &#x0003c; 0.001; MD = 0.035 mEq/L, 95% CI = 0.018, 0.053). Similarly, the last dose increased NEFAs by 9% (on average over 34 h) compared with baseline (F<sub>1, 880.629</sub> = 8.782, <em>p</em> = 0.003; MD = 0.027 mEq/L; 95% CI = 0.009, 0.044).</p></div><div id="sec3dot2dot2-cells-11-03372" class="sec"><p></p><h4 id="sec3dot2dot2-cells-11-03372title" class="inline">3.2.2. Empagliflozin Acutely Upregulated IGF-1/Insulin Cascade-Associated Proteins in Plasma-Derived NEVs, but Not in TEVs </h4><p class="p p-first">Cryo-TEM pictures of NEV preparations demonstrate multiple examples of small and medium size EVs with typical morphology (single membranous nanoparticles) and size distribution. These pictures are highly consistent with the isolation of a mixed population of exosomes and microvesicles (<a href="#app1-cells-11-03372" rid="app1-cells-11-03372" class=" app">Supplemental Figure S1</a>; scale bars included for reference).</p><p><a href="/pmc/articles/PMC9657243/figure/cells-11-03372-f003/" target="figure" class="fig-table-link figpopup" rid-figpopup="cells-11-03372-f003" rid-ob="ob-cells-11-03372-f003" co-legend-rid="lgnd_cells-11-03372-f003"><span>Figure 3</span></a> and <a href="/pmc/articles/PMC9657243/table/cells-11-03372-t003/" target="table" class="fig-table-link figpopup" rid-figpopup="cells-11-03372-t003" rid-ob="ob-cells-11-03372-t003" co-legend-rid=""><span>Table 3</span></a> show phosphorylated levels of IGF-1/insulin cascade mediators measured in TEVs and NEVs at visit 1 (t<sub>o</sub>), visit 2 (t<sub>24</sub>), and visit 3 (t<sub>24</sub>). No changes of pIGF-1R levels were identified in TEVs after the first or last empagliflozin doses compared with baseline. However, levels of pIGF-1R in NEVs significantly increased after the first empagliflozin dose compared with baseline (F <sub>1, 18</sub> = 7.706, <em>p</em> = 0.012; MD = 0.247; 95% CI = 0.075, 0.419). In addition, there was a significant interaction between Visit and BMI (F<sub>1, 18</sub> = 9.482, <em>p</em> = 0.06), with lower-than-mean BMI being associated with no change in NEV pIGF-1R levels (F<sub>1, 18</sub> = 0.013, <em>p</em> = 0.911), mean BMI being associated with NEVs pIGF-1R increase (F<sub>1, 18</sub> = 9.076, <em>p</em> = 0.007), and higher-than-mean BMI being associated with a sharper NEV pIGF-1R increase (F<sub>1, 18</sub> = 18.381, <em>p</em> &#x0003c; 0.001). After the last dose, NEV pIGF-1R levels were similar to baseline (F<sub>1, 17.267</sub> = 3.342, <em>p</em> = 0.085; MD = 0.229; 95% CI = 0.023, 0.434).</p><!--fig ft0--><!--fig mode=article f1--><div class="fig iconblock whole_rhythm" id="cells-11-03372-f003" co-legend-rid="lgnd_cells-11-03372-f003"><a href="/pmc/articles/PMC9657243/figure/cells-11-03372-f003/" target="figure" rid-figpopup="cells-11-03372-f003" rid-ob="ob-cells-11-03372-f003"><!--fig/graphic|fig/alternatives/graphic mode="anchored" m1--><div class="figure" data-largeobj="" data-largeobj-link-rid="largeobj_idm140106934935648"><a class="inline_block ts_canvas" href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=9657243_cells-11-03372-g003.jpg" target="tileshopwindow" rel="noopener"><div class="ts_bar small" title="Click on image to zoom"></div><img loading="lazy" alt="An external file that holds a picture, illustration, etc.&#10;Object name is cells-11-03372-g003.jpg" title="Click on image to zoom" class="tileshop" src="/pmc/articles/PMC9657243/bin/cells-11-03372-g003.jpg" /></a></div><div class="largeobj-link align_right" id="largeobj_idm140106934935648"><a target="object" rel="noopener" href="/pmc/articles/PMC9657243/figure/cells-11-03372-f003/?report=objectonly">Open in a separate window</a></div></a><div class="icnblk_cntnt" id="lgnd_cells-11-03372-f003"><div><a class="figpopup" href="/pmc/articles/PMC9657243/figure/cells-11-03372-f003/" target="figure" rid-figpopup="cells-11-03372-f003" rid-ob="ob-cells-11-03372-f003">Figure 3</a></div><!--caption a7--><div class="caption"><p>(<strong>a</strong>). means (SE) of phosphorylated (<em>p</em>) and total (t) levels of IGF-1/insulin cascade-associated proteins measured in extracellular vesicles enriched for neuronal origin (NEVs) at baseline (visit 1 t<sub>0</sub> (V1)), 24 h after the first dose (visit 2 t<sub>24</sub> (V2)), and 24 h after the last dose (visit 3 t<sub>24</sub> (V3)). Statistical analysis involved repeated-measures linear mixed models with &#x0201c;Visit&#x0201d; as the repeated-measures variable and additional variables as factors and covariates (see <a href="#sec2dot9-cells-11-03372" rid="sec2dot9-cells-11-03372" class=" sec">Section 2.9</a> for details). Significance is indicated as *, corresponding to <em>p</em> &#x02264; 0.05. (<strong>b</strong>). IGF-1/insulin signaling in neurons reflecting acute biomarker changes detected in NEVs. Significant increases are marked with * [<a href="#B17-cells-11-03372" rid="B17-cells-11-03372" class=" bibr popnode">17</a>].</p></div></div></div><!--table ft1--><!--table-wrap mode="anchored" t5--><div class="table-wrap anchored whole_rhythm" id="cells-11-03372-t003"><h3>Table 3</h3><!--caption a7--><div class="caption"><p>IGF-1/insulin cascade-associated proteins measured in total EVs (TEVs) and EVs enriched for neuronal origin (NEVs) at baseline (V1), after one dose (V2), and after multiple (V3) empagliflozin doses.</p></div><div class="xtable"><table frame="hsides" rules="groups" class="rendered small default_table"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
</th><th colspan="4" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">Type III Tests of Fixed Effects</th><th colspan="6" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">Pairwise Comparisons (Least Significant Difference)</th></tr><tr><th rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Biomarker</th><th rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Type of Exosomes</th><th rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Dosing</th><th rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Num df</th><th rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Den <br />df</th><th rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">F</th><th rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Sig.</th><th rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Mean Difference </th><th rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Std. Error</th><th rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">df</th><th rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Sig.</th><th colspan="2" align="center" valign="middle" rowspan="1">95% Confidence Interval</th></tr><tr><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Lower Bound</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Upper Bound</th></tr></thead><tbody><tr><td rowspan="4" align="center" valign="middle" colspan="1">pIGF-1R</td><td rowspan="2" align="center" valign="middle" colspan="1">TEVs</td><td align="center" valign="middle" rowspan="1" colspan="1">V2 vs. V1</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">18.000</td><td align="center" valign="middle" rowspan="1" colspan="1">0.410</td><td align="center" valign="middle" rowspan="1" colspan="1">0.530</td><td align="center" valign="middle" rowspan="1" colspan="1">0.429</td><td align="center" valign="middle" rowspan="1" colspan="1">0.164</td><td align="center" valign="middle" rowspan="1" colspan="1">18.000</td><td align="center" valign="middle" rowspan="1" colspan="1">
<strong>0.018</strong>
</td><td align="center" valign="middle" rowspan="1" colspan="1">0.084</td><td align="center" valign="middle" rowspan="1" colspan="1">0.773</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">V3 vs. V1 </td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">18.711</td><td align="center" valign="middle" rowspan="1" colspan="1">0.583</td><td align="center" valign="middle" rowspan="1" colspan="1">0.455</td><td align="center" valign="middle" rowspan="1" colspan="1">0.263</td><td align="center" valign="middle" rowspan="1" colspan="1">0.236</td><td align="center" valign="middle" rowspan="1" colspan="1">17.820</td><td align="center" valign="middle" rowspan="1" colspan="1">0.278</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;0.232</td><td align="center" valign="middle" rowspan="1" colspan="1">0.759</td></tr><tr><td rowspan="2" align="center" valign="middle" colspan="1">NEVs</td><td align="center" valign="middle" rowspan="1" colspan="1">V2 vs. V1</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">18.000</td><td align="center" valign="middle" rowspan="1" colspan="1">7.706</td><td align="center" valign="middle" rowspan="1" colspan="1">
<strong>0.012</strong>
</td><td align="center" valign="middle" rowspan="1" colspan="1">0.247</td><td align="center" valign="middle" rowspan="1" colspan="1">0.082</td><td align="center" valign="middle" rowspan="1" colspan="1">18.000</td><td align="center" valign="middle" rowspan="1" colspan="1">
<strong>0.007</strong>
</td><td align="center" valign="middle" rowspan="1" colspan="1">0.075</td><td align="center" valign="middle" rowspan="1" colspan="1">0.419</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">V3 vs. V1 </td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">17.267</td><td align="center" valign="middle" rowspan="1" colspan="1">3.342</td><td align="center" valign="middle" rowspan="1" colspan="1">0.085</td><td align="center" valign="middle" rowspan="1" colspan="1">0.229</td><td align="center" valign="middle" rowspan="1" colspan="1">0.098</td><td align="center" valign="middle" rowspan="1" colspan="1">18.087</td><td align="center" valign="middle" rowspan="1" colspan="1">
<strong>0.031</strong>
</td><td align="center" valign="middle" rowspan="1" colspan="1">0.023</td><td align="center" valign="middle" rowspan="1" colspan="1">0.434</td></tr><tr><td rowspan="4" align="center" valign="middle" colspan="1">pIR</td><td rowspan="2" align="center" valign="middle" colspan="1">TEVs</td><td align="center" valign="middle" rowspan="1" colspan="1">V2 vs. V1</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">18.000</td><td align="center" valign="middle" rowspan="1" colspan="1">0.469</td><td align="center" valign="middle" rowspan="1" colspan="1">0.502</td><td align="center" valign="middle" rowspan="1" colspan="1">0.088</td><td align="center" valign="middle" rowspan="1" colspan="1">0.163</td><td align="center" valign="middle" rowspan="1" colspan="1">18.000</td><td align="center" valign="middle" rowspan="1" colspan="1">0.595</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;0.254</td><td align="center" valign="middle" rowspan="1" colspan="1">0.430</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">V3 vs. V1 </td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">17.896</td><td align="center" valign="middle" rowspan="1" colspan="1">0.094</td><td align="center" valign="middle" rowspan="1" colspan="1">0.763</td><td align="center" valign="middle" rowspan="1" colspan="1">0.016</td><td align="center" valign="middle" rowspan="1" colspan="1">0.149</td><td align="center" valign="middle" rowspan="1" colspan="1">17.772</td><td align="center" valign="middle" rowspan="1" colspan="1">0.913</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;0.296</td><td align="center" valign="middle" rowspan="1" colspan="1">0.329</td></tr><tr><td rowspan="2" align="center" valign="middle" colspan="1">NEVs</td><td align="center" valign="middle" rowspan="1" colspan="1">V2 vs. V1</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">18.000</td><td align="center" valign="middle" rowspan="1" colspan="1">7.905</td><td align="center" valign="middle" rowspan="1" colspan="1">
<strong>0.012</strong>
</td><td align="center" valign="middle" rowspan="1" colspan="1">0.196</td><td align="center" valign="middle" rowspan="1" colspan="1">0.076</td><td align="center" valign="middle" rowspan="1" colspan="1">18.000</td><td align="center" valign="middle" rowspan="1" colspan="1">
<strong>0.019</strong>
</td><td align="center" valign="middle" rowspan="1" colspan="1">0.036</td><td align="center" valign="middle" rowspan="1" colspan="1">0.357</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">V3 vs. V1 </td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">17.465</td><td align="center" valign="middle" rowspan="1" colspan="1">1.151</td><td align="center" valign="middle" rowspan="1" colspan="1">0.298</td><td align="center" valign="middle" rowspan="1" colspan="1">0.120</td><td align="center" valign="middle" rowspan="1" colspan="1">0.136</td><td align="center" valign="middle" rowspan="1" colspan="1">17.820</td><td align="center" valign="middle" rowspan="1" colspan="1">0.391</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;0.167</td><td align="center" valign="middle" rowspan="1" colspan="1">0.406</td></tr><tr><td rowspan="4" align="center" valign="middle" colspan="1">pSer-<br />IRS-1</td><td rowspan="2" align="center" valign="middle" colspan="1">TEVs</td><td align="center" valign="middle" rowspan="1" colspan="1">V2 vs. V1</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">18.000</td><td align="center" valign="middle" rowspan="1" colspan="1">0.515</td><td align="center" valign="middle" rowspan="1" colspan="1">0.482</td><td align="center" valign="middle" rowspan="1" colspan="1">0.066</td><td align="center" valign="middle" rowspan="1" colspan="1">0.107</td><td align="center" valign="middle" rowspan="1" colspan="1">18.000</td><td align="center" valign="middle" rowspan="1" colspan="1">0.545</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;0.159</td><td align="center" valign="middle" rowspan="1" colspan="1">0.290</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">V3 vs. V1 </td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">17.302</td><td align="center" valign="middle" rowspan="1" colspan="1">0.378</td><td align="center" valign="middle" rowspan="1" colspan="1">0.547</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;0.059</td><td align="center" valign="middle" rowspan="1" colspan="1">0.086</td><td align="center" valign="middle" rowspan="1" colspan="1">17.942</td><td align="center" valign="middle" rowspan="1" colspan="1">0.498</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;0.240</td><td align="center" valign="middle" rowspan="1" colspan="1">0.121</td></tr><tr><td rowspan="2" align="center" valign="middle" colspan="1">NEVs</td><td align="center" valign="middle" rowspan="1" colspan="1">V2 vs. V1</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">18.000</td><td align="center" valign="middle" rowspan="1" colspan="1">0.004</td><td align="center" valign="middle" rowspan="1" colspan="1">0.948</td><td align="center" valign="middle" rowspan="1" colspan="1">0.117</td><td align="center" valign="middle" rowspan="1" colspan="1">0.098</td><td align="center" valign="middle" rowspan="1" colspan="1">18.000</td><td align="center" valign="middle" rowspan="1" colspan="1">0.245</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;0.088</td><td align="center" valign="middle" rowspan="1" colspan="1">0.322</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">V3 vs. V1 </td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">17.500</td><td align="center" valign="middle" rowspan="1" colspan="1">3.100</td><td align="center" valign="middle" rowspan="1" colspan="1">0.096</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;0.081</td><td align="center" valign="middle" rowspan="1" colspan="1">0.116</td><td align="center" valign="middle" rowspan="1" colspan="1">17.704</td><td align="center" valign="middle" rowspan="1" colspan="1">0.493</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;0.325</td><td align="center" valign="middle" rowspan="1" colspan="1">0.163</td></tr><tr><td rowspan="4" align="center" valign="middle" colspan="1">pY-IRS-1</td><td rowspan="2" align="center" valign="middle" colspan="1">TEVs</td><td align="center" valign="middle" rowspan="1" colspan="1">V2 vs. V1</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">18.000</td><td align="center" valign="middle" rowspan="1" colspan="1">0.175</td><td align="center" valign="middle" rowspan="1" colspan="1">0.681</td><td align="center" valign="middle" rowspan="1" colspan="1">0.025</td><td align="center" valign="middle" rowspan="1" colspan="1">0.130</td><td align="center" valign="middle" rowspan="1" colspan="1">18.000</td><td align="center" valign="middle" rowspan="1" colspan="1">0.848</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;0.249</td><td align="center" valign="middle" rowspan="1" colspan="1">0.299</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">V3 vs. V1 </td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">17.832</td><td align="center" valign="middle" rowspan="1" colspan="1">0.199</td><td align="center" valign="middle" rowspan="1" colspan="1">0.661</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;0.071</td><td align="center" valign="middle" rowspan="1" colspan="1">0.126</td><td align="center" valign="middle" rowspan="1" colspan="1">17.833</td><td align="center" valign="middle" rowspan="1" colspan="1">0.578</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;0.335</td><td align="center" valign="middle" rowspan="1" colspan="1">0.193</td></tr><tr><td rowspan="2" align="center" valign="middle" colspan="1">NEVs</td><td align="center" valign="middle" rowspan="1" colspan="1">V2 vs. V1</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">18.000</td><td align="center" valign="middle" rowspan="1" colspan="1">9.934</td><td align="center" valign="middle" rowspan="1" colspan="1">
<strong>0.006</strong>
</td><td align="center" valign="middle" rowspan="1" colspan="1">0.174</td><td align="center" valign="middle" rowspan="1" colspan="1">0.052</td><td align="center" valign="middle" rowspan="1" colspan="1">18.000</td><td align="center" valign="middle" rowspan="1" colspan="1">
<strong>0.004</strong>
</td><td align="center" valign="middle" rowspan="1" colspan="1">0.065</td><td align="center" valign="middle" rowspan="1" colspan="1">0.284</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">V3 vs. V1 </td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">17.235</td><td align="center" valign="middle" rowspan="1" colspan="1">0.832</td><td align="center" valign="middle" rowspan="1" colspan="1">0.374</td><td align="center" valign="middle" rowspan="1" colspan="1">0.140</td><td align="center" valign="middle" rowspan="1" colspan="1">0.087</td><td align="center" valign="middle" rowspan="1" colspan="1">17.916</td><td align="center" valign="middle" rowspan="1" colspan="1">0.125</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;0.043</td><td align="center" valign="middle" rowspan="1" colspan="1">0.323</td></tr><tr><td rowspan="4" align="center" valign="middle" colspan="1">(pSer-IRS-1)/<br />(pY-IRS-1)</td><td rowspan="2" align="center" valign="middle" colspan="1">TEVs</td><td align="center" valign="middle" rowspan="1" colspan="1">V2 vs. V1</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">18.000</td><td align="center" valign="middle" rowspan="1" colspan="1">0.060</td><td align="center" valign="middle" rowspan="1" colspan="1">0.809</td><td align="center" valign="middle" rowspan="1" colspan="1">0.040</td><td align="center" valign="middle" rowspan="1" colspan="1">0.090</td><td align="center" valign="middle" rowspan="1" colspan="1">18.000</td><td align="center" valign="middle" rowspan="1" colspan="1">0.659</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;0.149</td><td align="center" valign="middle" rowspan="1" colspan="1">0.230</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">V3 vs. V1 </td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">17.737</td><td align="center" valign="middle" rowspan="1" colspan="1">0.000</td><td align="center" valign="middle" rowspan="1" colspan="1">0.997</td><td align="center" valign="middle" rowspan="1" colspan="1">0.010</td><td align="center" valign="middle" rowspan="1" colspan="1">0.109</td><td align="center" valign="middle" rowspan="1" colspan="1">17.671</td><td align="center" valign="middle" rowspan="1" colspan="1">0.930</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;0.219</td><td align="center" valign="middle" rowspan="1" colspan="1">0.238</td></tr><tr><td rowspan="2" align="center" valign="middle" colspan="1">NEVs</td><td align="center" valign="middle" rowspan="1" colspan="1">V2 vs. V1</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">18.000</td><td align="center" valign="middle" rowspan="1" colspan="1">2.200</td><td align="center" valign="middle" rowspan="1" colspan="1">0.155</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;0.057</td><td align="center" valign="middle" rowspan="1" colspan="1">0.115</td><td align="center" valign="middle" rowspan="1" colspan="1">18.000</td><td align="center" valign="middle" rowspan="1" colspan="1">0.627</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;0.299</td><td align="center" valign="middle" rowspan="1" colspan="1">0.185</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">V3 vs. V1 </td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">17.375</td><td align="center" valign="middle" rowspan="1" colspan="1">6.732</td><td align="center" valign="middle" rowspan="1" colspan="1">
<strong>0.019</strong>
</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;0.222</td><td align="center" valign="middle" rowspan="1" colspan="1">0.111</td><td align="center" valign="middle" rowspan="1" colspan="1">17.316</td><td align="center" valign="middle" rowspan="1" colspan="1">0.062</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;0.456</td><td align="center" valign="middle" rowspan="1" colspan="1">0.013</td></tr><tr><td rowspan="4" align="center" valign="middle" colspan="1">pERK-1/2</td><td rowspan="2" align="center" valign="middle" colspan="1">TEVs</td><td align="center" valign="middle" rowspan="1" colspan="1">V2 vs. V1</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">18.000</td><td align="center" valign="middle" rowspan="1" colspan="1">0.591</td><td align="center" valign="middle" rowspan="1" colspan="1">0.452</td><td align="center" valign="middle" rowspan="1" colspan="1">0.294</td><td align="center" valign="middle" rowspan="1" colspan="1">0.117</td><td align="center" valign="middle" rowspan="1" colspan="1">18.000</td><td align="center" valign="middle" rowspan="1" colspan="1">
<strong>0.022</strong>
</td><td align="center" valign="middle" rowspan="1" colspan="1">0.048</td><td align="center" valign="middle" rowspan="1" colspan="1">0.540</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">V3 vs. V1 </td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">18.147</td><td align="center" valign="middle" rowspan="1" colspan="1">1.184</td><td align="center" valign="middle" rowspan="1" colspan="1">0.291</td><td align="center" valign="middle" rowspan="1" colspan="1">0.090</td><td align="center" valign="middle" rowspan="1" colspan="1">0.124</td><td align="center" valign="middle" rowspan="1" colspan="1">17.552</td><td align="center" valign="middle" rowspan="1" colspan="1">0.477</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;0.171</td><td align="center" valign="middle" rowspan="1" colspan="1">0.352</td></tr><tr><td rowspan="2" align="center" valign="middle" colspan="1">NEVs</td><td align="center" valign="middle" rowspan="1" colspan="1">V2 vs. V1</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">18.000</td><td align="center" valign="middle" rowspan="1" colspan="1">0.481</td><td align="center" valign="middle" rowspan="1" colspan="1">0.497</td><td align="center" valign="middle" rowspan="1" colspan="1">0.082</td><td align="center" valign="middle" rowspan="1" colspan="1">0.085</td><td align="center" valign="middle" rowspan="1" colspan="1">18.000</td><td align="center" valign="middle" rowspan="1" colspan="1">0.351</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;0.098</td><td align="center" valign="middle" rowspan="1" colspan="1">0.261</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">V3 vs. V1 </td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">17.039</td><td align="center" valign="middle" rowspan="1" colspan="1">4.284</td><td align="center" valign="middle" rowspan="1" colspan="1">0.054</td><td align="center" valign="middle" rowspan="1" colspan="1">0.062</td><td align="center" valign="middle" rowspan="1" colspan="1">0.072</td><td align="center" valign="middle" rowspan="1" colspan="1">17.098</td><td align="center" valign="middle" rowspan="1" colspan="1">0.403</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;0.090</td><td align="center" valign="middle" rowspan="1" colspan="1">0.213</td></tr><tr><td rowspan="4" align="center" valign="middle" colspan="1">pJNK</td><td rowspan="2" align="center" valign="middle" colspan="1">TEVs</td><td align="center" valign="middle" rowspan="1" colspan="1">V2 vs. V1</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">18.000</td><td align="center" valign="middle" rowspan="1" colspan="1">0.777</td><td align="center" valign="middle" rowspan="1" colspan="1">0.390</td><td align="center" valign="middle" rowspan="1" colspan="1">0.228</td><td align="center" valign="middle" rowspan="1" colspan="1">0.119</td><td align="center" valign="middle" rowspan="1" colspan="1">18.000</td><td align="center" valign="middle" rowspan="1" colspan="1">0.071</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;0.022</td><td align="center" valign="middle" rowspan="1" colspan="1">0.477</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">V3 vs. V1 </td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">18.956</td><td align="center" valign="middle" rowspan="1" colspan="1">0.579</td><td align="center" valign="middle" rowspan="1" colspan="1">0.456</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;0.012</td><td align="center" valign="middle" rowspan="1" colspan="1">0.120</td><td align="center" valign="middle" rowspan="1" colspan="1">18.009</td><td align="center" valign="middle" rowspan="1" colspan="1">0.922</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;0.265</td><td align="center" valign="middle" rowspan="1" colspan="1">0.241</td></tr><tr><td rowspan="2" align="center" valign="middle" colspan="1">NEVs</td><td align="center" valign="middle" rowspan="1" colspan="1">V2 vs. V1</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">18.000</td><td align="center" valign="middle" rowspan="1" colspan="1">0.147</td><td align="center" valign="middle" rowspan="1" colspan="1">0.706</td><td align="center" valign="middle" rowspan="1" colspan="1">0.015</td><td align="center" valign="middle" rowspan="1" colspan="1">0.128</td><td align="center" valign="middle" rowspan="1" colspan="1">18.000</td><td align="center" valign="middle" rowspan="1" colspan="1">0.908</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;0.254</td><td align="center" valign="middle" rowspan="1" colspan="1">0.284</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">V3 vs. V1 </td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">17.554</td><td align="center" valign="middle" rowspan="1" colspan="1">6.694</td><td align="center" valign="middle" rowspan="1" colspan="1">
<strong>0.019</strong>
</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;0.023</td><td align="center" valign="middle" rowspan="1" colspan="1">0.111</td><td align="center" valign="middle" rowspan="1" colspan="1">16.921</td><td align="center" valign="middle" rowspan="1" colspan="1">0.837</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;0.257</td><td align="center" valign="middle" rowspan="1" colspan="1">0.211</td></tr><tr><td rowspan="4" align="center" valign="middle" colspan="1">pAKT</td><td rowspan="2" align="center" valign="middle" colspan="1">TEVs</td><td align="center" valign="middle" rowspan="1" colspan="1">V2 vs. V1</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">18.000</td><td align="center" valign="middle" rowspan="1" colspan="1">0.317</td><td align="center" valign="middle" rowspan="1" colspan="1">0.580</td><td align="center" valign="middle" rowspan="1" colspan="1">0.061</td><td align="center" valign="middle" rowspan="1" colspan="1">0.088</td><td align="center" valign="middle" rowspan="1" colspan="1">18.000</td><td align="center" valign="middle" rowspan="1" colspan="1">0.496</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;0.123</td><td align="center" valign="middle" rowspan="1" colspan="1">0.245</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">V3 vs. V1 </td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">17.816</td><td align="center" valign="middle" rowspan="1" colspan="1">0.892</td><td align="center" valign="middle" rowspan="1" colspan="1">0.357</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;0.029</td><td align="center" valign="middle" rowspan="1" colspan="1">0.098</td><td align="center" valign="middle" rowspan="1" colspan="1">17.675</td><td align="center" valign="middle" rowspan="1" colspan="1">0.772</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;0.235</td><td align="center" valign="middle" rowspan="1" colspan="1">0.177</td></tr><tr><td rowspan="2" align="center" valign="middle" colspan="1">NEVs</td><td align="center" valign="middle" rowspan="1" colspan="1">V2 vs. V1</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">18.000</td><td align="center" valign="middle" rowspan="1" colspan="1">5.650</td><td align="center" valign="middle" rowspan="1" colspan="1">
<strong>0.029</strong>
</td><td align="center" valign="middle" rowspan="1" colspan="1">0.154 </td><td align="center" valign="middle" rowspan="1" colspan="1">0.055</td><td align="center" valign="middle" rowspan="1" colspan="1">18.000</td><td align="center" valign="middle" rowspan="1" colspan="1">
<strong>0.011</strong>
</td><td align="center" valign="middle" rowspan="1" colspan="1">0.039</td><td align="center" valign="middle" rowspan="1" colspan="1">0.269</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">V3 vs. V1 </td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">17.403</td><td align="center" valign="middle" rowspan="1" colspan="1">0.105</td><td align="center" valign="middle" rowspan="1" colspan="1">0.749</td><td align="center" valign="middle" rowspan="1" colspan="1">0.088</td><td align="center" valign="middle" rowspan="1" colspan="1">0.075</td><td align="center" valign="middle" rowspan="1" colspan="1">17.801</td><td align="center" valign="middle" rowspan="1" colspan="1">0.256</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;0.070</td><td align="center" valign="middle" rowspan="1" colspan="1">0.247</td></tr><tr><td rowspan="4" align="center" valign="middle" colspan="1">tAKT</td><td rowspan="2" align="center" valign="middle" colspan="1">TEVs</td><td align="center" valign="middle" rowspan="1" colspan="1">V2 vs. V1</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">18.000</td><td align="center" valign="middle" rowspan="1" colspan="1">0.309</td><td align="center" valign="middle" rowspan="1" colspan="1">0.585</td><td align="center" valign="middle" rowspan="1" colspan="1">0.106</td><td align="center" valign="middle" rowspan="1" colspan="1">0.096</td><td align="center" valign="middle" rowspan="1" colspan="1">18.000</td><td align="center" valign="middle" rowspan="1" colspan="1">0.281</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;0.095</td><td align="center" valign="middle" rowspan="1" colspan="1">0.307</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">V3 vs. V1 </td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">18.670</td><td align="center" valign="middle" rowspan="1" colspan="1">1.126</td><td align="center" valign="middle" rowspan="1" colspan="1">0.302</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;0.021</td><td align="center" valign="middle" rowspan="1" colspan="1">0.117</td><td align="center" valign="middle" rowspan="1" colspan="1">18.023</td><td align="center" valign="middle" rowspan="1" colspan="1">0.857</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;0.267</td><td align="center" valign="middle" rowspan="1" colspan="1">0.225</td></tr><tr><td rowspan="2" align="center" valign="middle" colspan="1">NEVs</td><td align="center" valign="middle" rowspan="1" colspan="1">V2 vs. V1</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">18.000</td><td align="center" valign="middle" rowspan="1" colspan="1">1.385</td><td align="center" valign="middle" rowspan="1" colspan="1">0.255</td><td align="center" valign="middle" rowspan="1" colspan="1">0.089</td><td align="center" valign="middle" rowspan="1" colspan="1">0.064</td><td align="center" valign="middle" rowspan="1" colspan="1">18.000</td><td align="center" valign="middle" rowspan="1" colspan="1">0.177</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;0.044</td><td align="center" valign="middle" rowspan="1" colspan="1">0.223</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">V3 vs. V1 </td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">18.197</td><td align="center" valign="middle" rowspan="1" colspan="1">2.108</td><td align="center" valign="middle" rowspan="1" colspan="1">0.164</td><td align="center" valign="middle" rowspan="1" colspan="1">0.075</td><td align="center" valign="middle" rowspan="1" colspan="1">0.072</td><td align="center" valign="middle" rowspan="1" colspan="1">17.707</td><td align="center" valign="middle" rowspan="1" colspan="1">0.310</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;0.076</td><td align="center" valign="middle" rowspan="1" colspan="1">0.226</td></tr><tr><td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">pp38</td><td rowspan="2" align="center" valign="middle" colspan="1">TEVs</td><td align="center" valign="middle" rowspan="1" colspan="1">V2 vs. V1</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">18.000</td><td align="center" valign="middle" rowspan="1" colspan="1">0.695</td><td align="center" valign="middle" rowspan="1" colspan="1">0.416</td><td align="center" valign="middle" rowspan="1" colspan="1">0.200</td><td align="center" valign="middle" rowspan="1" colspan="1">0.106</td><td align="center" valign="middle" rowspan="1" colspan="1">18.000</td><td align="center" valign="middle" rowspan="1" colspan="1">0.076</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;0.023</td><td align="center" valign="middle" rowspan="1" colspan="1">0.423</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">V3 vs. V1 </td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">17.071</td><td align="center" valign="middle" rowspan="1" colspan="1">0.383</td><td align="center" valign="middle" rowspan="1" colspan="1">0.544</td><td align="center" valign="middle" rowspan="1" colspan="1">0.067</td><td align="center" valign="middle" rowspan="1" colspan="1">0.140</td><td align="center" valign="middle" rowspan="1" colspan="1">17.844</td><td align="center" valign="middle" rowspan="1" colspan="1">0.639</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;0.228</td><td align="center" valign="middle" rowspan="1" colspan="1">0.361</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">NEVs</td><td align="center" valign="middle" rowspan="1" colspan="1">V2 vs. V1</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">18.000</td><td align="center" valign="middle" rowspan="1" colspan="1">0.558</td><td align="center" valign="middle" rowspan="1" colspan="1">0.465</td><td align="center" valign="middle" rowspan="1" colspan="1">0.037</td><td align="center" valign="middle" rowspan="1" colspan="1">0.086</td><td align="center" valign="middle" rowspan="1" colspan="1">18.000</td><td align="center" valign="middle" rowspan="1" colspan="1">0.674</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;0.144</td><td align="center" valign="middle" rowspan="1" colspan="1">0.218</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">V3 vs. V1 </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">15.292</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6.202</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<strong>0.025</strong>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.054</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.064</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">16.699</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.411</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;0.081</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.188</td></tr></tbody></table></div><div class="largeobj-link align_right" id="largeobj_idm140106939860640"><a target="object" rel="noopener" href="/pmc/articles/PMC9657243/table/cells-11-03372-t003/?report=objectonly">Open in a separate window</a></div></div><p>No change in TEV pIR was found after the first or last empagliflozin dose compared with baseline. However, levels of NEV pIR significantly increased after the first empagliflozin dose compared with baseline (F <sub>1, 18</sub> = 7.905, <em>p</em> = 0.012; MD = 0.196; 95% CI = 0.036, 0.357). In addition, there was a significant interaction between Visit and BMI (F<sub>1, 18</sub> = 9.435, <em>p</em> = 0.007) with lower-than-mean BMI being associated with no NEV pIR change (F<sub>1, 18</sub> = 0.177, <em>p</em> = 0.679), mean BMI being associated with an NEV pIR increase (F<sub>1, 18</sub> = 6.582, <em>p</em> = 0.019), and higher-than-mean BMI being associated with a sharper NEV pIR increase (F<sub>1, 18</sub> = 15.778, <em>p</em> &#x0003c; 0.001). After the last dose, NEV pIR levels were similar to baseline (F<sub>1, 17.465</sub> = 1.151, <em>p</em> = 0.298; MD = 1.20; 95% CI = &#x02212;0.167, 0.406).</p><p>No change was found for TEV pY-IRS-1 after the first or last empagliflozin dose. However, the first empagliflozin dose increased NEV pY-IRS-1 (F<sub>1, 18</sub> = 9.934, <em>p</em> = 0.006; MD = 0.174; 95% CI = 0.065, 0.284). In addition, there was a significant interaction between Visit and BMI (F<sub>1, 18</sub> = 12.168, <em>p</em> = 0.003) with lower-than-mean BMI being associated with no NEV pY-IRS-1 change (F<sub>1, 18</sub> = 0.003, <em>p</em> = 0.859), mean BMI being associated with an NEV pY-IRS-1 increase (F<sub>1, 18</sub> = 11.149, <em>p</em> = 0.004), and higher-than-mean BMI being associated with a sharp NEV pY-IRS-1 increase (F<sub>1, 18</sub> = 23.096, <em>p</em> &#x0003c; 0.001). After the last dose, NEV pY-IRS-1 levels were not different compared with baseline (F<sub>1, 17.235</sub> = 0.832, <em>p</em> = 0.374; MD = 0.140; 95% CI = &#x02212;0.043, 0.323).</p><p>No changes were found for pAKT measured in TEVs after the first or last dose, compared with baseline. Levels of pAKT in NEVs significantly increased after the first empagliflozin dose compared with baseline (F <sub>1, 18</sub> = 5.650, <em>p</em> = 0.029; MD = 0.154; 95% CI = 0.039, 0.269). In addition, there was a significant interaction between Visit and BMI (F<sub>1, 18</sub> = 7.075, <em>p</em> = 0.016) with lower-than-mean BMI being associated with no NEV pAKT change (F<sub>1, 18</sub> = 0.003, <em>p</em> = 0.958), mean BMI being associated with an NEV pAKT increase (F<sub>1, 18</sub> = 7.950, <em>p</em> = 0.011), and higher-than-mean BMI being associated with a sharper NEV pAKT increase (F<sub>1, 18</sub> = 14.854, <em>p</em> = 0.001). After the last dose, NEV pAKT levels were not different compared with baseline (F<sub>1, 17.403</sub> = 0.105, <em>p</em> = 0.749; MD = 0.088; 95% CI = &#x02212;0.070, 0.247). However, results regarding pAKT should be interpreted with caution as its CV for internal control exceeded 25%.</p><p class="p p-last">No changes were identified for pSer-IRS-1, tAKT, pJNK, pp38, pERK1/2 in TEVs or NEVs after the first or last empagliflozin dose, compared with baseline.</p></div><div id="sec3dot2dot3-cells-11-03372" class="sec sec-last"><p></p><h4 id="sec3dot2dot3-cells-11-03372title" class="inline">3.2.3. Chronic Empagliflozin Administration Decreased Brain Glutamate and Glutamine Concentrations </h4><p class="p p-first-last"><a href="/pmc/articles/PMC9657243/figure/cells-11-03372-f004/" target="figure" class="fig-table-link figpopup" rid-figpopup="cells-11-03372-f004" rid-ob="ob-cells-11-03372-f004" co-legend-rid="lgnd_cells-11-03372-f004"><span>Figure 4</span></a> and <a href="/pmc/articles/PMC9657243/table/cells-11-03372-t004/" target="table" class="fig-table-link figpopup" rid-figpopup="cells-11-03372-t004" rid-ob="ob-cells-11-03372-t004" co-legend-rid=""><span>Table 4</span></a> show details on water-scaled <sup>1</sup>H MRS metabolite concentrations (mmol/L) over the course of the study. The concentrations of Gln (F<sub>2,34</sub> = 4.15, <em>p</em> = 0.024) and Glu (F<sub>2,35</sub> = 4.82, <em>p</em> = 0.014) decreased over the three visits, as did the combined Glu &#x00026; Gln (or &#x0201c;Glx&#x0201d;) measure (F<sub>2,35</sub> = 7.33, <em>p</em> = 0.002). No other metabolites changed significantly over the course of the study. Post-hoc pairwise comparisons via the least significant difference method (LSD) show a 9% Gln decrease after the last empagliflozin dose compared with baseline (<em>p</em> = 0.036, MD = &#x02212;0.270 mmol/L, 95% CI = &#x02212;0.522, &#x02212;0.0188). A 5% decrease by the last dose was also evident for the combination of Glu and Gln (<em>p</em> = 0.010, MD = &#x02212;0.545 mmol/L, 95% CI = &#x02212;0.951, &#x02212;0.138) but fell short of significance for Glu itself (<em>p</em> = 0.051, MD = &#x02212;0.231 mmol/L, 95% CI = &#x02212;0.462, 0.001). There were no significant pairwise differences between the first dose and baseline.</p><!--fig ft0--><!--fig mode=article f1--><div class="fig iconblock whole_rhythm" id="cells-11-03372-f004" co-legend-rid="lgnd_cells-11-03372-f004"><a href="/pmc/articles/PMC9657243/figure/cells-11-03372-f004/" target="figure" rid-figpopup="cells-11-03372-f004" rid-ob="ob-cells-11-03372-f004"><!--fig/graphic|fig/alternatives/graphic mode="anchored" m1--><div class="figure" data-largeobj="" data-largeobj-link-rid="largeobj_idm140106909706064"><a class="inline_block ts_canvas" href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=9657243_cells-11-03372-g004.jpg" target="tileshopwindow" rel="noopener"><div class="ts_bar small" title="Click on image to zoom"></div><img loading="lazy" alt="An external file that holds a picture, illustration, etc.&#10;Object name is cells-11-03372-g004.jpg" title="Click on image to zoom" class="tileshop" src="/pmc/articles/PMC9657243/bin/cells-11-03372-g004.jpg" /></a></div><div class="largeobj-link align_right" id="largeobj_idm140106909706064"><a target="object" rel="noopener" href="/pmc/articles/PMC9657243/figure/cells-11-03372-f004/?report=objectonly">Open in a separate window</a></div></a><div class="icnblk_cntnt" id="lgnd_cells-11-03372-f004"><div><a class="figpopup" href="/pmc/articles/PMC9657243/figure/cells-11-03372-f004/" target="figure" rid-figpopup="cells-11-03372-f004" rid-ob="ob-cells-11-03372-f004">Figure 4</a></div><!--caption a7--><div class="caption"><p>Select precuneal water-scaled MRS metabolite concentrations (mmol/L) over the three study visits. Standard error bars indicate the water-scaled concentration of Creatine (Cr), Glutamine (Gln), myo-Inositol (Ins), N-acetyl aspartate (NAA), Acetoacetate (AcAc) and beta-hydroxybutyrate (BHB). Statistical analysis involved repeated-measures linear mixed models with &#x0201c;Visit&#x0201d; as the repeated-measures variable and concentration as the dependent variable. Additional factors and covariates are detailed in the Statistical Methods <a href="#sec2dot9-cells-11-03372" rid="sec2dot9-cells-11-03372" class=" sec">Section 2.9</a>. Bars and error bars are shown for baseline (visit 1 t<sub>0</sub> (1)), 24 h after the first dose (visit 2 t<sub>24</sub> (2)), and 24 h after the last dose (visit 3 t<sub>24</sub> (3)). Significant results for the omnibus test across all three visits are indicated by a black horizontal bar above the individual plot, with the <em>p</em>-value above.</p></div></div></div><!--table ft1--><!--table-wrap mode="anchored" t5--><div class="table-wrap anchored whole_rhythm" id="cells-11-03372-t004"><h3>Table 4</h3><!--caption a7--><div class="caption"><p>MRS metabolite reliability measures, descriptive statistics, and omnibus statistical results over the baseline (V1), after one dose (V2), and after multiple (V3) empagliflozin doses.</p></div><div class="xtable"><table frame="hsides" rules="groups" class="rendered small default_table"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Metabolite</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">CRLB%</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Visit 1</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Visit 2</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Visit 3</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">DOF</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">F Value</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1"><em>p</em> Value</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<strong>Glu&#x00026;Gln</strong>
</td><td align="center" valign="middle" rowspan="1" colspan="1">
<strong>5.2 &#x000b1; 0.6</strong>
</td><td align="center" valign="middle" rowspan="1" colspan="1">10.37 &#x000b1; 1.05</td><td align="center" valign="middle" rowspan="1" colspan="1">10.16 &#x000b1; 0.94</td><td align="center" valign="middle" rowspan="1" colspan="1">9.66 &#x000b1; 1.16</td><td align="center" valign="middle" rowspan="1" colspan="1">
<strong>2, 35</strong>
</td><td align="center" valign="middle" rowspan="1" colspan="1">
<strong>7.34</strong>
</td><td align="center" valign="middle" rowspan="1" colspan="1">
<strong>0.002</strong>
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<strong>Glu</strong>
</td><td align="center" valign="middle" rowspan="1" colspan="1">
<strong>5 &#x000b1; 0.5</strong>
</td><td align="center" valign="middle" rowspan="1" colspan="1">7.5 &#x000b1; 0.61</td><td align="center" valign="middle" rowspan="1" colspan="1">7.44 &#x000b1; 0.69</td><td align="center" valign="middle" rowspan="1" colspan="1">7.19 &#x000b1; 0.72</td><td align="center" valign="middle" rowspan="1" colspan="1">
<strong>2, 35</strong>
</td><td align="center" valign="middle" rowspan="1" colspan="1">
<strong>4.82</strong>
</td><td align="center" valign="middle" rowspan="1" colspan="1">
<strong>0.014</strong>
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<strong>Gln</strong>
</td><td align="center" valign="middle" rowspan="1" colspan="1">
<strong>14.5 &#x000b1; 1.9</strong>
</td><td align="center" valign="middle" rowspan="1" colspan="1">2.87 &#x000b1; 0.6</td><td align="center" valign="middle" rowspan="1" colspan="1">2.72 &#x000b1; 0.39</td><td align="center" valign="middle" rowspan="1" colspan="1">2.53 &#x000b1; 0.52</td><td align="center" valign="middle" rowspan="1" colspan="1">
<strong>2, 34</strong>
</td><td align="center" valign="middle" rowspan="1" colspan="1">
<strong>4.15</strong>
</td><td align="center" valign="middle" rowspan="1" colspan="1">
<strong>0.024</strong>
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">AcAc</td><td align="center" valign="middle" rowspan="1" colspan="1">32.3 &#x000b1; 12.1</td><td align="center" valign="middle" rowspan="1" colspan="1">1.23 &#x000b1; 0.15</td><td align="center" valign="middle" rowspan="1" colspan="1">1.16 &#x000b1; 0.1</td><td align="center" valign="middle" rowspan="1" colspan="1">1.25 &#x000b1; 0.14</td><td align="center" valign="middle" rowspan="1" colspan="1">2, 34</td><td align="center" valign="middle" rowspan="1" colspan="1">1.79</td><td align="center" valign="middle" rowspan="1" colspan="1">0.289</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">PCr</td><td align="center" valign="middle" rowspan="1" colspan="1">8.2 &#x000b1; 1.3</td><td align="center" valign="middle" rowspan="1" colspan="1">0.18 &#x000b1; 0.07</td><td align="center" valign="middle" rowspan="1" colspan="1">0.16 &#x000b1; 0.04</td><td align="center" valign="middle" rowspan="1" colspan="1">0.16 &#x000b1; 0.06</td><td align="center" valign="middle" rowspan="1" colspan="1">2, 35</td><td align="center" valign="middle" rowspan="1" colspan="1">1.29</td><td align="center" valign="middle" rowspan="1" colspan="1">0.583</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">BHB</td><td align="center" valign="middle" rowspan="1" colspan="1">38 &#x000b1; 14.1</td><td align="center" valign="middle" rowspan="1" colspan="1">2.69 &#x000b1; 0.33</td><td align="center" valign="middle" rowspan="1" colspan="1">2.65 &#x000b1; 0.35</td><td align="center" valign="middle" rowspan="1" colspan="1">2.61 &#x000b1; 0.34</td><td align="center" valign="middle" rowspan="1" colspan="1">2, 33</td><td align="center" valign="middle" rowspan="1" colspan="1">0.55</td><td align="center" valign="middle" rowspan="1" colspan="1">0.585</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">GSH</td><td align="center" valign="middle" rowspan="1" colspan="1">11.3 &#x000b1; 1.7</td><td align="center" valign="middle" rowspan="1" colspan="1">0.35 &#x000b1; 0.1</td><td align="center" valign="middle" rowspan="1" colspan="1">0.36 &#x000b1; 0.1</td><td align="center" valign="middle" rowspan="1" colspan="1">0.36 &#x000b1; 0.14</td><td align="center" valign="middle" rowspan="1" colspan="1">2, 33</td><td align="center" valign="middle" rowspan="1" colspan="1">0.55</td><td align="center" valign="middle" rowspan="1" colspan="1">0.739</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">NAA</td><td align="center" valign="middle" rowspan="1" colspan="1">2.2 &#x000b1; 0.4</td><td align="center" valign="middle" rowspan="1" colspan="1">1.17 &#x000b1; 0.16</td><td align="center" valign="middle" rowspan="1" colspan="1">1.17 &#x000b1; 0.19</td><td align="center" valign="middle" rowspan="1" colspan="1">1.14 &#x000b1; 0.18</td><td align="center" valign="middle" rowspan="1" colspan="1">2, 35</td><td align="center" valign="middle" rowspan="1" colspan="1">0.31</td><td align="center" valign="middle" rowspan="1" colspan="1">0.777</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Ins</td><td align="center" valign="middle" rowspan="1" colspan="1">3.9 &#x000b1; 0.4</td><td align="center" valign="middle" rowspan="1" colspan="1">6.96 &#x000b1; 0.59</td><td align="center" valign="middle" rowspan="1" colspan="1">6.95 &#x000b1; 0.38</td><td align="center" valign="middle" rowspan="1" colspan="1">6.87 &#x000b1; 0.6</td><td align="center" valign="middle" rowspan="1" colspan="1">2, 35</td><td align="center" valign="middle" rowspan="1" colspan="1">0.25</td><td align="center" valign="middle" rowspan="1" colspan="1">0.847</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">GPC</td><td align="center" valign="middle" rowspan="1" colspan="1">3.3 &#x000b1; 1.7</td><td align="center" valign="middle" rowspan="1" colspan="1">4.14 &#x000b1; 0.42</td><td align="center" valign="middle" rowspan="1" colspan="1">4.09 &#x000b1; 0.44</td><td align="center" valign="middle" rowspan="1" colspan="1">4.1 &#x000b1; 0.43</td><td align="center" valign="middle" rowspan="1" colspan="1">2, 35</td><td align="center" valign="middle" rowspan="1" colspan="1">0.17</td><td align="center" valign="middle" rowspan="1" colspan="1">0.859</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">GPC&#x00026;PCh</td><td align="center" valign="middle" rowspan="1" colspan="1">3.1 &#x000b1; 0.3</td><td align="center" valign="middle" rowspan="1" colspan="1">1 &#x000b1; 0.14</td><td align="center" valign="middle" rowspan="1" colspan="1">0.99 &#x000b1; 0.14</td><td align="center" valign="middle" rowspan="1" colspan="1">0.97 &#x000b1; 0.18</td><td align="center" valign="middle" rowspan="1" colspan="1">2, 35</td><td align="center" valign="middle" rowspan="1" colspan="1">0.15</td><td align="center" valign="middle" rowspan="1" colspan="1">0.893</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Acn</td><td align="center" valign="middle" rowspan="1" colspan="1">58.5 &#x000b1; 18.8</td><td align="center" valign="middle" rowspan="1" colspan="1">1 &#x000b1; 0.14</td><td align="center" valign="middle" rowspan="1" colspan="1">0.99 &#x000b1; 0.14</td><td align="center" valign="middle" rowspan="1" colspan="1">1 &#x000b1; 0.16</td><td align="center" valign="middle" rowspan="1" colspan="1">2, 6</td><td align="center" valign="middle" rowspan="1" colspan="1">0.11</td><td align="center" valign="middle" rowspan="1" colspan="1">0.940</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Cr</td><td align="center" valign="middle" rowspan="1" colspan="1">6.9 &#x000b1; 1.4</td><td align="center" valign="middle" rowspan="1" colspan="1">0.05 &#x000b1; 0.02</td><td align="center" valign="middle" rowspan="1" colspan="1">0.06 &#x000b1; 0.02</td><td align="center" valign="middle" rowspan="1" colspan="1">0.06 &#x000b1; 0.02</td><td align="center" valign="middle" rowspan="1" colspan="1">2, 35</td><td align="center" valign="middle" rowspan="1" colspan="1">0.06</td><td align="center" valign="middle" rowspan="1" colspan="1">0.960</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NAA&#x00026;NAAG</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.1 &#x000b1; 0.3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.07 &#x000b1; 0.56</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.12 &#x000b1; 0.5</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.09 &#x000b1; 0.52</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2, 35</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.04</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.986</td></tr></tbody></table></div><div class="largeobj-link align_right" id="largeobj_idm140106928102704"><a target="object" rel="noopener" href="/pmc/articles/PMC9657243/table/cells-11-03372-t004/?report=objectonly">Open in a separate window</a></div><div class="tblwrap-foot"><div id="fn-a.s.h.e.a"><p class="p p-first-last">Columns from left to right include the standard abbreviation for each metabolite, mean overall Cramer&#x02013;Rao lower bounds and its standard deviation (SD), mean and SD for each water-scaled metabolite concentration for the three visits, degrees of freedom (numerator, denominator), F-value, and <em>p</em>-value. Statistical analysis involved repeated-measures linear mixed models with &#x0201c;Visit&#x0201d; as the repeated-measures variable and water-scaled concentration as the dependent variable. Additional factors and covariates are detailed in the Statistical Methods <a href="#sec2dot9-cells-11-03372" rid="sec2dot9-cells-11-03372" class=" sec">Section 2.9</a>. Table is sorted by <em>p</em>-value, bold measures are significant for the omnibus test at <em>p</em> &#x0003c; 0.05.</p></div></div></div></div></div><div id="sec3dot3-cells-11-03372" class="sec sec-last"><h3 id="sec3dot3-cells-11-03372title">3.3. Adverse Events</h3><p class="p p-first-last">Except for one participant (1/21) who was stopped from the study due to mild Cr elevation, no other adverse event was observed.</p></div></div><div id="sec4-cells-11-03372" class="tsec sec"><h2 class="head no_bottom_margin" id="sec4-cells-11-03372title">4. Discussion</h2><p class="p p-first">In this clinical study, we found that empagliflozin decreased insulin, increased glucagon, and increased NEFAs and BHB blood levels in individuals without diabetes [<a href="#B33-cells-11-03372" rid="B33-cells-11-03372" class=" bibr popnode">33</a>]. While the first dose of empagliflozin lowered circulating glucose levels, after 14 days of daily empagliflozin (visit 3), glucose levels were similar to baseline (visit 1). These findings suggest a rapid diminution of the glucose-lowering effect of empagliflozin in individuals without diabetes and a restoration of glucose homeostasis, which facilitates any potential repurposing of the drug for medical indications besides diabetes. Interestingly, we found that empagliflozin acutely elevated pIGF-1R, pIR and common downstream mediators of IGF and insulin signaling such as pY-IRS-1 and pAKT in NEVs but not in TEVs, indicating a neuronal-specific upregulation of these pathways. Although no elevation of ketone bodies was directly observed in the brain using MRS, empagliflozin reduced the excitatory neurotransmitter glutamate and its precursor glutamine, metabolites that have been shown to respond to ketogenic interventions.</p><p>Overall, empagliflozin induced metabolic changes that overlap with those of fasting and calorie restriction, such as a metabolic shift towards lipolysis and ketogenesis [<a href="#B3-cells-11-03372" rid="B3-cells-11-03372" class=" bibr popnode">3</a>,<a href="#B33-cells-11-03372" rid="B33-cells-11-03372" class=" bibr popnode">33</a>,<a href="#B34-cells-11-03372" rid="B34-cells-11-03372" class=" bibr popnode">34</a>]. Also analogous to calorie restriction, chronic empagliflozin administration decreased circulating insulin levels without significantly altering glucose homeostasis [<a href="#B34-cells-11-03372" rid="B34-cells-11-03372" class=" bibr popnode">34</a>,<a href="#B35-cells-11-03372" rid="B35-cells-11-03372" class=" bibr popnode">35</a>]. Empagliflozin&#x02019;s insulin-reducing capability is of great importance for neurodegenerative diseases, as chronically elevated insulin levels downregulate autophagy and inhibit clearance of abnormal proteins [<a href="#B4-cells-11-03372" rid="B4-cells-11-03372" class=" bibr popnode">4</a>,<a href="#B36-cells-11-03372" rid="B36-cells-11-03372" class=" bibr popnode">36</a>,<a href="#B37-cells-11-03372" rid="B37-cells-11-03372" class=" bibr popnode">37</a>]. Evidence from other clinical studies suggests that empagliflozin induces beneficial cellular responses regardless of presence or absence of hyperglycemia [<a href="#B2-cells-11-03372" rid="B2-cells-11-03372" class=" bibr popnode">2</a>,<a href="#B4-cells-11-03372" rid="B4-cells-11-03372" class=" bibr popnode">4</a>]. Such benefits may be due to empagliflozin-induced activation of <em>SIRT1</em> and <em>AMPK</em>, potentially as a response to glucose loss in the urine, which constitutes a form of nutrient deprivation. Activation of <em>SIRT1</em> and <em>AMPK</em> has been associated with increased autophagy and reduced inflammation and oxidative stress. These downstream effects may promote cellular resilience in the brain and other organs [<a href="#B4-cells-11-03372" rid="B4-cells-11-03372" class=" bibr popnode">4</a>,<a href="#B38-cells-11-03372" rid="B38-cells-11-03372" class=" bibr popnode">38</a>,<a href="#B39-cells-11-03372" rid="B39-cells-11-03372" class=" bibr popnode">39</a>].</p><p>We showed that empagliflozin elevated circulating BHB levels after acute and chronic dosing, in agreement with a previous study of empagliflozin that showed a trend towards BHB elevation in a non-diabetic population [<a href="#B33-cells-11-03372" rid="B33-cells-11-03372" class=" bibr popnode">33</a>]. Accumulating evidence suggests that ketones are an efficient alternative to glucose as an energy fuel, and so may be potentially useful as an intervention in chronic neurodegenerative disorders such as AD, in which the brain has a decreased ability to efficiently utilize glucose [<a href="#B14-cells-11-03372" rid="B14-cells-11-03372" class=" bibr popnode">14</a>,<a href="#B15-cells-11-03372" rid="B15-cells-11-03372" class=" bibr popnode">15</a>,<a href="#B40-cells-11-03372" rid="B40-cells-11-03372" class=" bibr popnode">40</a>]. Therefore, BHB elevation by empagliflozin may be beneficial for such disorders. Interestingly, despite the observed BHB increase, AcAc was decreased and the ratio AcAc/BHB was also decreased. The decreased AcAc/BHB ratio may reflect increased conversion of AcAc to BHB, typically associated with an elevated NAD<sup>+</sup>/NADH ratio. Evidence from animal models indicates that NAD<sup>+</sup> induces enzymes involved in promoting neuronal health, such as sirtuins, and therefore a potential NAD<sup>+</sup> increase by empagliflozin would be beneficial in AD and other neurodegenerative disorders [<a href="#B41-cells-11-03372" rid="B41-cells-11-03372" class=" bibr popnode">41</a>].</p><p>Following the first dose, empagliflozin induced significant elevations of pIGF-1R, pIR, and common downstream mediators of the IGF and insulin signaling pathways such as pY-IRS-1 and pAKT (with the caveat of high CV for the internal control) in NEVs. These changes indicate an activation of the IGF-1 and insulin signaling pathways in neurons. No NEV biomarker differences were observed after the last empagliflozin dose compared with baseline, perhaps due to a potential adaptation to repeated dosing. Our findings on the acute elevation of proteins of the IGF-1 and insulin signaling pathways detected in NEVs are important because these NEV biomarkers have been linked to AD diagnosis [<a href="#B42-cells-11-03372" rid="B42-cells-11-03372" class=" bibr popnode">42</a>], age-related cognitive decline [<a href="#B43-cells-11-03372" rid="B43-cells-11-03372" class=" bibr popnode">43</a>], grey matter volume and volume of white matter hyperintensities [<a href="#B44-cells-11-03372" rid="B44-cells-11-03372" class=" bibr popnode">44</a>]. Post-mortem studies, have shown that AD brains are characterized by decreased IGF-1R and IGF-1 mRNA levels (that worsen with increasing Braak stage) [<a href="#B45-cells-11-03372" rid="B45-cells-11-03372" class=" bibr popnode">45</a>], as well as decreased IRS-1 levels [<a href="#B46-cells-11-03372" rid="B46-cells-11-03372" class=" bibr popnode">46</a>]. In the Framingham study, decreased serum IGF-1 levels predicted the development of future AD, providing additional evidence for the involvement of IGF-1/IGF-1R signaling disturbances in AD [<a href="#B47-cells-11-03372" rid="B47-cells-11-03372" class=" bibr popnode">47</a>]. In contrast, evidence mainly from animal models indicates that inhibition of IGF-1R is associated with longevity and neuronal resilience to AD pathologies [<a href="#B48-cells-11-03372" rid="B48-cells-11-03372" class=" bibr popnode">48</a>,<a href="#B49-cells-11-03372" rid="B49-cells-11-03372" class=" bibr popnode">49</a>,<a href="#B50-cells-11-03372" rid="B50-cells-11-03372" class=" bibr popnode">50</a>]. Therefore, the effects of empagliflozin on the IGF-1 signaling cascade and its interplay with AD pathologies requires further investigation in vitro and in vivo. Of note, empagliflozin induced elevations of proteins of the canonical pathway of insulin signaling (pIR, pY-IRS-1, pAKT). Interestingly, activation of the canonical pathway is known to promote neuronal survival [<a href="#B51-cells-11-03372" rid="B51-cells-11-03372" class=" bibr popnode">51</a>,<a href="#B52-cells-11-03372" rid="B52-cells-11-03372" class=" bibr popnode">52</a>]. Empagliflozin did not alter proteins of the alternative pathway (i.e., (i) ERK which has been associated with both neuronal survival (acute activation) and death (chronic activation), and is additionally involved in synaptic plasticity [<a href="#B53-cells-11-03372" rid="B53-cells-11-03372" class=" bibr popnode">53</a>,<a href="#B54-cells-11-03372" rid="B54-cells-11-03372" class=" bibr popnode">54</a>,<a href="#B55-cells-11-03372" rid="B55-cells-11-03372" class=" bibr popnode">55</a>,<a href="#B56-cells-11-03372" rid="B56-cells-11-03372" class=" bibr popnode">56</a>]; (ii) JNK which has been associated with neuronal death and synaptic plasticity [<a href="#B57-cells-11-03372" rid="B57-cells-11-03372" class=" bibr popnode">57</a>]; and (iii) p38 which has been associated with neurotoxicity or neuroprotection, depending on the p38 subtype activated or neuron type involved [<a href="#B58-cells-11-03372" rid="B58-cells-11-03372" class=" bibr popnode">58</a>]). Prior NEV studies have shown that drugs with different mechanisms of action can affect the cascade downstream of IRS-1 differently; for example, exenatide acts on AKT [<a href="#B59-cells-11-03372" rid="B59-cells-11-03372" class=" bibr popnode">59</a>], but infliximab acts on JNK, p38, ERK1/2 [<a href="#B60-cells-11-03372" rid="B60-cells-11-03372" class=" bibr popnode">60</a>].</p><p>The primary MRS finding was a significant decrease in brain glutamate and glutamine after empagliflozin administration, which is consistent with earlier findings in ketogenic intervention studies. BHB has been shown to decrease glutamate availability in vitro, ostensibly due to reduced malate-aspartate shuttle activity in neurons reliant on BHB [<a href="#B61-cells-11-03372" rid="B61-cells-11-03372" class=" bibr popnode">61</a>]. This finding is also consistent with the effect of ketogenic diets on glutamine levels as a treatment for glioblastoma, in which ketogenic diets inhibit both glycolysis and glutaminolysis [<a href="#B62-cells-11-03372" rid="B62-cells-11-03372" class=" bibr popnode">62</a>]. This decrease in glutamate is also interesting in the context of both epilepsy [<a href="#B63-cells-11-03372" rid="B63-cells-11-03372" class=" bibr popnode">63</a>] and AD [<a href="#B64-cells-11-03372" rid="B64-cells-11-03372" class=" bibr popnode">64</a>,<a href="#B65-cells-11-03372" rid="B65-cells-11-03372" class=" bibr popnode">65</a>], in which glutamatergic excitotoxicity has long been implicated in their respective pathological cascades. In AD, the presence of Tau tangles and A&#x003b2; plaques appears to exacerbate the effects of glutamatergic excitotoxicity [<a href="#B66-cells-11-03372" rid="B66-cells-11-03372" class=" bibr popnode">66</a>,<a href="#B67-cells-11-03372" rid="B67-cells-11-03372" class=" bibr popnode">67</a>]. Unfortunately, the ketone metabolites (BHB, AcAc, Ace) were difficult to detect reliably in this study due to their low concentration.</p><p>The main limitation of this study was its small sample size. Nevertheless, the study had many strengths. First, it included repeated assessments of metabolites and hormones over 34 h to provide detailed time courses of their change. Second, we gained insight into how drug effects may change with meals, the sleep&#x02013;wake cycle, and duration of treatment. Third, our study included equal numbers of men and women, and therefore our findings have added value, demonstrating that both sexes have increased circulating BHB, upregulated IGF-1/insulin receptors and proteins of the canonical pathway of insulin signaling in neurons, and decreased brain Gln and Glu. Fourth, our study population reflects the age at which this class of drugs may be studied as potential therapies for cognitive impairment. Additional strengths were the integration of multiple complementary methodologies to probe brain effects, particularly NEV isolation, and brain MRS. This enabled us to derive a plethora of biologically relevant outcomes, including circulating metabolites and hormones, brain metabolites, and EV biomarkers. This study also distinguished between neuronal-specific and systemic effects on biomarkers of the IGF-1/insulin cascade by isolating different EV populations.</p><p class="p p-last">Overall, our findings confirm the known ketogenic effect of empagliflozin and additionally provide novel evidence that empagliflozin potentially promotes neuronal survival through activation of the canonical pathway of insulin signaling and may act as a neuroprotectant through upregulation of IGF-1R (based on studying NEVs). We also showed that empagliflozin decreases potentially harmful excitatory neurotransmission in the brain by decreasing glutamate and glutamine (based on brain MRS). These neuronal and brain effects may be beneficial in relevance to AD and related dementias and motivate the repurposing of empagliflozin for these disorders. Future double-blind placebo-controlled randomized clinical trials that may include these and additional biomarkers, as well as cognitive and functional brain outcomes, are needed to test this hypothesis.</p></div><div id="app1-cells-11-03372" class="tsec sec"><h2 class="head no_bottom_margin" id="app1-cells-11-03372title">Supplementary Materials</h2><!--/article/back/app-group/app/--><p>The following supporting information can be downloaded at: <a href="https://www.mdpi.com/article/10.3390/cells1936224/s1">https://www.mdpi.com/article/10.3390/cells1936224/s1</a>. Figure S1. Cryo-EM; Supplemental Othor material S1: Study protocol; Supplemental Othor material S2: Scanner specific LCModel &#x0201c;control.txt&#x0201d; file.</p><div class="sec suppmat" id="cells-11-03372-s001"><div class="sup-box half_rhythm" id="media-a.r.b.a.c.a"><a href="/pmc/articles/PMC9657243/bin/cells-11-03372-s001.zip" data-ga-action="click_feat_suppl">Click here for additional data file.</a><sup>(1.7M, zip)</sup></div></div></div><div id="funding-group-a.p.b.r" class="tsec sec"><h2 class="head no_bottom_margin" id="funding-group-a.p.b.rtitle">Funding Statement</h2><p>This research was supported entirely by the Intramural Research Program of the National Institute on Aging (NIA/NIH).</p></div><div id="notes-a.r.c" class="tsec sec"><h2 class="head no_bottom_margin" id="notes-a.r.ctitle">Author Contributions</h2><p>Conceptualization, J.M.E. and D.K.; methodology, J.M.E., D.K, R.J.M., M.M., M.V. and K.I.A.; software, R.J.M., K.I.A., M.M. and M.V.; validation, J.M.E. and D.K.; formal analysis, K.I.A., R.J.M., M.M., M.V. and Q.C.; investigation, J.M.E., D.M., D.K, R.J.M. and K.I.A.; resources, J.M.E. and D.K.; data curation, D.M., R.J.M., M.V., Q.C. and K.I.A.; writing&#x02014;original draft preparation, K.I.A. and R.J.M.; writing&#x02014;review and editing, K.I.A., R.J.M., M.V., M.M., Q.C., D.M., D.K. and J.M.E.; visualization, K.I.A. and R.J.M.; supervision, J.M.E. and D.K.; funding acquisition, J.M.E. All authors have read and agreed to the published version of the manuscript.</p></div><div id="notes-a.r.d" class="tsec sec"><h2 class="head no_bottom_margin" id="notes-a.r.dtitle">Institutional Review Board Statement</h2><p>The study protocol was approved by the NIH IRB.</p></div><div id="notes-a.r.e" class="tsec sec"><h2 class="head no_bottom_margin" id="notes-a.r.etitle">Informed Consent Statement</h2><p>Informed consent was obtained from all subjects involved in the study during the screening visit.</p></div><div id="notes-a.r.f" class="tsec sec"><h2 class="head no_bottom_margin" id="notes-a.r.ftitle">Data Availability Statement</h2><p>Datasets generated and/or analyzed during the current study are not publicly available but are available from the corresponding author on reasonable request.</p></div><div id="notes-a.r.g" class="tsec sec"><h2 class="head no_bottom_margin" id="notes-a.r.gtitle">Conflicts of Interest</h2><p>The authors declare no conflict of interest.</p></div><div id="fn-group-a.r.a" class="tsec sec"><h2 class="head no_bottom_margin" id="fn-group-a.r.atitle">Footnotes</h2><!--back/fn-group--><div class="fm-sec half_rhythm small"><p class="fn sec" id="fn-a.r.a.a"><p class="p p-first-last"><strong>Publisher&#x02019;s Note:</strong> MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></p></div></div><div id="ref-list-a.r.h" class="tsec sec"><h2 class="head no_bottom_margin" id="ref-list-a.r.htitle">References</h2><div class="ref-list-sec sec" id="reference-list"><div class="ref-cit-blk half_rhythm" id="B1-cells-11-03372">1. <span class="element-citation">Jardiance Prescribing Information.  [(accessed on 9 September 2022)].  Available online:  <a href="https://docs.boehringer-ingelheim.com/Prescribing%20Information/PIs/Jardiance/jardiance.pdf" data-ga-action="click_feat_suppl" ref="reftype=extlink&amp;article-id=9657243&amp;issue-id=421422&amp;journal-id=2106&amp;FROM=Article%7CCitationRef&amp;TO=External%7CLink%7CURI" target="_blank">https://docs.boehringer-ingelheim.com/Prescribing%20Information/PIs/Jardiance/jardiance.pdf</a></span></div><div class="ref-cit-blk half_rhythm" id="B2-cells-11-03372">2. <span class="element-citation">Packer M., Anker S.D., Butler J., Filippatos G., Pocock S.J., Carson P., Januzzi J., Verma S., Tsutsui H., Brueckmann M., et al. Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. <span><span class="ref-journal">N. Engl. J. Med. </span>2020;<span class="ref-vol">383</span>:1413–1424. doi: 10.1056/NEJMoa2022190.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/32865377" ref="reftype=pubmed&amp;article-id=9657243&amp;issue-id=421422&amp;journal-id=2106&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1056%2FNEJMoa2022190" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9657243&amp;issue-id=421422&amp;journal-id=2106&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=N.+Engl.+J.+Med.&amp;title=Cardiovascular+and+Renal+Outcomes+with+Empagliflozin+in+Heart+Failure&amp;author=M.+Packer&amp;author=S.D.+Anker&amp;author=J.+Butler&amp;author=G.+Filippatos&amp;author=S.J.+Pocock&amp;volume=383&amp;publication_year=2020&amp;pages=1413-1424&amp;pmid=32865377&amp;doi=10.1056/NEJMoa2022190&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9657243&amp;issue-id=421422&amp;journal-id=2106&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B3-cells-11-03372">3. <span class="element-citation">Osataphan S., Macchi C., Singhal G., Chimene-Weiss J., Sales V., Kozuka C., Dreyfuss J.M., Pan H., Tangcharoenpaisan Y., Morningstar J., et al. SGLT2 inhibition reprograms systemic metabolism via FGF21-dependent and -independent mechanisms. <span><span class="ref-journal">JCI Insight. </span>2019;<span class="ref-vol">4</span>:5. doi: 10.1172/jci.insight.123130.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC6483601/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/30843877" ref="reftype=pubmed&amp;article-id=9657243&amp;issue-id=421422&amp;journal-id=2106&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1172%2Fjci.insight.123130" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9657243&amp;issue-id=421422&amp;journal-id=2106&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=JCI+Insight&amp;title=SGLT2+inhibition+reprograms+systemic+metabolism+via+FGF21-dependent+and+-independent+mechanisms&amp;author=S.+Osataphan&amp;author=C.+Macchi&amp;author=G.+Singhal&amp;author=J.+Chimene-Weiss&amp;author=V.+Sales&amp;volume=4&amp;publication_year=2019&amp;pages=5&amp;pmid=30843877&amp;doi=10.1172/jci.insight.123130&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9657243&amp;issue-id=421422&amp;journal-id=2106&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B4-cells-11-03372">4. <span class="element-citation">Packer M. SGLT2 Inhibitors Produce Cardiorenal Benefits by Promoting Adaptive Cellular Reprogramming to Induce a State of Fasting Mimicry: A Paradigm Shift in Understanding Their Mechanism of Action. <span><span class="ref-journal">Diabetes Care. </span>2020;<span class="ref-vol">43</span>:508–511. doi: 10.2337/dci19-0074.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/32079684" ref="reftype=pubmed&amp;article-id=9657243&amp;issue-id=421422&amp;journal-id=2106&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.2337%2Fdci19-0074" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9657243&amp;issue-id=421422&amp;journal-id=2106&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Diabetes+Care&amp;title=SGLT2+Inhibitors+Produce+Cardiorenal+Benefits+by+Promoting+Adaptive+Cellular+Reprogramming+to+Induce+a+State+of+Fasting+Mimicry:+A+Paradigm+Shift+in+Understanding+Their+Mechanism+of+Action&amp;author=M.+Packer&amp;volume=43&amp;publication_year=2020&amp;pages=508-511&amp;pmid=32079684&amp;doi=10.2337/dci19-0074&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9657243&amp;issue-id=421422&amp;journal-id=2106&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B5-cells-11-03372">5. <span class="element-citation">Ferrannini E., Mark M., Mayoux E. CV Protection in the EMPA-REG OUTCOME Trial: A &#x0201c;Thrifty Substrate&#x0201d; Hypothesis. <span><span class="ref-journal">Diabetes Care. </span>2016;<span class="ref-vol">39</span>:1108–1114. doi: 10.2337/dc16-0330.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/27289126" ref="reftype=pubmed&amp;article-id=9657243&amp;issue-id=421422&amp;journal-id=2106&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.2337%2Fdc16-0330" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9657243&amp;issue-id=421422&amp;journal-id=2106&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Diabetes+Care&amp;title=CV+Protection+in+the+EMPA-REG+OUTCOME+Trial:+A+&#x0201c;Thrifty+Substrate&#x0201d;+Hypothesis&amp;author=E.+Ferrannini&amp;author=M.+Mark&amp;author=E.+Mayoux&amp;volume=39&amp;publication_year=2016&amp;pages=1108-1114&amp;pmid=27289126&amp;doi=10.2337/dc16-0330&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9657243&amp;issue-id=421422&amp;journal-id=2106&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B6-cells-11-03372">6. <span class="element-citation">Aragon-Herrera A., Feijoo-Bandin S., Otero Santiago M., Barral L., Campos-Toimil M., Gil-Longo J., Costa Pereira T.M., Garcia-Caballero T., Rodriguez-Segade S., Rodriguez J., et al. Empagliflozin reduces the levels of CD36 and cardiotoxic lipids while improving autophagy in the hearts of Zucker diabetic fatty rats. <span><span class="ref-journal">Biochem. Pharmacol. </span>2019;<span class="ref-vol">170</span>:113677. doi: 10.1016/j.bcp.2019.113677.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/31647926" ref="reftype=pubmed&amp;article-id=9657243&amp;issue-id=421422&amp;journal-id=2106&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1016%2Fj.bcp.2019.113677" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9657243&amp;issue-id=421422&amp;journal-id=2106&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Biochem.+Pharmacol.&amp;title=Empagliflozin+reduces+the+levels+of+CD36+and+cardiotoxic+lipids+while+improving+autophagy+in+the+hearts+of+Zucker+diabetic+fatty+rats&amp;author=A.+Aragon-Herrera&amp;author=S.+Feijoo-Bandin&amp;author=M.+Otero+Santiago&amp;author=L.+Barral&amp;author=M.+Campos-Toimil&amp;volume=170&amp;publication_year=2019&amp;pages=113677&amp;pmid=31647926&amp;doi=10.1016/j.bcp.2019.113677&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9657243&amp;issue-id=421422&amp;journal-id=2106&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B7-cells-11-03372">7. <span class="element-citation">Halagappa V.K., Guo Z., Pearson M., Matsuoka Y., Cutler R.G., Laferla F.M., Mattson M.P. Intermittent fasting and caloric restriction ameliorate age-related behavioral deficits in the triple-transgenic mouse model of Alzheimer&#x02019;s disease. <span><span class="ref-journal">Neurobiol. Dis. </span>2007;<span class="ref-vol">26</span>:212–220. doi: 10.1016/j.nbd.2006.12.019.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/17306982" ref="reftype=pubmed&amp;article-id=9657243&amp;issue-id=421422&amp;journal-id=2106&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1016%2Fj.nbd.2006.12.019" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9657243&amp;issue-id=421422&amp;journal-id=2106&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Neurobiol.+Dis.&amp;title=Intermittent+fasting+and+caloric+restriction+ameliorate+age-related+behavioral+deficits+in+the+triple-transgenic+mouse+model+of+Alzheimer&#x02019;s+disease&amp;author=V.K.+Halagappa&amp;author=Z.+Guo&amp;author=M.+Pearson&amp;author=Y.+Matsuoka&amp;author=R.G.+Cutler&amp;volume=26&amp;publication_year=2007&amp;pages=212-220&amp;pmid=17306982&amp;doi=10.1016/j.nbd.2006.12.019&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9657243&amp;issue-id=421422&amp;journal-id=2106&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B8-cells-11-03372">8. <span class="element-citation">Rubovitch V., Pharayra A., Har-Even M., Dvir O., Mattson M.P., Pick C.G. Dietary Energy Restriction Ameliorates Cognitive Impairment in a Mouse Model of Traumatic Brain Injury. <span><span class="ref-journal">J. Mol. Neurosci. </span>2019;<span class="ref-vol">67</span>:613–621. doi: 10.1007/s12031-019-01271-6.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC6588397/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/30734244" ref="reftype=pubmed&amp;article-id=9657243&amp;issue-id=421422&amp;journal-id=2106&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1007%2Fs12031-019-01271-6" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9657243&amp;issue-id=421422&amp;journal-id=2106&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J.+Mol.+Neurosci.&amp;title=Dietary+Energy+Restriction+Ameliorates+Cognitive+Impairment+in+a+Mouse+Model+of+Traumatic+Brain+Injury&amp;author=V.+Rubovitch&amp;author=A.+Pharayra&amp;author=M.+Har-Even&amp;author=O.+Dvir&amp;author=M.P.+Mattson&amp;volume=67&amp;publication_year=2019&amp;pages=613-621&amp;pmid=30734244&amp;doi=10.1007/s12031-019-01271-6&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9657243&amp;issue-id=421422&amp;journal-id=2106&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B9-cells-11-03372">9. <span class="element-citation">Diehl T., Mullins R., Kapogiannis D. Insulin resistance in Alzheimer&#x02019;s disease. <span><span class="ref-journal">Transl. Res. </span>2017;<span class="ref-vol">183</span>:26–40. doi: 10.1016/j.trsl.2016.12.005.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC5393926/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/28034760" ref="reftype=pubmed&amp;article-id=9657243&amp;issue-id=421422&amp;journal-id=2106&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1016%2Fj.trsl.2016.12.005" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9657243&amp;issue-id=421422&amp;journal-id=2106&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Transl.+Res.&amp;title=Insulin+resistance+in+Alzheimer&#x02019;s+disease&amp;author=T.+Diehl&amp;author=R.+Mullins&amp;author=D.+Kapogiannis&amp;volume=183&amp;publication_year=2017&amp;pages=26-40&amp;pmid=28034760&amp;doi=10.1016/j.trsl.2016.12.005&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9657243&amp;issue-id=421422&amp;journal-id=2106&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B10-cells-11-03372">10. <span class="element-citation">Ekblad L.L., Johansson J., Helin S., Viitanen M., Laine H., Puukka P., Jula A., Rinne J.O. Midlife insulin resistance, APOE genotype, and late-life brain amyloid accumulation. <span><span class="ref-journal">Neurology. </span>2018;<span class="ref-vol">90</span>:e1150–e1157. doi: 10.1212/WNL.0000000000005214.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC5880630/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/29476033" ref="reftype=pubmed&amp;article-id=9657243&amp;issue-id=421422&amp;journal-id=2106&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1212%2FWNL.0000000000005214" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9657243&amp;issue-id=421422&amp;journal-id=2106&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Neurology&amp;title=Midlife+insulin+resistance,+APOE+genotype,+and+late-life+brain+amyloid+accumulation&amp;author=L.L.+Ekblad&amp;author=J.+Johansson&amp;author=S.+Helin&amp;author=M.+Viitanen&amp;author=H.+Laine&amp;volume=90&amp;publication_year=2018&amp;pages=e1150-e1157&amp;pmid=29476033&amp;doi=10.1212/WNL.0000000000005214&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9657243&amp;issue-id=421422&amp;journal-id=2106&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B11-cells-11-03372">11. <span class="element-citation">Hoscheidt S.M., Starks E.J., Oh J.M., Zetterberg H., Blennow K., Krause R.A., Gleason C.E., Puglielli L., Atwood C.S., Carlsson C.M., et al. Insulin Resistance is Associated with Increased Levels of Cerebrospinal Fluid Biomarkers of Alzheimer&#x02019;s Disease and Reduced Memory Function in At-Risk Healthy Middle-Aged Adults. <span><span class="ref-journal">J. Alzheimers Dis. </span>2016;<span class="ref-vol">52</span>:1373–1383. doi: 10.3233/JAD-160110.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC5066305/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/27079723" ref="reftype=pubmed&amp;article-id=9657243&amp;issue-id=421422&amp;journal-id=2106&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.3233%2FJAD-160110" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9657243&amp;issue-id=421422&amp;journal-id=2106&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J.+Alzheimers+Dis.&amp;title=Insulin+Resistance+is+Associated+with+Increased+Levels+of+Cerebrospinal+Fluid+Biomarkers+of+Alzheimer&#x02019;s+Disease+and+Reduced+Memory+Function+in+At-Risk+Healthy+Middle-Aged+Adults&amp;author=S.M.+Hoscheidt&amp;author=E.J.+Starks&amp;author=J.M.+Oh&amp;author=H.+Zetterberg&amp;author=K.+Blennow&amp;volume=52&amp;publication_year=2016&amp;pages=1373-1383&amp;pmid=27079723&amp;doi=10.3233/JAD-160110&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9657243&amp;issue-id=421422&amp;journal-id=2106&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B12-cells-11-03372">12. <span class="element-citation">Laws S.M., Gaskin S., Woodfield A., Srikanth V., Bruce D., Fraser P.E., Porter T., Newsholme P., Wijesekara N., Burnham S., et al. Insulin resistance is associated with reductions in specific cognitive domains and increases in CSF tau in cognitively normal adults. <span><span class="ref-journal">Sci. Rep. </span>2017;<span class="ref-vol">7</span>:9766. doi: 10.1038/s41598-017-09577-4.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC5575049/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/28852028" ref="reftype=pubmed&amp;article-id=9657243&amp;issue-id=421422&amp;journal-id=2106&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1038%2Fs41598-017-09577-4" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9657243&amp;issue-id=421422&amp;journal-id=2106&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Sci.+Rep.&amp;title=Insulin+resistance+is+associated+with+reductions+in+specific+cognitive+domains+and+increases+in+CSF+tau+in+cognitively+normal+adults&amp;author=S.M.+Laws&amp;author=S.+Gaskin&amp;author=A.+Woodfield&amp;author=V.+Srikanth&amp;author=D.+Bruce&amp;volume=7&amp;publication_year=2017&amp;pages=9766&amp;pmid=28852028&amp;doi=10.1038/s41598-017-09577-4&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9657243&amp;issue-id=421422&amp;journal-id=2106&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B13-cells-11-03372">13. <span class="element-citation">Willette A.A., Johnson S.C., Birdsill A.C., Sager M.A., Christian B., Baker L.D., Craft S., Oh J., Statz E., Hermann B.P., et al. Insulin resistance predicts brain amyloid deposition in late middle-aged adults. <span><span class="ref-journal">Alzheimers Dement. </span>2015;<span class="ref-vol">11</span>:504–510.e501. doi: 10.1016/j.jalz.2014.03.011.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC4297592/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/25043908" ref="reftype=pubmed&amp;article-id=9657243&amp;issue-id=421422&amp;journal-id=2106&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1016%2Fj.jalz.2014.03.011" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9657243&amp;issue-id=421422&amp;journal-id=2106&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Alzheimers+Dement.&amp;title=Insulin+resistance+predicts+brain+amyloid+deposition+in+late+middle-aged+adults&amp;author=A.A.+Willette&amp;author=S.C.+Johnson&amp;author=A.C.+Birdsill&amp;author=M.A.+Sager&amp;author=B.+Christian&amp;volume=11&amp;publication_year=2015&amp;pages=504-510.e501&amp;pmid=25043908&amp;doi=10.1016/j.jalz.2014.03.011&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9657243&amp;issue-id=421422&amp;journal-id=2106&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B14-cells-11-03372">14. <span class="element-citation">Croteau E., Castellano C.A., Fortier M., Bocti C., Fulop T., Paquet N., Cunnane S.C. A cross-sectional comparison of brain glucose and ketone metabolism in cognitively healthy older adults, mild cognitive impairment and early Alzheimer&#x02019;s disease. <span><span class="ref-journal">Exp. Gerontol. </span>2018;<span class="ref-vol">107</span>:18–26. doi: 10.1016/j.exger.2017.07.004.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/28709938" ref="reftype=pubmed&amp;article-id=9657243&amp;issue-id=421422&amp;journal-id=2106&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1016%2Fj.exger.2017.07.004" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9657243&amp;issue-id=421422&amp;journal-id=2106&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Exp.+Gerontol.&amp;title=A+cross-sectional+comparison+of+brain+glucose+and+ketone+metabolism+in+cognitively+healthy+older+adults,+mild+cognitive+impairment+and+early+Alzheimer&#x02019;s+disease&amp;author=E.+Croteau&amp;author=C.A.+Castellano&amp;author=M.+Fortier&amp;author=C.+Bocti&amp;author=T.+Fulop&amp;volume=107&amp;publication_year=2018&amp;pages=18-26&amp;pmid=28709938&amp;doi=10.1016/j.exger.2017.07.004&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9657243&amp;issue-id=421422&amp;journal-id=2106&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B15-cells-11-03372">15. <span class="element-citation">Cunnane S.C., Trushina E., Morland C., Prigione A., Casadesus G., Andrews Z.B., Beal M.F., Bergersen L.H., Brinton R.D., de la Monte S., et al. Brain energy rescue: An emerging therapeutic concept for neurodegenerative disorders of ageing. <span><span class="ref-journal">Nat. Rev. Drug Discov. </span>2020;<span class="ref-vol">19</span>:609–633. doi: 10.1038/s41573-020-0072-x.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC7948516/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/32709961" ref="reftype=pubmed&amp;article-id=9657243&amp;issue-id=421422&amp;journal-id=2106&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1038%2Fs41573-020-0072-x" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9657243&amp;issue-id=421422&amp;journal-id=2106&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Nat.+Rev.+Drug+Discov.&amp;title=Brain+energy+rescue:+An+emerging+therapeutic+concept+for+neurodegenerative+disorders+of+ageing&amp;author=S.C.+Cunnane&amp;author=E.+Trushina&amp;author=C.+Morland&amp;author=A.+Prigione&amp;author=G.+Casadesus&amp;volume=19&amp;publication_year=2020&amp;pages=609-633&amp;pmid=32709961&amp;doi=10.1038/s41573-020-0072-x&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9657243&amp;issue-id=421422&amp;journal-id=2106&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B16-cells-11-03372">16. <span class="element-citation">Thery C., Witwer K.W., Aikawa E., Alcaraz M.J., Anderson J.D., Andriantsitohaina R., Antoniou A., Arab T., Archer F., Atkin-Smith G.K., et al. Minimal information for studies of extracellular vesicles 2018 (MISEV2018): A position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines. <span><span class="ref-journal">J. Extracell. Vesicles. </span>2018;<span class="ref-vol">7</span>:1535750. doi: 10.1080/20013078.2018.1535750.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC6322352/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/30637094" ref="reftype=pubmed&amp;article-id=9657243&amp;issue-id=421422&amp;journal-id=2106&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1080%2F20013078.2018.1535750" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9657243&amp;issue-id=421422&amp;journal-id=2106&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J.+Extracell.+Vesicles&amp;title=Minimal+information+for+studies+of+extracellular+vesicles+2018+(MISEV2018):+A+position+statement+of+the+International+Society+for+Extracellular+Vesicles+and+update+of+the+MISEV2014+guidelines&amp;author=C.+Thery&amp;author=K.W.+Witwer&amp;author=E.+Aikawa&amp;author=M.J.+Alcaraz&amp;author=J.D.+Anderson&amp;volume=7&amp;publication_year=2018&amp;pages=1535750&amp;pmid=30637094&amp;doi=10.1080/20013078.2018.1535750&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9657243&amp;issue-id=421422&amp;journal-id=2106&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B17-cells-11-03372">17. <span class="element-citation">The Figure was Partly Generated Using Servier Medical Art, Provided by Servier, Licensed under a Creative Commons Attribution 3.0 Unported License.  [(accessed on 9 September 2022)].  Available online:  <a href="https://smart.servier.com/" data-ga-action="click_feat_suppl" ref="reftype=extlink&amp;article-id=9657243&amp;issue-id=421422&amp;journal-id=2106&amp;FROM=Article%7CCitationRef&amp;TO=External%7CLink%7CURI" target="_blank">https://smart.servier.com/</a></span></div><div class="ref-cit-blk half_rhythm" id="B18-cells-11-03372">18. <span class="element-citation">Chia C.W., Carlson O.D., Liu D.D., Gonzalez-Mariscal I., Santa-Cruz Calvo S., Egan J.M. Incretin secretion in humans is under the influence of cannabinoid receptors. <span><span class="ref-journal">Am. J Physiol. Endocrinol. Metab. </span>2017;<span class="ref-vol">313</span>:E359–E366. doi: 10.1152/ajpendo.00080.2017.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC5625085/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/28655715" ref="reftype=pubmed&amp;article-id=9657243&amp;issue-id=421422&amp;journal-id=2106&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1152%2Fajpendo.00080.2017" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9657243&amp;issue-id=421422&amp;journal-id=2106&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Am.+J+Physiol.+Endocrinol.+Metab.&amp;title=Incretin+secretion+in+humans+is+under+the+influence+of+cannabinoid+receptors&amp;author=C.W.+Chia&amp;author=O.D.+Carlson&amp;author=D.D.+Liu&amp;author=I.+Gonzalez-Mariscal&amp;author=S.+Santa-Cruz+Calvo&amp;volume=313&amp;publication_year=2017&amp;pages=E359-E366&amp;pmid=28655715&amp;doi=10.1152/ajpendo.00080.2017&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9657243&amp;issue-id=421422&amp;journal-id=2106&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B19-cells-11-03372">19. <span class="element-citation">Carlson O.D., David J.D., Schrieder J.M., Muller D.C., Jang H.J., Kim B.J., Egan J.M. Contribution of nonesterified fatty acids to insulin resistance in the elderly with normal fasting but diabetic 2-hour postchallenge plasma glucose levels: The Baltimore Longitudinal Study of Aging. <span><span class="ref-journal">Metabolism. </span>2007;<span class="ref-vol">56</span>:1444–1451. doi: 10.1016/j.metabol.2007.06.009.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC2084355/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/17884459" ref="reftype=pubmed&amp;article-id=9657243&amp;issue-id=421422&amp;journal-id=2106&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1016%2Fj.metabol.2007.06.009" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9657243&amp;issue-id=421422&amp;journal-id=2106&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Metabolism&amp;title=Contribution+of+nonesterified+fatty+acids+to+insulin+resistance+in+the+elderly+with+normal+fasting+but+diabetic+2-hour+postchallenge+plasma+glucose+levels:+The+Baltimore+Longitudinal+Study+of+Aging&amp;author=O.D.+Carlson&amp;author=J.D.+David&amp;author=J.M.+Schrieder&amp;author=D.C.+Muller&amp;author=H.J.+Jang&amp;volume=56&amp;publication_year=2007&amp;pages=1444-1451&amp;pmid=17884459&amp;doi=10.1016/j.metabol.2007.06.009&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9657243&amp;issue-id=421422&amp;journal-id=2106&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B20-cells-11-03372">20. <span class="element-citation">Mustapic M., Eitan E., Werner J.K., Jr., Berkowitz S.T., Lazaropoulos M.P., Tran J., Goetzl E.J., Kapogiannis D. Plasma Extracellular Vesicles Enriched for Neuronal Origin: A Potential Window into Brain Pathologic Processes. <span><span class="ref-journal">Front. Neurosci. </span>2017;<span class="ref-vol">11</span>:278. doi: 10.3389/fnins.2017.00278.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC5439289/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/28588440" ref="reftype=pubmed&amp;article-id=9657243&amp;issue-id=421422&amp;journal-id=2106&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.3389%2Ffnins.2017.00278" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9657243&amp;issue-id=421422&amp;journal-id=2106&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Front.+Neurosci.&amp;title=Plasma+Extracellular+Vesicles+Enriched+for+Neuronal+Origin:+A+Potential+Window+into+Brain+Pathologic+Processes&amp;author=M.+Mustapic&amp;author=E.+Eitan&amp;author=J.K.+Werner&amp;author=S.T.+Berkowitz&amp;author=M.P.+Lazaropoulos&amp;volume=11&amp;publication_year=2017&amp;pages=278&amp;pmid=28588440&amp;doi=10.3389/fnins.2017.00278&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9657243&amp;issue-id=421422&amp;journal-id=2106&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B21-cells-11-03372">21. <span class="element-citation">Blommer J., Pitcher T., Mustapic M., Eren E., Yao P.J., Vreones M.P., Pucha K.A., Dalrymple-Alford J., Shoorangiz R., Meissner W.G., et al. Extracellular vesicle biomarkers for cognitive impairment in Parkinson&#x02019;s disease. <span><span class="ref-journal">Brain. </span>2022:awac258. doi: 10.1093/brain/awac258.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC10060702/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/35833836" ref="reftype=pubmed&amp;article-id=9657243&amp;issue-id=421422&amp;journal-id=2106&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1093%2Fbrain%2Fawac258" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9657243&amp;issue-id=421422&amp;journal-id=2106&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Brain&amp;title=Extracellular+vesicle+biomarkers+for+cognitive+impairment+in+Parkinson&#x02019;s+disease&amp;author=J.+Blommer&amp;author=T.+Pitcher&amp;author=M.+Mustapic&amp;author=E.+Eren&amp;author=P.J.+Yao&amp;publication_year=2022&amp;pages=awac258&amp;pmid=35833836&amp;doi=10.1093/brain/awac258&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9657243&amp;issue-id=421422&amp;journal-id=2106&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B22-cells-11-03372">22. <span class="element-citation">Mullins R., Reiter D., Kapogiannis D. Magnetic resonance spectroscopy reveals abnormalities of glucose metabolism in the Alzheimer&#x02019;s brain. <span><span class="ref-journal">Ann. Clin. Transl. Neurol. </span>2018;<span class="ref-vol">5</span>:262–272. doi: 10.1002/acn3.530.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC5846391/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/29560372" ref="reftype=pubmed&amp;article-id=9657243&amp;issue-id=421422&amp;journal-id=2106&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1002%2Facn3.530" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9657243&amp;issue-id=421422&amp;journal-id=2106&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Ann.+Clin.+Transl.+Neurol.&amp;title=Magnetic+resonance+spectroscopy+reveals+abnormalities+of+glucose+metabolism+in+the+Alzheimer&#x02019;s+brain&amp;author=R.+Mullins&amp;author=D.+Reiter&amp;author=D.+Kapogiannis&amp;volume=5&amp;publication_year=2018&amp;pages=262-272&amp;pmid=29560372&amp;doi=10.1002/acn3.530&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9657243&amp;issue-id=421422&amp;journal-id=2106&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B23-cells-11-03372">23. <span class="element-citation">Heimer J., Gascho D., Chatzaraki V., Knaute D.F., Sterzik V., Martinez R.M., Thali M.J., Zoelch N. Postmortem (1)H-MRS-Detection of Ketone Bodies and Glucose in Diabetic Ketoacidosis. <span><span class="ref-journal">Int. J. Legal Med. </span>2018;<span class="ref-vol">132</span>:593–598. doi: 10.1007/s00414-017-1741-0.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/29170817" ref="reftype=pubmed&amp;article-id=9657243&amp;issue-id=421422&amp;journal-id=2106&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1007%2Fs00414-017-1741-0" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9657243&amp;issue-id=421422&amp;journal-id=2106&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Int.+J.+Legal+Med.&amp;title=Postmortem+(1)H-MRS-Detection+of+Ketone+Bodies+and+Glucose+in+Diabetic+Ketoacidosis&amp;author=J.+Heimer&amp;author=D.+Gascho&amp;author=V.+Chatzaraki&amp;author=D.F.+Knaute&amp;author=V.+Sterzik&amp;volume=132&amp;publication_year=2018&amp;pages=593-598&amp;pmid=29170817&amp;doi=10.1007/s00414-017-1741-0&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9657243&amp;issue-id=421422&amp;journal-id=2106&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B24-cells-11-03372">24. <span class="element-citation">Wright J.N., Saneto R.P., Friedman S.D. beta-Hydroxybutyrate Detection with Proton MR Spectroscopy in Children with Drug-Resistant Epilepsy on the Ketogenic Diet. <span><span class="ref-journal">AJNR Am. J. Neuroradiol. </span>2018;<span class="ref-vol">39</span>:1336–1340. doi: 10.3174/ajnr.A5648.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC7655448/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/29724763" ref="reftype=pubmed&amp;article-id=9657243&amp;issue-id=421422&amp;journal-id=2106&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.3174%2Fajnr.A5648" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9657243&amp;issue-id=421422&amp;journal-id=2106&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=AJNR+Am.+J.+Neuroradiol.&amp;title=beta-Hydroxybutyrate+Detection+with+Proton+MR+Spectroscopy+in+Children+with+Drug-Resistant+Epilepsy+on+the+Ketogenic+Diet&amp;author=J.N.+Wright&amp;author=R.P.+Saneto&amp;author=S.D.+Friedman&amp;volume=39&amp;publication_year=2018&amp;pages=1336-1340&amp;pmid=29724763&amp;doi=10.3174/ajnr.A5648&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9657243&amp;issue-id=421422&amp;journal-id=2106&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B25-cells-11-03372">25. <span class="element-citation">Bolliger C.S., Boesch C., Kreis R. On the use of Cramer-Rao minimum variance bounds for the design of magnetic resonance spectroscopy experiments. <span><span class="ref-journal">Neuroimage. </span>2013;<span class="ref-vol">83</span>:1031–1040. doi: 10.1016/j.neuroimage.2013.07.062.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/23933043" ref="reftype=pubmed&amp;article-id=9657243&amp;issue-id=421422&amp;journal-id=2106&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1016%2Fj.neuroimage.2013.07.062" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9657243&amp;issue-id=421422&amp;journal-id=2106&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Neuroimage&amp;title=On+the+use+of+Cramer-Rao+minimum+variance+bounds+for+the+design+of+magnetic+resonance+spectroscopy+experiments&amp;author=C.S.+Bolliger&amp;author=C.+Boesch&amp;author=R.+Kreis&amp;volume=83&amp;publication_year=2013&amp;pages=1031-1040&amp;pmid=23933043&amp;doi=10.1016/j.neuroimage.2013.07.062&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9657243&amp;issue-id=421422&amp;journal-id=2106&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B26-cells-11-03372">26. <span class="element-citation">McMurray J.J.V., Solomon S.D., Inzucchi S.E., Kober L., Kosiborod M.N., Martinez F.A., Ponikowski P., Sabatine M.S., Anand I.S., Belohlavek J., et al. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. <span><span class="ref-journal">N. Engl. J. Med. </span>2019;<span class="ref-vol">381</span>:1995–2008. doi: 10.1056/NEJMoa1911303.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/31535829" ref="reftype=pubmed&amp;article-id=9657243&amp;issue-id=421422&amp;journal-id=2106&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1056%2FNEJMoa1911303" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9657243&amp;issue-id=421422&amp;journal-id=2106&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=N.+Engl.+J.+Med.&amp;title=Dapagliflozin+in+Patients+with+Heart+Failure+and+Reduced+Ejection+Fraction&amp;author=J.J.V.+McMurray&amp;author=S.D.+Solomon&amp;author=S.E.+Inzucchi&amp;author=L.+Kober&amp;author=M.N.+Kosiborod&amp;volume=381&amp;publication_year=2019&amp;pages=1995-2008&amp;pmid=31535829&amp;doi=10.1056/NEJMoa1911303&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9657243&amp;issue-id=421422&amp;journal-id=2106&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B27-cells-11-03372">27. <span class="element-citation">Singh A.K., Singh R. Gender difference in cardiovascular outcomes with SGLT-2 inhibitors and GLP-1 receptor agonist in type 2 diabetes: A systematic review and meta-analysis of cardio-vascular outcome trials. <span><span class="ref-journal">Diabetes Metab. Syndr. </span>2020;<span class="ref-vol">14</span>:181–187. doi: 10.1016/j.dsx.2020.02.012.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/32142999" ref="reftype=pubmed&amp;article-id=9657243&amp;issue-id=421422&amp;journal-id=2106&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1016%2Fj.dsx.2020.02.012" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9657243&amp;issue-id=421422&amp;journal-id=2106&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Diabetes+Metab.+Syndr.&amp;title=Gender+difference+in+cardiovascular+outcomes+with+SGLT-2+inhibitors+and+GLP-1+receptor+agonist+in+type+2+diabetes:+A+systematic+review+and+meta-analysis+of+cardio-vascular+outcome+trials&amp;author=A.K.+Singh&amp;author=R.+Singh&amp;volume=14&amp;publication_year=2020&amp;pages=181-187&amp;pmid=32142999&amp;doi=10.1016/j.dsx.2020.02.012&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9657243&amp;issue-id=421422&amp;journal-id=2106&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B28-cells-11-03372">28. <span class="element-citation">Anker S.D., Butler J., Filippatos G., Ferreira J.P., Bocchi E., Bohm M., Brunner-La Rocca H.P., Choi D.J., Chopra V., Chuquiure-Valenzuela E., et al. Empagliflozin in Heart Failure with a Preserved Ejection Fraction. <span><span class="ref-journal">N. Engl. J. Med. </span>2021;<span class="ref-vol">385</span>:1451–1461. doi: 10.1056/NEJMoa2107038.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/34449189" ref="reftype=pubmed&amp;article-id=9657243&amp;issue-id=421422&amp;journal-id=2106&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1056%2FNEJMoa2107038" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9657243&amp;issue-id=421422&amp;journal-id=2106&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=N.+Engl.+J.+Med.&amp;title=Empagliflozin+in+Heart+Failure+with+a+Preserved+Ejection+Fraction&amp;author=S.D.+Anker&amp;author=J.+Butler&amp;author=G.+Filippatos&amp;author=J.P.+Ferreira&amp;author=E.+Bocchi&amp;volume=385&amp;publication_year=2021&amp;pages=1451-1461&amp;pmid=34449189&amp;doi=10.1056/NEJMoa2107038&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9657243&amp;issue-id=421422&amp;journal-id=2106&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B29-cells-11-03372">29. <span class="element-citation">Provencher S.W. Estimation of metabolite concentrations from localized in vivo proton NMR spectra. <span><span class="ref-journal">Magn. Reson. Med. </span>1993;<span class="ref-vol">30</span>:672–679. doi: 10.1002/mrm.1910300604.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/8139448" ref="reftype=pubmed&amp;article-id=9657243&amp;issue-id=421422&amp;journal-id=2106&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1002%2Fmrm.1910300604" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9657243&amp;issue-id=421422&amp;journal-id=2106&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Magn.+Reson.+Med.&amp;title=Estimation+of+metabolite+concentrations+from+localized+in+vivo+proton+NMR+spectra&amp;author=S.W.+Provencher&amp;volume=30&amp;publication_year=1993&amp;pages=672-679&amp;pmid=8139448&amp;doi=10.1002/mrm.1910300604&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9657243&amp;issue-id=421422&amp;journal-id=2106&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B30-cells-11-03372">30. <span class="element-citation">Kapogiannis D., Reiter D.A., Willette A.A., Mattson M.P. Posteromedial cortex glutamate and GABA predict intrinsic functional connectivity of the default mode network. <span><span class="ref-journal">Neuroimage. </span>2013;<span class="ref-vol">64</span>:112–119. doi: 10.1016/j.neuroimage.2012.09.029.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC3801193/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/23000786" ref="reftype=pubmed&amp;article-id=9657243&amp;issue-id=421422&amp;journal-id=2106&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1016%2Fj.neuroimage.2012.09.029" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9657243&amp;issue-id=421422&amp;journal-id=2106&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Neuroimage&amp;title=Posteromedial+cortex+glutamate+and+GABA+predict+intrinsic+functional+connectivity+of+the+default+mode+network&amp;author=D.+Kapogiannis&amp;author=D.A.+Reiter&amp;author=A.A.+Willette&amp;author=M.P.+Mattson&amp;volume=64&amp;publication_year=2013&amp;pages=112-119&amp;pmid=23000786&amp;doi=10.1016/j.neuroimage.2012.09.029&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9657243&amp;issue-id=421422&amp;journal-id=2106&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B31-cells-11-03372">31. <span class="element-citation">Gasparovic C., Song T., Devier D., Bockholt H.J., Caprihan A., Mullins P.G., Posse S., Jung R.E., Morrison L.A. Use of tissue water as a concentration reference for proton spectroscopic imaging. <span><span class="ref-journal">Magn. Reson. Med. </span>2006;<span class="ref-vol">55</span>:1219–1226. doi: 10.1002/mrm.20901.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/16688703" ref="reftype=pubmed&amp;article-id=9657243&amp;issue-id=421422&amp;journal-id=2106&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1002%2Fmrm.20901" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9657243&amp;issue-id=421422&amp;journal-id=2106&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Magn.+Reson.+Med.&amp;title=Use+of+tissue+water+as+a+concentration+reference+for+proton+spectroscopic+imaging&amp;author=C.+Gasparovic&amp;author=T.+Song&amp;author=D.+Devier&amp;author=H.J.+Bockholt&amp;author=A.+Caprihan&amp;volume=55&amp;publication_year=2006&amp;pages=1219-1226&amp;pmid=16688703&amp;doi=10.1002/mrm.20901&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9657243&amp;issue-id=421422&amp;journal-id=2106&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B32-cells-11-03372">32. <span class="element-citation">Kapogiannis D., Avgerinos K.I. Brain glucose and ketone utilization in brain aging and neurodegenerative diseases. <span><span class="ref-journal">Int. Rev. Neurobiol. </span>2020;<span class="ref-vol">154</span>:79–110. doi: 10.1016/bs.irn.2020.03.015.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC9989941/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/32739015" ref="reftype=pubmed&amp;article-id=9657243&amp;issue-id=421422&amp;journal-id=2106&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1016%2Fbs.irn.2020.03.015" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9657243&amp;issue-id=421422&amp;journal-id=2106&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Int.+Rev.+Neurobiol.&amp;title=Brain+glucose+and+ketone+utilization+in+brain+aging+and+neurodegenerative+diseases&amp;author=D.+Kapogiannis&amp;author=K.I.+Avgerinos&amp;volume=154&amp;publication_year=2020&amp;pages=79-110&amp;pmid=32739015&amp;doi=10.1016/bs.irn.2020.03.015&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9657243&amp;issue-id=421422&amp;journal-id=2106&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B33-cells-11-03372">33. <span class="element-citation">Ferrannini E., Baldi S., Frascerra S., Astiarraga B., Heise T., Bizzotto R., Mari A., Pieber T.R., Muscelli E. Shift to Fatty Substrate Utilization in Response to Sodium-Glucose Cotransporter 2 Inhibition in Subjects Without Diabetes and Patients With Type 2 Diabetes. <span><span class="ref-journal">Diabetes. </span>2016;<span class="ref-vol">65</span>:1190–1195. doi: 10.2337/db15-1356.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/26861783" ref="reftype=pubmed&amp;article-id=9657243&amp;issue-id=421422&amp;journal-id=2106&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.2337%2Fdb15-1356" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9657243&amp;issue-id=421422&amp;journal-id=2106&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Diabetes&amp;title=Shift+to+Fatty+Substrate+Utilization+in+Response+to+Sodium-Glucose+Cotransporter+2+Inhibition+in+Subjects+Without+Diabetes+and+Patients+With+Type+2+Diabetes&amp;author=E.+Ferrannini&amp;author=S.+Baldi&amp;author=S.+Frascerra&amp;author=B.+Astiarraga&amp;author=T.+Heise&amp;volume=65&amp;publication_year=2016&amp;pages=1190-1195&amp;pmid=26861783&amp;doi=10.2337/db15-1356&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9657243&amp;issue-id=421422&amp;journal-id=2106&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B34-cells-11-03372">34. <span class="element-citation">Heilbronn L.K., de Jonge L., Frisard M.I., DeLany J.P., Larson-Meyer D.E., Rood J., Nguyen T., Martin C.K., Volaufova J., Most M.M., et al. Effect of 6-month calorie restriction on biomarkers of longevity, metabolic adaptation, and oxidative stress in overweight individuals: A randomized controlled trial. <span><span class="ref-journal">JAMA. </span>2006;<span class="ref-vol">295</span>:1539–1548. doi: 10.1001/jama.295.13.1539.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC2692623/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/16595757" ref="reftype=pubmed&amp;article-id=9657243&amp;issue-id=421422&amp;journal-id=2106&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1001%2Fjama.295.13.1539" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9657243&amp;issue-id=421422&amp;journal-id=2106&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=JAMA&amp;title=Effect+of+6-month+calorie+restriction+on+biomarkers+of+longevity,+metabolic+adaptation,+and+oxidative+stress+in+overweight+individuals:+A+randomized+controlled+trial&amp;author=L.K.+Heilbronn&amp;author=L.+de+Jonge&amp;author=M.I.+Frisard&amp;author=J.P.+DeLany&amp;author=D.E.+Larson-Meyer&amp;volume=295&amp;publication_year=2006&amp;pages=1539-1548&amp;pmid=16595757&amp;doi=10.1001/jama.295.13.1539&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9657243&amp;issue-id=421422&amp;journal-id=2106&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B35-cells-11-03372">35. <span class="element-citation">Sutton E.F., Beyl R., Early K.S., Cefalu W.T., Ravussin E., Peterson C.M. Early Time-Restricted Feeding Improves Insulin Sensitivity, Blood Pressure, and Oxidative Stress Even without Weight Loss in Men with Prediabetes. <span><span class="ref-journal">Cell Metab. </span>2018;<span class="ref-vol">27</span>:1212–1221.e1213. doi: 10.1016/j.cmet.2018.04.010.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC5990470/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/29754952" ref="reftype=pubmed&amp;article-id=9657243&amp;issue-id=421422&amp;journal-id=2106&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1016%2Fj.cmet.2018.04.010" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9657243&amp;issue-id=421422&amp;journal-id=2106&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Cell+Metab.&amp;title=Early+Time-Restricted+Feeding+Improves+Insulin+Sensitivity,+Blood+Pressure,+and+Oxidative+Stress+Even+without+Weight+Loss+in+Men+with+Prediabetes&amp;author=E.F.+Sutton&amp;author=R.+Beyl&amp;author=K.S.+Early&amp;author=W.T.+Cefalu&amp;author=E.+Ravussin&amp;volume=27&amp;publication_year=2018&amp;pages=1212-1221.e1213&amp;pmid=29754952&amp;doi=10.1016/j.cmet.2018.04.010&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9657243&amp;issue-id=421422&amp;journal-id=2106&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B36-cells-11-03372">36. <span class="element-citation">Paula-Gomes S., Goncalves D.A., Baviera A.M., Zanon N.M., Navegantes L.C., Kettelhut I.C. Insulin suppresses atrophy- and autophagy-related genes in heart tissue and cardiomyocytes through AKT/FOXO signaling. <span><span class="ref-journal">Horm. Metab. Res. </span>2013;<span class="ref-vol">45</span>:849–855. doi: 10.1055/s-0033-1347209.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/23757118" ref="reftype=pubmed&amp;article-id=9657243&amp;issue-id=421422&amp;journal-id=2106&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1055%2Fs-0033-1347209" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9657243&amp;issue-id=421422&amp;journal-id=2106&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Horm.+Metab.+Res.&amp;title=Insulin+suppresses+atrophy-+and+autophagy-related+genes+in+heart+tissue+and+cardiomyocytes+through+AKT/FOXO+signaling&amp;author=S.+Paula-Gomes&amp;author=D.A.+Goncalves&amp;author=A.M.+Baviera&amp;author=N.M.+Zanon&amp;author=L.C.+Navegantes&amp;volume=45&amp;publication_year=2013&amp;pages=849-855&amp;pmid=23757118&amp;doi=10.1055/s-0033-1347209&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9657243&amp;issue-id=421422&amp;journal-id=2106&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B37-cells-11-03372">37. <span class="element-citation">Mattson M.P., Moehl K., Ghena N., Schmaedick M., Cheng A. Intermittent metabolic switching, neuroplasticity and brain health. <span><span class="ref-journal">Nat. Rev. Neurosci. </span>2018;<span class="ref-vol">19</span>:63–80. doi: 10.1038/nrn.2017.156.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC5913738/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/29321682" ref="reftype=pubmed&amp;article-id=9657243&amp;issue-id=421422&amp;journal-id=2106&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1038%2Fnrn.2017.156" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9657243&amp;issue-id=421422&amp;journal-id=2106&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Nat.+Rev.+Neurosci.&amp;title=Intermittent+metabolic+switching,+neuroplasticity+and+brain+health&amp;author=M.P.+Mattson&amp;author=K.+Moehl&amp;author=N.+Ghena&amp;author=M.+Schmaedick&amp;author=A.+Cheng&amp;volume=19&amp;publication_year=2018&amp;pages=63-80&amp;pmid=29321682&amp;doi=10.1038/nrn.2017.156&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9657243&amp;issue-id=421422&amp;journal-id=2106&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B38-cells-11-03372">38. <span class="element-citation">Zare-Shahabadi A., Masliah E., Johnson G.V., Rezaei N. Autophagy in Alzheimer&#x02019;s disease. <span><span class="ref-journal">Rev. Neurosci. </span>2015;<span class="ref-vol">26</span>:385–395. doi: 10.1515/revneuro-2014-0076.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC5039008/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/25870960" ref="reftype=pubmed&amp;article-id=9657243&amp;issue-id=421422&amp;journal-id=2106&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1515%2Frevneuro-2014-0076" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9657243&amp;issue-id=421422&amp;journal-id=2106&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Rev.+Neurosci.&amp;title=Autophagy+in+Alzheimer&#x02019;s+disease&amp;author=A.+Zare-Shahabadi&amp;author=E.+Masliah&amp;author=G.V.+Johnson&amp;author=N.+Rezaei&amp;volume=26&amp;publication_year=2015&amp;pages=385-395&amp;pmid=25870960&amp;doi=10.1515/revneuro-2014-0076&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9657243&amp;issue-id=421422&amp;journal-id=2106&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B39-cells-11-03372">39. <span class="element-citation">Hadar A., Milanesi E., Walczak M., Puzianowska-Kuznicka M., Kuznicki J., Squassina A., Niola P., Chillotti C., Attems J., Gozes I., et al. SIRT1, miR-132 and miR-212 link human longevity to Alzheimer&#x02019;s Disease. <span><span class="ref-journal">Sci. Rep. </span>2018;<span class="ref-vol">8</span>:8465. doi: 10.1038/s41598-018-26547-6.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC5981646/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/29855513" ref="reftype=pubmed&amp;article-id=9657243&amp;issue-id=421422&amp;journal-id=2106&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1038%2Fs41598-018-26547-6" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9657243&amp;issue-id=421422&amp;journal-id=2106&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Sci.+Rep.&amp;title=SIRT1,+miR-132+and+miR-212+link+human+longevity+to+Alzheimer&#x02019;s+Disease&amp;author=A.+Hadar&amp;author=E.+Milanesi&amp;author=M.+Walczak&amp;author=M.+Puzianowska-Kuznicka&amp;author=J.+Kuznicki&amp;volume=8&amp;publication_year=2018&amp;pages=8465&amp;pmid=29855513&amp;doi=10.1038/s41598-018-26547-6&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9657243&amp;issue-id=421422&amp;journal-id=2106&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B40-cells-11-03372">40. <span class="element-citation">Castellano C.A., Nugent S., Paquet N., Tremblay S., Bocti C., Lacombe G., Imbeault H., Turcotte E., Fulop T., Cunnane S.C. Lower brain 18F-fluorodeoxyglucose uptake but normal 11C-acetoacetate metabolism in mild Alzheimer&#x02019;s disease dementia. <span><span class="ref-journal">J. Alzheimers Dis. </span>2015;<span class="ref-vol">43</span>:1343–1353. doi: 10.3233/JAD-141074.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/25147107" ref="reftype=pubmed&amp;article-id=9657243&amp;issue-id=421422&amp;journal-id=2106&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.3233%2FJAD-141074" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9657243&amp;issue-id=421422&amp;journal-id=2106&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J.+Alzheimers+Dis.&amp;title=Lower+brain+18F-fluorodeoxyglucose+uptake+but+normal+11C-acetoacetate+metabolism+in+mild+Alzheimer&#x02019;s+disease+dementia&amp;author=C.A.+Castellano&amp;author=S.+Nugent&amp;author=N.+Paquet&amp;author=S.+Tremblay&amp;author=C.+Bocti&amp;volume=43&amp;publication_year=2015&amp;pages=1343-1353&amp;pmid=25147107&amp;doi=10.3233/JAD-141074&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9657243&amp;issue-id=421422&amp;journal-id=2106&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B41-cells-11-03372">41. <span class="element-citation">Lautrup S., Sinclair D.A., Mattson M.P., Fang E.F. NAD(+) in Brain Aging and Neurodegenerative Disorders. <span><span class="ref-journal">Cell Metab. </span>2019;<span class="ref-vol">30</span>:630–655. doi: 10.1016/j.cmet.2019.09.001.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC6787556/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/31577933" ref="reftype=pubmed&amp;article-id=9657243&amp;issue-id=421422&amp;journal-id=2106&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1016%2Fj.cmet.2019.09.001" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9657243&amp;issue-id=421422&amp;journal-id=2106&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Cell+Metab.&amp;title=NAD(+)+in+Brain+Aging+and+Neurodegenerative+Disorders&amp;author=S.+Lautrup&amp;author=D.A.+Sinclair&amp;author=M.P.+Mattson&amp;author=E.F.+Fang&amp;volume=30&amp;publication_year=2019&amp;pages=630-655&amp;pmid=31577933&amp;doi=10.1016/j.cmet.2019.09.001&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9657243&amp;issue-id=421422&amp;journal-id=2106&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B42-cells-11-03372">42. <span class="element-citation">Kapogiannis D., Boxer A., Schwartz J.B., Abner E.L., Biragyn A., Masharani U., Frassetto L., Petersen R.C., Miller B.L., Goetzl E.J. Dysfunctionally phosphorylated type 1 insulin receptor substrate in neural-derived blood exosomes of preclinical Alzheimer&#x02019;s disease. <span><span class="ref-journal">FASEB J. </span>2015;<span class="ref-vol">29</span>:589–596. doi: 10.1096/fj.14-262048.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC4314222/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/25342129" ref="reftype=pubmed&amp;article-id=9657243&amp;issue-id=421422&amp;journal-id=2106&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1096%2Ffj.14-262048" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9657243&amp;issue-id=421422&amp;journal-id=2106&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=FASEB+J.&amp;title=Dysfunctionally+phosphorylated+type+1+insulin+receptor+substrate+in+neural-derived+blood+exosomes+of+preclinical+Alzheimer&#x02019;s+disease&amp;author=D.+Kapogiannis&amp;author=A.+Boxer&amp;author=J.B.+Schwartz&amp;author=E.L.+Abner&amp;author=A.+Biragyn&amp;volume=29&amp;publication_year=2015&amp;pages=589-596&amp;pmid=25342129&amp;doi=10.1096/fj.14-262048&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9657243&amp;issue-id=421422&amp;journal-id=2106&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B43-cells-11-03372">43. <span class="element-citation">Eren E., Hunt J.F.V., Shardell M., Chawla S., Tran J., Gu J., Vogt N.M., Johnson S.C., Bendlin B.B., Kapogiannis D. Extracellular vesicle biomarkers of Alzheimer&#x02019;s disease associated with sub-clinical cognitive decline in late middle age. <span><span class="ref-journal">Alzheimers Dement. </span>2020;<span class="ref-vol">16</span>:1293–1304. doi: 10.1002/alz.12130.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC7984100/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/32588967" ref="reftype=pubmed&amp;article-id=9657243&amp;issue-id=421422&amp;journal-id=2106&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1002%2Falz.12130" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9657243&amp;issue-id=421422&amp;journal-id=2106&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Alzheimers+Dement.&amp;title=Extracellular+vesicle+biomarkers+of+Alzheimer&#x02019;s+disease+associated+with+sub-clinical+cognitive+decline+in+late+middle+age&amp;author=E.+Eren&amp;author=J.F.V.+Hunt&amp;author=M.+Shardell&amp;author=S.+Chawla&amp;author=J.+Tran&amp;volume=16&amp;publication_year=2020&amp;pages=1293-1304&amp;pmid=32588967&amp;doi=10.1002/alz.12130&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9657243&amp;issue-id=421422&amp;journal-id=2106&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B44-cells-11-03372">44. <span class="element-citation">Walker K.A., Chawla S., Nogueras-Ortiz C., Coresh J., Sharrett A.R., Wong D.F., Jack C.R., Jr., Spychalla A.J., Gottesman R.F., Kapogiannis D. Neuronal insulin signaling and brain structure in nondemented older adults: The Atherosclerosis Risk in Communities Study. <span><span class="ref-journal">Neurobiol. Aging. </span>2021;<span class="ref-vol">97</span>:65–72. doi: 10.1016/j.neurobiolaging.2020.09.022.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC7736127/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/33160263" ref="reftype=pubmed&amp;article-id=9657243&amp;issue-id=421422&amp;journal-id=2106&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1016%2Fj.neurobiolaging.2020.09.022" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9657243&amp;issue-id=421422&amp;journal-id=2106&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Neurobiol.+Aging&amp;title=Neuronal+insulin+signaling+and+brain+structure+in+nondemented+older+adults:+The+Atherosclerosis+Risk+in+Communities+Study&amp;author=K.A.+Walker&amp;author=S.+Chawla&amp;author=C.+Nogueras-Ortiz&amp;author=J.+Coresh&amp;author=A.R.+Sharrett&amp;volume=97&amp;publication_year=2021&amp;pages=65-72&amp;pmid=33160263&amp;doi=10.1016/j.neurobiolaging.2020.09.022&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9657243&amp;issue-id=421422&amp;journal-id=2106&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B45-cells-11-03372">45. <span class="element-citation">Rivera E.J., Goldin A., Fulmer N., Tavares R., Wands J.R., de la Monte S.M. Insulin and insulin-like growth factor expression and function deteriorate with progression of Alzheimer&#x02019;s disease: Link to brain reductions in acetylcholine. <span><span class="ref-journal">J. Alzheimers Dis. </span>2005;<span class="ref-vol">8</span>:247–268. doi: 10.3233/JAD-2005-8304.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/16340083" ref="reftype=pubmed&amp;article-id=9657243&amp;issue-id=421422&amp;journal-id=2106&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.3233%2FJAD-2005-8304" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9657243&amp;issue-id=421422&amp;journal-id=2106&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J.+Alzheimers+Dis.&amp;title=Insulin+and+insulin-like+growth+factor+expression+and+function+deteriorate+with+progression+of+Alzheimer&#x02019;s+disease:+Link+to+brain+reductions+in+acetylcholine&amp;author=E.J.+Rivera&amp;author=A.+Goldin&amp;author=N.+Fulmer&amp;author=R.+Tavares&amp;author=J.R.+Wands&amp;volume=8&amp;publication_year=2005&amp;pages=247-268&amp;pmid=16340083&amp;doi=10.3233/JAD-2005-8304&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9657243&amp;issue-id=421422&amp;journal-id=2106&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B46-cells-11-03372">46. <span class="element-citation">Moloney A.M., Griffin R.J., Timmons S., O&#x02019;Connor R., Ravid R., O&#x02019;Neill C. Defects in IGF-1 receptor, insulin receptor and IRS-1/2 in Alzheimer&#x02019;s disease indicate possible resistance to IGF-1 and insulin signalling. <span><span class="ref-journal">Neurobiol. Aging. </span>2010;<span class="ref-vol">31</span>:224–243. doi: 10.1016/j.neurobiolaging.2008.04.002.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/18479783" ref="reftype=pubmed&amp;article-id=9657243&amp;issue-id=421422&amp;journal-id=2106&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1016%2Fj.neurobiolaging.2008.04.002" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9657243&amp;issue-id=421422&amp;journal-id=2106&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Neurobiol.+Aging&amp;title=Defects+in+IGF-1+receptor,+insulin+receptor+and+IRS-1/2+in+Alzheimer&#x02019;s+disease+indicate+possible+resistance+to+IGF-1+and+insulin+signalling&amp;author=A.M.+Moloney&amp;author=R.J.+Griffin&amp;author=S.+Timmons&amp;author=R.+O&#x02019;Connor&amp;author=R.+Ravid&amp;volume=31&amp;publication_year=2010&amp;pages=224-243&amp;pmid=18479783&amp;doi=10.1016/j.neurobiolaging.2008.04.002&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9657243&amp;issue-id=421422&amp;journal-id=2106&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B47-cells-11-03372">47. <span class="element-citation">Westwood A.J., Beiser A., Decarli C., Harris T.B., Chen T.C., He X.M., Roubenoff R., Pikula A., Au R., Braverman L.E., et al. Insulin-like growth factor-1 and risk of Alzheimer dementia and brain atrophy. <span><span class="ref-journal">Neurology. </span>2014;<span class="ref-vol">82</span>:1613–1619. doi: 10.1212/WNL.0000000000000382.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC4013812/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/24706014" ref="reftype=pubmed&amp;article-id=9657243&amp;issue-id=421422&amp;journal-id=2106&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1212%2FWNL.0000000000000382" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9657243&amp;issue-id=421422&amp;journal-id=2106&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Neurology&amp;title=Insulin-like+growth+factor-1+and+risk+of+Alzheimer+dementia+and+brain+atrophy&amp;author=A.J.+Westwood&amp;author=A.+Beiser&amp;author=C.+Decarli&amp;author=T.B.+Harris&amp;author=T.C.+Chen&amp;volume=82&amp;publication_year=2014&amp;pages=1613-1619&amp;pmid=24706014&amp;doi=10.1212/WNL.0000000000000382&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9657243&amp;issue-id=421422&amp;journal-id=2106&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B48-cells-11-03372">48. <span class="element-citation">Vitale G., Pellegrino G., Vollery M., Hofland L.J. ROLE of IGF-1 System in the Modulation of Longevity: Controversies and New Insights From a Centenarians&#x02019; Perspective. <span><span class="ref-journal">Front. Endocrinol. </span>2019;<span class="ref-vol">10</span>:27. doi: 10.3389/fendo.2019.00027.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC6367275/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/30774624" ref="reftype=pubmed&amp;article-id=9657243&amp;issue-id=421422&amp;journal-id=2106&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.3389%2Ffendo.2019.00027" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9657243&amp;issue-id=421422&amp;journal-id=2106&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Front.+Endocrinol.&amp;title=ROLE+of+IGF-1+System+in+the+Modulation+of+Longevity:+Controversies+and+New+Insights+From+a+Centenarians&#x02019;+Perspective&amp;author=G.+Vitale&amp;author=G.+Pellegrino&amp;author=M.+Vollery&amp;author=L.J.+Hofland&amp;volume=10&amp;publication_year=2019&amp;pages=27&amp;doi=10.3389/fendo.2019.00027&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9657243&amp;issue-id=421422&amp;journal-id=2106&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B49-cells-11-03372">49. <span class="element-citation">Gontier G., George C., Chaker Z., Holzenberger M., Aid S. Blocking IGF Signaling in Adult Neurons Alleviates Alzheimer&#x02019;s Disease Pathology through Amyloid-beta Clearance. <span><span class="ref-journal">J. Neurosci. </span>2015;<span class="ref-vol">35</span>:11500–11513. doi: 10.1523/JNEUROSCI.0343-15.2015.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC6605240/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/26290229" ref="reftype=pubmed&amp;article-id=9657243&amp;issue-id=421422&amp;journal-id=2106&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1523%2FJNEUROSCI.0343-15.2015" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9657243&amp;issue-id=421422&amp;journal-id=2106&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J.+Neurosci.&amp;title=Blocking+IGF+Signaling+in+Adult+Neurons+Alleviates+Alzheimer&#x02019;s+Disease+Pathology+through+Amyloid-beta+Clearance&amp;author=G.+Gontier&amp;author=C.+George&amp;author=Z.+Chaker&amp;author=M.+Holzenberger&amp;author=S.+Aid&amp;volume=35&amp;publication_year=2015&amp;pages=11500-11513&amp;pmid=26290229&amp;doi=10.1523/JNEUROSCI.0343-15.2015&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9657243&amp;issue-id=421422&amp;journal-id=2106&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B50-cells-11-03372">50. <span class="element-citation">Freude S., Hettich M.M., Schumann C., Stohr O., Koch L., Kohler C., Udelhoven M., Leeser U., Muller M., Kubota N., et al. Neuronal IGF-1 resistance reduces Abeta accumulation and protects against premature death in a model of Alzheimer&#x02019;s disease. <span><span class="ref-journal">FASEB J. </span>2009;<span class="ref-vol">23</span>:3315–3324. doi: 10.1096/fj.09-132043.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/19487308" ref="reftype=pubmed&amp;article-id=9657243&amp;issue-id=421422&amp;journal-id=2106&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1096%2Ffj.09-132043" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9657243&amp;issue-id=421422&amp;journal-id=2106&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=FASEB+J.&amp;title=Neuronal+IGF-1+resistance+reduces+Abeta+accumulation+and+protects+against+premature+death+in+a+model+of+Alzheimer&#x02019;s+disease&amp;author=S.+Freude&amp;author=M.M.+Hettich&amp;author=C.+Schumann&amp;author=O.+Stohr&amp;author=L.+Koch&amp;volume=23&amp;publication_year=2009&amp;pages=3315-3324&amp;pmid=19487308&amp;doi=10.1096/fj.09-132043&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9657243&amp;issue-id=421422&amp;journal-id=2106&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B51-cells-11-03372">51. <span class="element-citation">Brunet A., Bonni A., Zigmond M.J., Lin M.Z., Juo P., Hu L.S., Anderson M.J., Arden K.C., Blenis J., Greenberg M.E. Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. <span><span class="ref-journal">Cell. </span>1999;<span class="ref-vol">96</span>:857–868. doi: 10.1016/S0092-8674(00)80595-4.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/10102273" ref="reftype=pubmed&amp;article-id=9657243&amp;issue-id=421422&amp;journal-id=2106&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1016%2FS0092-8674(00)80595-4" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9657243&amp;issue-id=421422&amp;journal-id=2106&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Cell&amp;title=Akt+promotes+cell+survival+by+phosphorylating+and+inhibiting+a+Forkhead+transcription+factor&amp;author=A.+Brunet&amp;author=A.+Bonni&amp;author=M.J.+Zigmond&amp;author=M.Z.+Lin&amp;author=P.+Juo&amp;volume=96&amp;publication_year=1999&amp;pages=857-868&amp;pmid=10102273&amp;doi=10.1016/S0092-8674(00)80595-4&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9657243&amp;issue-id=421422&amp;journal-id=2106&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B52-cells-11-03372">52. <span class="element-citation">Dudek H., Datta S.R., Franke T.F., Birnbaum M.J., Yao R., Cooper G.M., Segal R.A., Kaplan D.R., Greenberg M.E. Regulation of neuronal survival by the serine-threonine protein kinase Akt. <span><span class="ref-journal">Science. </span>1997;<span class="ref-vol">275</span>:661–665. doi: 10.1126/science.275.5300.661.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/9005851" ref="reftype=pubmed&amp;article-id=9657243&amp;issue-id=421422&amp;journal-id=2106&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1126%2Fscience.275.5300.661" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9657243&amp;issue-id=421422&amp;journal-id=2106&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Science&amp;title=Regulation+of+neuronal+survival+by+the+serine-threonine+protein+kinase+Akt&amp;author=H.+Dudek&amp;author=S.R.+Datta&amp;author=T.F.+Franke&amp;author=M.J.+Birnbaum&amp;author=R.+Yao&amp;volume=275&amp;publication_year=1997&amp;pages=661-665&amp;pmid=9005851&amp;doi=10.1126/science.275.5300.661&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9657243&amp;issue-id=421422&amp;journal-id=2106&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B53-cells-11-03372">53. <span class="element-citation">Cheung E.C., Slack R.S. Emerging role for ERK as a key regulator of neuronal apoptosis. <span><span class="ref-journal">Sci. STKE Signal Transduct. Knowl. Environ. </span>2004;<span class="ref-vol">2004</span>:PE45. doi: 10.1126/stke.2512004pe45.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/15383672" ref="reftype=pubmed&amp;article-id=9657243&amp;issue-id=421422&amp;journal-id=2106&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1126%2Fstke.2512004pe45" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9657243&amp;issue-id=421422&amp;journal-id=2106&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Sci.+STKE+Signal+Transduct.+Knowl.+Environ.&amp;title=Emerging+role+for+ERK+as+a+key+regulator+of+neuronal+apoptosis&amp;author=E.C.+Cheung&amp;author=R.S.+Slack&amp;volume=2004&amp;publication_year=2004&amp;pages=PE45&amp;doi=10.1126/stke.2512004pe45&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9657243&amp;issue-id=421422&amp;journal-id=2106&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B54-cells-11-03372">54. <span class="element-citation">Colucci-D&#x02019;Amato L., Perrone-Capano C., di Porzio U. Chronic activation of ERK and neurodegenerative diseases. <span><span class="ref-journal">BioEssays News Rev. Mol. Cell. Dev. Biol. </span>2003;<span class="ref-vol">25</span>:1085–1095. doi: 10.1002/bies.10355.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/14579249" ref="reftype=pubmed&amp;article-id=9657243&amp;issue-id=421422&amp;journal-id=2106&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1002%2Fbies.10355" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9657243&amp;issue-id=421422&amp;journal-id=2106&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=BioEssays+News+Rev.+Mol.+Cell.+Dev.+Biol.&amp;title=Chronic+activation+of+ERK+and+neurodegenerative+diseases&amp;author=L.+Colucci-D&#x02019;Amato&amp;author=C.+Perrone-Capano&amp;author=U.+di+Porzio&amp;volume=25&amp;publication_year=2003&amp;pages=1085-1095&amp;pmid=14579249&amp;doi=10.1002/bies.10355&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9657243&amp;issue-id=421422&amp;journal-id=2106&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B55-cells-11-03372">55. <span class="element-citation">Karmarkar S.W., Bottum K.M., Krager S.L., Tischkau S.A. ERK/MAPK is essential for endogenous neuroprotection in SCN2.2 cells. <span><span class="ref-journal">PLoS ONE. </span>2011;<span class="ref-vol">6</span>:e23493.  doi: 10.1371/journal.pone.0023493.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC3157406/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/21858143" ref="reftype=pubmed&amp;article-id=9657243&amp;issue-id=421422&amp;journal-id=2106&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1371%2Fjournal.pone.0023493" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9657243&amp;issue-id=421422&amp;journal-id=2106&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=PLoS+ONE&amp;title=ERK/MAPK+is+essential+for+endogenous+neuroprotection+in+SCN2.2+cells&amp;author=S.W.+Karmarkar&amp;author=K.M.+Bottum&amp;author=S.L.+Krager&amp;author=S.A.+Tischkau&amp;volume=6&amp;publication_year=2011&amp;pages=e23493&amp;pmid=21858143&amp;doi=10.1371/journal.pone.0023493&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9657243&amp;issue-id=421422&amp;journal-id=2106&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B56-cells-11-03372">56. <span class="element-citation">Thiels E., Klann E. Extracellular signal-regulated kinase, synaptic plasticity, and memory. <span><span class="ref-journal">Rev. Neurosci. </span>2001;<span class="ref-vol">12</span>:327–345. doi: 10.1515/REVNEURO.2001.12.4.327.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/11783718" ref="reftype=pubmed&amp;article-id=9657243&amp;issue-id=421422&amp;journal-id=2106&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1515%2FREVNEURO.2001.12.4.327" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9657243&amp;issue-id=421422&amp;journal-id=2106&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Rev.+Neurosci.&amp;title=Extracellular+signal-regulated+kinase,+synaptic+plasticity,+and+memory&amp;author=E.+Thiels&amp;author=E.+Klann&amp;volume=12&amp;publication_year=2001&amp;pages=327-345&amp;pmid=11783718&amp;doi=10.1515/REVNEURO.2001.12.4.327&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9657243&amp;issue-id=421422&amp;journal-id=2106&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B57-cells-11-03372">57. <span class="element-citation">Coffey E.T. Nuclear and cytosolic JNK signalling in neurons. <span><span class="ref-journal">Nat. Rev. Neurosci. </span>2014;<span class="ref-vol">15</span>:285–299. doi: 10.1038/nrn3729.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/24739785" ref="reftype=pubmed&amp;article-id=9657243&amp;issue-id=421422&amp;journal-id=2106&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1038%2Fnrn3729" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9657243&amp;issue-id=421422&amp;journal-id=2106&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Nat.+Rev.+Neurosci.&amp;title=Nuclear+and+cytosolic+JNK+signalling+in+neurons&amp;author=E.T.+Coffey&amp;volume=15&amp;publication_year=2014&amp;pages=285-299&amp;pmid=24739785&amp;doi=10.1038/nrn3729&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9657243&amp;issue-id=421422&amp;journal-id=2106&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B58-cells-11-03372">58. <span class="element-citation">Asih P.R., Prikas E., Stefanoska K., Tan A.R.P., Ahel H.I., Ittner A. Functions of p38 MAP Kinases in the Central Nervous System. <span><span class="ref-journal">Front. Mol. Neurosci. </span>2020;<span class="ref-vol">13</span>:570586. doi: 10.3389/fnmol.2020.570586.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC7509416/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/33013322" ref="reftype=pubmed&amp;article-id=9657243&amp;issue-id=421422&amp;journal-id=2106&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.3389%2Ffnmol.2020.570586" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9657243&amp;issue-id=421422&amp;journal-id=2106&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Front.+Mol.+Neurosci.&amp;title=Functions+of+p38+MAP+Kinases+in+the+Central+Nervous+System&amp;author=P.R.+Asih&amp;author=E.+Prikas&amp;author=K.+Stefanoska&amp;author=A.R.P.+Tan&amp;author=H.I.+Ahel&amp;volume=13&amp;publication_year=2020&amp;pages=570586&amp;pmid=33013322&amp;doi=10.3389/fnmol.2020.570586&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9657243&amp;issue-id=421422&amp;journal-id=2106&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B59-cells-11-03372">59. <span class="element-citation">Athauda D., Gulyani S., Karnati H.K., Li Y., Tweedie D., Mustapic M., Chawla S., Chowdhury K., Skene S.S., Greig N.H., et al. Utility of Neuronal-Derived Exosomes to Examine Molecular Mechanisms That Affect Motor Function in Patients With Parkinson Disease: A Secondary Analysis of the Exenatide-PD Trial. <span><span class="ref-journal">JAMA Neurol. </span>2019;<span class="ref-vol">76</span>:420–429. doi: 10.1001/jamaneurol.2018.4304.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC6459135/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/30640362" ref="reftype=pubmed&amp;article-id=9657243&amp;issue-id=421422&amp;journal-id=2106&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1001%2Fjamaneurol.2018.4304" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9657243&amp;issue-id=421422&amp;journal-id=2106&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=JAMA+Neurol.&amp;title=Utility+of+Neuronal-Derived+Exosomes+to+Examine+Molecular+Mechanisms+That+Affect+Motor+Function+in+Patients+With+Parkinson+Disease:+A+Secondary+Analysis+of+the+Exenatide-PD+Trial&amp;author=D.+Athauda&amp;author=S.+Gulyani&amp;author=H.K.+Karnati&amp;author=Y.+Li&amp;author=D.+Tweedie&amp;volume=76&amp;publication_year=2019&amp;pages=420-429&amp;pmid=30640362&amp;doi=10.1001/jamaneurol.2018.4304&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9657243&amp;issue-id=421422&amp;journal-id=2106&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B60-cells-11-03372">60. <span class="element-citation">Mansur R.B., Delgado-Peraza F., Subramaniapillai M., Lee Y., Iacobucci M., Nasri F., Rodrigues N., Rosenblat J.D., Brietzke E., Cosgrove V.E., et al. Exploring brain insulin resistance in adults with bipolar depression using extracellular vesicles of neuronal origin. <span><span class="ref-journal">J. Psychiatr. Res. </span>2021;<span class="ref-vol">133</span>:82–92. doi: 10.1016/j.jpsychires.2020.12.007.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC7855678/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/33316649" ref="reftype=pubmed&amp;article-id=9657243&amp;issue-id=421422&amp;journal-id=2106&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1016%2Fj.jpsychires.2020.12.007" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9657243&amp;issue-id=421422&amp;journal-id=2106&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J.+Psychiatr.+Res.&amp;title=Exploring+brain+insulin+resistance+in+adults+with+bipolar+depression+using+extracellular+vesicles+of+neuronal+origin&amp;author=R.B.+Mansur&amp;author=F.+Delgado-Peraza&amp;author=M.+Subramaniapillai&amp;author=Y.+Lee&amp;author=M.+Iacobucci&amp;volume=133&amp;publication_year=2021&amp;pages=82-92&amp;pmid=33316649&amp;doi=10.1016/j.jpsychires.2020.12.007&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9657243&amp;issue-id=421422&amp;journal-id=2106&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B61-cells-11-03372">61. <span class="element-citation">Lund T.M., Risa O., Sonnewald U., Schousboe A., Waagepetersen H.S. Availability of neurotransmitter glutamate is diminished when beta-hydroxybutyrate replaces glucose in cultured neurons. <span><span class="ref-journal">J. Neurochem. </span>2009;<span class="ref-vol">110</span>:80–91. doi: 10.1111/j.1471-4159.2009.06115.x.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/19457063" ref="reftype=pubmed&amp;article-id=9657243&amp;issue-id=421422&amp;journal-id=2106&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1111%2Fj.1471-4159.2009.06115.x" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9657243&amp;issue-id=421422&amp;journal-id=2106&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J.+Neurochem.&amp;title=Availability+of+neurotransmitter+glutamate+is+diminished+when+beta-hydroxybutyrate+replaces+glucose+in+cultured+neurons&amp;author=T.M.+Lund&amp;author=O.+Risa&amp;author=U.+Sonnewald&amp;author=A.+Schousboe&amp;author=H.S.+Waagepetersen&amp;volume=110&amp;publication_year=2009&amp;pages=80-91&amp;pmid=19457063&amp;doi=10.1111/j.1471-4159.2009.06115.x&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9657243&amp;issue-id=421422&amp;journal-id=2106&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B62-cells-11-03372">62. <span class="element-citation">Mukherjee P., Augur Z.M., Li M., Hill C., Greenwood B., Domin M.A., Kondakci G., Narain N.R., Kiebish M.A., Bronson R.T., et al. Therapeutic benefit of combining calorie-restricted ketogenic diet and glutamine targeting in late-stage experimental glioblastoma. <span><span class="ref-journal">Commun. Biol. </span>2019;<span class="ref-vol">2</span>:200. doi: 10.1038/s42003-019-0455-x.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC6541653/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/31149644" ref="reftype=pubmed&amp;article-id=9657243&amp;issue-id=421422&amp;journal-id=2106&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1038%2Fs42003-019-0455-x" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9657243&amp;issue-id=421422&amp;journal-id=2106&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Commun.+Biol.&amp;title=Therapeutic+benefit+of+combining+calorie-restricted+ketogenic+diet+and+glutamine+targeting+in+late-stage+experimental+glioblastoma&amp;author=P.+Mukherjee&amp;author=Z.M.+Augur&amp;author=M.+Li&amp;author=C.+Hill&amp;author=B.+Greenwood&amp;volume=2&amp;publication_year=2019&amp;pages=200&amp;pmid=31149644&amp;doi=10.1038/s42003-019-0455-x&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9657243&amp;issue-id=421422&amp;journal-id=2106&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B63-cells-11-03372">63. <span class="element-citation">Lehmann L., Lo A., Knox K.M., Barker-Haliski M. Alzheimer&#x02019;s Disease and Epilepsy: A Perspective on the Opportunities for Overlapping Therapeutic Innovation. <span><span class="ref-journal">Neurochem. Res. </span>2021;<span class="ref-vol">46</span>:1895–1912. doi: 10.1007/s11064-021-03332-y.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC8254705/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/33929683" ref="reftype=pubmed&amp;article-id=9657243&amp;issue-id=421422&amp;journal-id=2106&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1007%2Fs11064-021-03332-y" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9657243&amp;issue-id=421422&amp;journal-id=2106&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Neurochem.+Res.&amp;title=Alzheimer&#x02019;s+Disease+and+Epilepsy:+A+Perspective+on+the+Opportunities+for+Overlapping+Therapeutic+Innovation&amp;author=L.+Lehmann&amp;author=A.+Lo&amp;author=K.M.+Knox&amp;author=M.+Barker-Haliski&amp;volume=46&amp;publication_year=2021&amp;pages=1895-1912&amp;pmid=33929683&amp;doi=10.1007/s11064-021-03332-y&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9657243&amp;issue-id=421422&amp;journal-id=2106&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B64-cells-11-03372">64. <span class="element-citation">Hynd M.R., Scott H.L., Dodd P.R. Glutamate-mediated excitotoxicity and neurodegeneration in Alzheimer&#x02019;s disease. <span><span class="ref-journal">Neurochem. Int. </span>2004;<span class="ref-vol">45</span>:583–595. doi: 10.1016/j.neuint.2004.03.007.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/15234100" ref="reftype=pubmed&amp;article-id=9657243&amp;issue-id=421422&amp;journal-id=2106&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1016%2Fj.neuint.2004.03.007" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9657243&amp;issue-id=421422&amp;journal-id=2106&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Neurochem.+Int.&amp;title=Glutamate-mediated+excitotoxicity+and+neurodegeneration+in+Alzheimer&#x02019;s+disease&amp;author=M.R.+Hynd&amp;author=H.L.+Scott&amp;author=P.R.+Dodd&amp;volume=45&amp;publication_year=2004&amp;pages=583-595&amp;pmid=15234100&amp;doi=10.1016/j.neuint.2004.03.007&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9657243&amp;issue-id=421422&amp;journal-id=2106&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B65-cells-11-03372">65. <span class="element-citation">Mattson M.P. Advances fuel Alzheimer&#x02019;s conundrum. <span><span class="ref-journal">Nat. Genet. </span>1997;<span class="ref-vol">17</span>:254–256. doi: 10.1038/ng1197-254.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/9354778" ref="reftype=pubmed&amp;article-id=9657243&amp;issue-id=421422&amp;journal-id=2106&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1038%2Fng1197-254" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9657243&amp;issue-id=421422&amp;journal-id=2106&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Nat.+Genet.&amp;title=Advances+fuel+Alzheimer&#x02019;s+conundrum&amp;author=M.P.+Mattson&amp;volume=17&amp;publication_year=1997&amp;pages=254-256&amp;pmid=9354778&amp;doi=10.1038/ng1197-254&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9657243&amp;issue-id=421422&amp;journal-id=2106&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B66-cells-11-03372">66. <span class="element-citation">Crimins J.L., Pooler A., Polydoro M., Luebke J.I., Spires-Jones T.L. The intersection of amyloid beta and tau in glutamatergic synaptic dysfunction and collapse in Alzheimer&#x02019;s disease. <span><span class="ref-journal">Ageing Res. Rev. </span>2013;<span class="ref-vol">12</span>:757–763. doi: 10.1016/j.arr.2013.03.002.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC3735866/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/23528367" ref="reftype=pubmed&amp;article-id=9657243&amp;issue-id=421422&amp;journal-id=2106&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1016%2Fj.arr.2013.03.002" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9657243&amp;issue-id=421422&amp;journal-id=2106&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Ageing+Res.+Rev.&amp;title=The+intersection+of+amyloid+beta+and+tau+in+glutamatergic+synaptic+dysfunction+and+collapse+in+Alzheimer&#x02019;s+disease&amp;author=J.L.+Crimins&amp;author=A.+Pooler&amp;author=M.+Polydoro&amp;author=J.I.+Luebke&amp;author=T.L.+Spires-Jones&amp;volume=12&amp;publication_year=2013&amp;pages=757-763&amp;pmid=23528367&amp;doi=10.1016/j.arr.2013.03.002&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9657243&amp;issue-id=421422&amp;journal-id=2106&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B67-cells-11-03372">67. <span class="element-citation">Wu M., Zhang M., Yin X., Chen K., Hu Z., Zhou Q., Cao X., Chen Z., Liu D. The role of pathological tau in synaptic dysfunction in Alzheimer&#x02019;s diseases. <span><span class="ref-journal">Transl. Neurodegener. </span>2021;<span class="ref-vol">10</span>:45. doi: 10.1186/s40035-021-00270-1.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC8579533/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/34753506" ref="reftype=pubmed&amp;article-id=9657243&amp;issue-id=421422&amp;journal-id=2106&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1186%2Fs40035-021-00270-1" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9657243&amp;issue-id=421422&amp;journal-id=2106&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Transl.+Neurodegener.&amp;title=The+role+of+pathological+tau+in+synaptic+dysfunction+in+Alzheimer&#x02019;s+diseases&amp;author=M.+Wu&amp;author=M.+Zhang&amp;author=X.+Yin&amp;author=K.+Chen&amp;author=Z.+Hu&amp;volume=10&amp;publication_year=2021&amp;pages=45&amp;pmid=34753506&amp;doi=10.1186/s40035-021-00270-1&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=9657243&amp;issue-id=421422&amp;journal-id=2106&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div></div></div></div><!--post-content--><div class="courtesy-note whole_rhythm small"><hr /><div class="half_rhythm">Articles from <span class="acknowledgment-journal-title">Cells</span> are provided here courtesy of <strong>Multidisciplinary Digital Publishing Institute  (MDPI)</strong></div><hr /></div><div id="body-link-poppers"><span></span></div></div>
            
        </section>
    </article>
    <aside class="usa-width-one-fourth usa-layout-docs-sidenav pmc-sidebar">
         
  

<div class="scroller">

    
        <section>
                <h6>Other Formats</h6>
                <ul class="pmc-sidebar__formats">
                  <li class="pdf-link other_item"><a href="/pmc/articles/PMC9657243/pdf/cells-11-03372.pdf" class="int-view">PDF (3.2M)</a></li>
                </ul>
        </section>
    
    <section>
        <h6>Actions</h6>
        <ul class="pmc-sidebar__actions">
            <li>
                <button role="button" class="citation-button citation-dialog-trigger ctxp"
                        aria-label="Open dialog with citation text in different styles" data-ga-category="save_share" data-ga-action="cite" data-ga-label="open"
                        data-all-citations-url="/pmc/resources/citations/9657243/"
                        data-citation-style="nlm"
                        data-download-format-link="/pmc/resources/citations/9657243/export/"
                >
                    <span class="button-label">Cite</span>
                </button>
            </li>
            <li>
                
                    

<link type="text/css" href="ncbi-overlay-block/src/overlay-block.css">
<div class="collections-button-container" data-article-id="9657243" data-article-db="pmc">
  <button class="collections-button collections-dialog-trigger"
          aria-label="Save article in MyNCBI collections."
          data-ga-category="collections_button"
          data-ga-action="click"
          data-ga-label="collections_button"
          data-collections-open-dialog-enabled="false"
          data-collections-open-dialog-url="https://www.ncbi.nlm.nih.gov/account?back_url=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC9657243%2F%23open-collections-dialog"
          data-in-collections="false">
      <span class="button-label">Collections</span>
  </button>
  <div class="overlay" role="dialog">
  <div id="collections-action-dialog"
       class="dialog collections-dialog"
       aria-hidden="true">
    <div class="title">Add to Collections</div>
    <div class="collections-action-panel action-panel">
      


<form id="collections-action-dialog-form"
      class="collections-action-panel-form action-panel-content action-form action-panel-smaller-selectors"
      data-existing-collections-url="/pmc/list-existing-collections/"
      data-add-to-existing-collection-url="/pmc/add-to-existing-collection/"
      data-create-and-add-to-new-collection-url="/pmc/create-and-add-to-new-collection/"
      data-myncbi-max-collection-name-length="100"
      data-collections-root-url="https://www.ncbi.nlm.nih.gov/myncbi/collections/">

  <input type="hidden" name="csrfmiddlewaretoken" value="mWzWnwbOACVdPxPnDywVlQqoLqyYan1R3aEWXQkb8n1TRqtpTJdjovMgOXLgSRHA">

  

  <div class="choice-group" role="radiogroup">
    <ul class="radio-group-items">
      <li>
        <input type="radio"
               id="collections-action-dialog-new-aside "
               class="collections-new"
               name="collections"
               value="new"
               data-ga-category="collections_button"
               data-ga-action="click"
               data-ga-label="collections_radio_new">
        <label for="collections-action-dialog-new-aside ">Create a new collection</label>
      </li>
      <li>
        <input type="radio"
               id="collections-action-dialog-existing-aside "
               class="collections-existing"
               name="collections"
               value="existing"
               checked="true"
               data-ga-category="collections_button"
               data-ga-action="click"
               data-ga-label="collections_radio_existing">
        <label for="collections-action-dialog-existing-aside ">Add to an existing collection</label>
      </li>
    </ul>
  </div>

  <div class="controls-wrapper">
    <div class="action-panel-control-wrap new-collections-controls">
      <label for="collections-action-dialog-add-to-new" class="action-panel-label required-field-asterisk">
        Name your collection:
      </label>
      <input
        type="text"
        name="add-to-new-collection"
        id="collections-action-dialog-add-to-new"
        class="collections-action-add-to-new"
        pattern="[^&quot;&amp;=&lt;&gt;/]*" title="The following characters are not allowed in the Name field: &quot;&amp;=&lt;&gt;/"
        maxlength=""
        data-ga-category="collections_button"
        data-ga-action="create_collection"
        data-ga-label="non_favorties_collection">
      <div class="collections-new-name-too-long usa-input-error-message selection-validation-message">
        Name must be less than  characters
      </div>
    </div>
    <div class="action-panel-control-wrap existing-collections-controls">
      <label for="collections-action-dialog-add-to-existing" class="action-panel-label">
        Choose a collection:
      </label>
      <select id="collections-action-dialog-add-to-existing"
              class="action-panel-selector collections-action-add-to-existing"
              data-ga-category="collections_button"
              data-ga-action="select_collection"
              data-ga-label="($('.collections-action-add-to-existing').val() === 'Favorites') ? 'Favorites' : 'non_favorites_collection'">
      </select>
      <div class="collections-retry-load-on-error usa-input-error-message selection-validation-message">
        Unable to load your collection due to an error<br>
        <a href="#">Please try again</a>
      </div>
    </div>
  </div>

  <div class="action-panel-actions">
    <button class="action-panel-submit"
            type="submit"
            data-loading-label="Adding..."
            data-pinger-ignore
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="add">
      Add
    </button>
    <button class="action-panel-cancel"
            aria-label="Close 'Add to Collections' panel"
            ref="linksrc=close_collections_panel"
            aria-controls="collections-action-panel"
            aria-expanded="false"
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="cancel">
      Cancel
    </button>
  </div>
</form>
    </div>
  </div>
</div>
</div>
                
            </li>

        </ul>
    </section>
    
        <section class="social-sharing">
            <h6>Share</h6>
            <ul class="pmc-sidebar__share">
                <li><a class="fa-stack fa-lg" target="_blank" rel="noopener noreferrer" role="button" href="https://twitter.com/intent/tweet?url=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC9657243%2F&amp;text=Empagliflozin%20Induced%20Ketosis%2C%20Upregulated%20IGF-1%2FInsulin%20Receptors%20and%20the%20Canonical%20Insulin%20Signaling%20Pathway%20in%20..." alt="Share on Twitter"><i class="fa fa-twitter fa-stack-1x">&#160;</i></a></li> 
<li><a class="fa-stack fa-lg" target="_blank" rel="noopener noreferrer" role="button" href="https://www.facebook.com/sharer/sharer.php?u=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC9657243%2F" alt="Share on Facebook"><i class="fa fa-facebook fa-stack-1x">&#160;</i></a></li>
                <li>
                    <div class="share-permalink">
                        <button class="trigger"  alt="Show article permalink" aria-expanded="false" aria-haspopup="true">
                            <i class="fa-stack fa-lg" >
                                <i class="fa fa-link fa-stack-1x">&nbsp;</i>
                            </i>
                        </button>
                        <div class="dropdown dropdown-container" hidden>
                              <div class="title">
                                Permalink
                              </div>
                              <div class="content">
                                  <input type="text" class="permalink-text" value="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9657243/" aria-label="Article permalink"><button class="permalink-copy-button usa-button-primary" title="Copy article permalink" data-ga-category="save_share" data-ga-action="link" data-ga-label="copy_link">
                                      <span class="button-title">Copy</span>
                                  </button>
                              </div>
                        </div>
                    </div>
                </li>
            </ul>
        </section>
    
    <section>
        <h6>RESOURCES</h6>
        <ul class="pmc-sidebar__resources">
        
            <li>
                <div class="usa-accordion">
                    <button
                            data-ga-category="resources_accordion"
                            data-ga-action="open_similar_articles"
                            data-ga-label="/pmc/articles/PMC9657243/"
                            class="usa-accordion-button"
                            aria-controls="similar-articles-accordion-aside"
                            aria-expanded="false"
                            data-action-open="open_similar_articles"
                            data-action-close="close_similar_articles"
                    >
                        Similar articles
                    </button>
                    <div
                            
                                data-source-url="/pmc/resources/similar-article-links/36359767/"
                            

                         class="usa-accordion-content pmc-sidebar__resources--citations" id="similar-articles-accordion-aside" aria-hidden="true">
                        
                    </div>
                </div>
            </li>
            <li>
                <div class="usa-accordion">
                    <button
                            data-ga-category="resources_accordion"
                            data-ga-action="open_cited_by"
                            data-ga-label="/pmc/articles/PMC9657243/"
                            class="usa-accordion-button"
                            aria-controls="cited-by-accordion-aside"
                            aria-expanded="false"
                            data-action-open="open_cited_by"
                            data-action-close="close_cited_by"
                    >
                        Cited by other articles
                    </button>
                    <div
                            
                                data-source-url="/pmc/resources/cited-by-links/36359767/"
                            
                            class="usa-accordion-content pmc-sidebar__resources--citations"
                            id="cited-by-accordion-aside"
                            aria-hidden="true"
                    >
                        
                    </div>
                </div>
            </li>
            <li>
                <div class="usa-accordion">
                    <button
                            data-ga-category="resources_accordion"
                            data-ga-action="open_NCBI_links"
                            data-ga-label="/pmc/articles/PMC9657243/"
                            class="usa-accordion-button"
                            aria-controls="links-accordion-aside"
                            aria-expanded="false"
                            data-action-open="open_NCBI_links"
                            data-action-close="close_NCBI_link"
                    >
                        Links to NCBI Databases
                    </button>
                    <div data-source-url="/pmc/resources/db-links/9657243/" class="usa-accordion-content" id="links-accordion-aside" aria-hidden="true"></div>
                </div>
            </li>

            
        
        </ul>
    </section>

 </div>

    </aside>
</main>

    <div class="overlay" role="dialog" aria-label="Citation Dialog">
  <div class="dialog citation-dialog">
    <button class="close-overlay" tabindex="1">[x]</button>
    <div class="title">Cite</div>
    <div class="citation-text-block">
  <div class="citation-text"></div>
  <div class="citation-actions">
    <button
      class="copy-button dialog-focus"
      data-ga-category="save_share"
      data-ga-action="cite"
      data-ga-label="copy"
      tabindex="2">
      Copy
    </button>

      <a href="#"
              class="export-button"
              data-ga-category="save_share"
              data-ga-action="cite"
              data-ga-label="download"
              title="Download a file for external citation management software"
              tabindex="3">
          <span class="title">Download .nbib</span>
          <span class="title-mobile">.nbib</span>
      </a>


    

<div class="citation-style-selector-wrapper">
  <label class="selector-label">Format:</label>
  <select aria-label="Format" class="citation-style-selector" tabindex="4" >
    
      <option data-style-url-name="ama"
              value="AMA"
              >
        AMA
      </option>
    
      <option data-style-url-name="apa"
              value="APA"
              >
        APA
      </option>
    
      <option data-style-url-name="mla"
              value="MLA"
              >
        MLA
      </option>
    
      <option data-style-url-name="nlm"
              value="NLM"
              selected="selected">
        NLM
      </option>
    
  </select>
</div>
  </div>
</div>
  </div>
</div>

     <!-- ========== BEGIN FOOTER ========== -->
 <footer>
      <section class="icon-section">
        <div id="icon-section-header" class="icon-section_header">Follow NCBI</div>
        <div class="grid-container container">
          <div class="icon-section_container">
            <a class="footer-icon" id="footer_twitter" href="https://twitter.com/ncbi" aria-label="Twitter"><svg
                data-name="Layer 1" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 300 300">
                <defs>
                  <style>
                    .cls-11 {
                      fill: #737373;
                    }
                  </style>
                </defs>
                <title>Twitter</title>
                <path class="cls-11"
                  d="M250.11,105.48c-7,3.14-13,3.25-19.27.14,8.12-4.86,8.49-8.27,11.43-17.46a78.8,78.8,0,0,1-25,9.55,39.35,39.35,0,0,0-67,35.85,111.6,111.6,0,0,1-81-41.08A39.37,39.37,0,0,0,81.47,145a39.08,39.08,0,0,1-17.8-4.92c0,.17,0,.33,0,.5a39.32,39.32,0,0,0,31.53,38.54,39.26,39.26,0,0,1-17.75.68,39.37,39.37,0,0,0,36.72,27.3A79.07,79.07,0,0,1,56,223.34,111.31,111.31,0,0,0,116.22,241c72.3,0,111.83-59.9,111.83-111.84,0-1.71,0-3.4-.1-5.09C235.62,118.54,244.84,113.37,250.11,105.48Z">
                </path>
              </svg></a>
            <a class="footer-icon" id="footer_facebook" href="https://www.facebook.com/ncbi.nlm" aria-label="Facebook"><svg
                data-name="Layer 1" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 300 300">
                <title>Facebook</title>
                <path class="cls-11"
                  d="M210.5,115.12H171.74V97.82c0-8.14,5.39-10,9.19-10h27.14V52l-39.32-.12c-35.66,0-42.42,26.68-42.42,43.77v19.48H99.09v36.32h27.24v109h45.41v-109h35Z">
                </path>
              </svg></a>
            <a class="footer-icon" id="footer_linkedin"
              href="https://www.linkedin.com/company/ncbinlm"
              aria-label="LinkedIn"><svg data-name="Layer 1" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 300 300">
                <title>LinkedIn</title>
                <path class="cls-11"
                  d="M101.64,243.37H57.79v-114h43.85Zm-22-131.54h-.26c-13.25,0-21.82-10.36-21.82-21.76,0-11.65,8.84-21.15,22.33-21.15S101.7,78.72,102,90.38C102,101.77,93.4,111.83,79.63,111.83Zm100.93,52.61A17.54,17.54,0,0,0,163,182v61.39H119.18s.51-105.23,0-114H163v13a54.33,54.33,0,0,1,34.54-12.66c26,0,44.39,18.8,44.39,55.29v58.35H198.1V182A17.54,17.54,0,0,0,180.56,164.44Z">
                </path>
              </svg></a>
            <a class="footer-icon" id="footer_github" href="https://github.com/ncbi" aria-label="GitHub"><svg
                data-name="Layer 1" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 300 300">
                <defs>
                  <style>
                    .cls-11,
                    .cls-12 {
                      fill: #737373;
                    }

                    .cls-11 {
                      fill-rule: evenodd;
                    }
                  </style>
                </defs>
                <title>GitHub</title>
                <path class="cls-11"
                  d="M151.36,47.28a105.76,105.76,0,0,0-33.43,206.1c5.28,1,7.22-2.3,7.22-5.09,0-2.52-.09-10.85-.14-19.69-29.42,6.4-35.63-12.48-35.63-12.48-4.81-12.22-11.74-15.47-11.74-15.47-9.59-6.56.73-6.43.73-6.43,10.61.75,16.21,10.9,16.21,10.9,9.43,16.17,24.73,11.49,30.77,8.79,1-6.83,3.69-11.5,6.71-14.14C108.57,197.1,83.88,188,83.88,147.51a40.92,40.92,0,0,1,10.9-28.39c-1.1-2.66-4.72-13.42,1-28,0,0,8.88-2.84,29.09,10.84a100.26,100.26,0,0,1,53,0C198,88.3,206.9,91.14,206.9,91.14c5.76,14.56,2.14,25.32,1,28a40.87,40.87,0,0,1,10.89,28.39c0,40.62-24.74,49.56-48.29,52.18,3.79,3.28,7.17,9.71,7.17,19.58,0,14.15-.12,25.54-.12,29,0,2.82,1.9,6.11,7.26,5.07A105.76,105.76,0,0,0,151.36,47.28Z">
                </path>
                <path class="cls-12"
                  d="M85.66,199.12c-.23.52-1.06.68-1.81.32s-1.2-1.06-.95-1.59,1.06-.69,1.82-.33,1.21,1.07.94,1.6Zm-1.3-1">
                </path>
                <path class="cls-12"
                  d="M90,203.89c-.51.47-1.49.25-2.16-.49a1.61,1.61,0,0,1-.31-2.19c.52-.47,1.47-.25,2.17.49s.82,1.72.3,2.19Zm-1-1.08">
                </path>
                <path class="cls-12"
                  d="M94.12,210c-.65.46-1.71,0-2.37-.91s-.64-2.07,0-2.52,1.7,0,2.36.89.65,2.08,0,2.54Zm0,0"></path>
                <path class="cls-12"
                  d="M99.83,215.87c-.58.64-1.82.47-2.72-.41s-1.18-2.06-.6-2.7,1.83-.46,2.74.41,1.2,2.07.58,2.7Zm0,0">
                </path>
                <path class="cls-12"
                  d="M107.71,219.29c-.26.82-1.45,1.2-2.64.85s-2-1.34-1.74-2.17,1.44-1.23,2.65-.85,2,1.32,1.73,2.17Zm0,0">
                </path>
                <path class="cls-12"
                  d="M116.36,219.92c0,.87-1,1.59-2.24,1.61s-2.29-.68-2.3-1.54,1-1.59,2.26-1.61,2.28.67,2.28,1.54Zm0,0">
                </path>
                <path class="cls-12"
                  d="M124.42,218.55c.15.85-.73,1.72-2,1.95s-2.37-.3-2.52-1.14.73-1.75,2-2,2.37.29,2.53,1.16Zm0,0"></path>
              </svg></a>
            <a class="footer-icon" id="footer_blog" href="https://ncbiinsights.ncbi.nlm.nih.gov/" aria-label="Blog">
              <svg id="Layer_1" data-name="Layer 1" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 40 40"><defs><style>.cls-1{fill:#737373;}</style></defs><path class="cls-1" d="M14,30a4,4,0,1,1-4-4,4,4,0,0,1,4,4Zm11,3A19,19,0,0,0,7.05,15a1,1,0,0,0-1,1v3a1,1,0,0,0,.93,1A14,14,0,0,1,20,33.07,1,1,0,0,0,21,34h3a1,1,0,0,0,1-1Zm9,0A28,28,0,0,0,7,6,1,1,0,0,0,6,7v3a1,1,0,0,0,1,1A23,23,0,0,1,29,33a1,1,0,0,0,1,1h3A1,1,0,0,0,34,33Z"/></svg>
            </a>
          </div>
        </div>
      </section>

      <section class="container-fluid bg-primary">
        <div class="container pt-5">
          <div class="row mt-3">
            <div class="col-lg-3 col-12">
              <p><a class="text-white" href="https://www.nlm.nih.gov/socialmedia/index.html">Connect with NLM</a></p>
              <ul class="list-inline social_media">
                <li class="list-inline-item"><a href="https://twitter.com/NLM_NIH" aria-label="Twitter"
                    target="_blank" rel="noopener noreferrer"><svg version="1.1" xmlns="http://www.w3.org/2000/svg"
                      xmlns:xlink="http://www.w3.org/1999/xlink" x="0px" y="0px" viewBox="0 0 249 249"
                      style="enable-background:new 0 0 249 249;" xml:space="preserve">
                      <style type="text/css">
                        .st20 {
                          fill: #FFFFFF;
                        }

                        .st30 {
                          fill: none;
                          stroke: #FFFFFF;
                          stroke-width: 8;
                          stroke-miterlimit: 10;
                        }
                      </style>
                      <title>SM-Twitter</title>
                      <g>
                        <g>
                          <g>
                            <path class="st20" d="M192.9,88.1c-5,2.2-9.2,2.3-13.6,0.1c5.7-3.4,6-5.8,8.1-12.3c-5.4,3.2-11.4,5.5-17.6,6.7
                                                c-10.5-11.2-28.1-11.7-39.2-1.2c-7.2,6.8-10.2,16.9-8,26.5c-22.3-1.1-43.1-11.7-57.2-29C58,91.6,61.8,107.9,74,116
                                                c-4.4-0.1-8.7-1.3-12.6-3.4c0,0.1,0,0.2,0,0.4c0,13.2,9.3,24.6,22.3,27.2c-4.1,1.1-8.4,1.3-12.5,0.5c3.6,11.3,14,19,25.9,19.3
                                                c-11.6,9.1-26.4,13.2-41.1,11.5c12.7,8.1,27.4,12.5,42.5,12.5c51,0,78.9-42.2,78.9-78.9c0-1.2,0-2.4-0.1-3.6
                                                C182.7,97.4,189.2,93.7,192.9,88.1z"></path>
                          </g>
                        </g>
                        <circle class="st30" cx="124.4" cy="128.8" r="108.2"></circle>
                      </g>
                    </svg></a></li>
                <li class="list-inline-item"><a href="https://www.facebook.com/nationallibraryofmedicine"
                    aria-label="Facebook" rel="noopener noreferrer" target="_blank">
                    <svg version="1.1" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" x="0px"
                      y="0px" viewBox="0 0 249 249" style="enable-background:new 0 0 249 249;" xml:space="preserve">
                      <style type="text/css">
                        .st10 {
                          fill: #FFFFFF;
                        }

                        .st110 {
                          fill: none;
                          stroke: #FFFFFF;
                          stroke-width: 8;
                          stroke-miterlimit: 10;
                        }
                      </style>
                      <title>SM-Facebook</title>
                      <g>
                        <g>
                          <path class="st10" d="M159,99.1h-24V88.4c0-5,3.3-6.2,5.7-6.2h16.8V60l-24.4-0.1c-22.1,0-26.2,16.5-26.2,27.1v12.1H90v22.5h16.9
                                                      v67.5H135v-67.5h21.7L159,99.1z"></path>
                        </g>
                      </g>
                      <circle class="st110" cx="123.6" cy="123.2" r="108.2"></circle>
                    </svg>
                  </a></li>
                <li class="list-inline-item"><a href="https://www.youtube.com/user/NLMNIH" aria-label="Youtube"
                    target="_blank" rel="noopener noreferrer"><svg version="1.1" xmlns="http://www.w3.org/2000/svg"
                      xmlns:xlink="http://www.w3.org/1999/xlink" x="0px" y="0px" viewBox="0 0 249 249"
                      style="enable-background:new 0 0 249 249;" xml:space="preserve">
                      <title>SM-Youtube</title>
                      <style type="text/css">
                        .st4 {
                          fill: none;
                          stroke: #FFFFFF;
                          stroke-width: 8;
                          stroke-miterlimit: 10;
                        }

                        .st5 {
                          fill: #FFFFFF;
                        }
                      </style>
                      <circle class="st4" cx="124.2" cy="123.4" r="108.2"></circle>
                      <g transform="translate(0,-952.36218)">
                        <path class="st5"
                          d="M88.4,1037.4c-10.4,0-18.7,8.3-18.7,18.7v40.1c0,10.4,8.3,18.7,18.7,18.7h72.1c10.4,0,18.7-8.3,18.7-18.7
                                            v-40.1c0-10.4-8.3-18.7-18.7-18.7H88.4z M115.2,1058.8l29.4,17.4l-29.4,17.4V1058.8z"></path>
                      </g>
                    </svg></a></li>
              </ul>
            </div>
            <div class="col-lg-3 col-12">
              <p class="address_footer text-white">National Library of Medicine<br>
                <a href="https://www.google.com/maps/place/8600+Rockville+Pike,+Bethesda,+MD+20894/@38.9959508,-77.101021,17z/data=!3m1!4b1!4m5!3m4!1s0x89b7c95e25765ddb:0x19156f88b27635b8!8m2!3d38.9959508!4d-77.0988323"
                  class="text-white" target="_blank" rel="noopener noreferrer">8600 Rockville Pike<br>
                  Bethesda, MD 20894</a></p>
            </div>
            <div class="col-lg-3 col-12 centered-lg">
              <p><a href="https://www.nlm.nih.gov/web_policies.html" class="text-white">Web Policies</a><br>
                <a href="https://www.nih.gov/institutes-nih/nih-office-director/office-communications-public-liaison/freedom-information-act-office"
                  class="text-white">FOIA</a><br>
                <a href="https://www.hhs.gov/vulnerability-disclosure-policy/index.html" class="text-white" id="vdp">HHS Vulnerability Disclosure</a></p>
            </div>
            <div class="col-lg-3 col-12 centered-lg">
              <p><a class="supportLink text-white" href="https://support.nlm.nih.gov/">Help</a><br>
                <a href="https://www.nlm.nih.gov/accessibility.html" class="text-white">Accessibility</a><br>
                <a href="https://www.nlm.nih.gov/careers/careers.html" class="text-white">Careers</a></p>
            </div>
          </div>
          <div class="row">
            <div class="col-lg-12 centered-lg">
              <nav class="bottom-links">
                <ul class="mt-3">
                  <li>
                    <a class="text-white" href="//www.nlm.nih.gov/">NLM</a>
                  </li>
                  <li>
                    <a class="text-white"
                  href="https://www.nih.gov/">NIH</a>
                  </li>
                  <li>
                    <a class="text-white" href="https://www.hhs.gov/">HHS</a>
                  </li>
                  <li>
                    <a
                  class="text-white" href="https://www.usa.gov/">USA.gov</a>
                  </li>
                </ul>
              </nav>
            </div>
          </div>
        </div>
      </section>
    </footer>
 <!-- ========== END FOOTER ========== -->
  <!-- javascript to inject NWDS meta tags. Note: value of nwds_version is updated by "npm version" command -->
 
  <script type="text/javascript">
    var nwds_version = "1.1.9-2";

    var meta_nwds_ver = document.createElement('meta');
    meta_nwds_ver.name = 'ncbi_nwds_ver';
    meta_nwds_ver.content = nwds_version;
    document.getElementsByTagName('head')[0].appendChild(meta_nwds_ver);

    var meta_nwds = document.createElement('meta');
    meta_nwds.name = 'ncbi_nwds';
    meta_nwds.content = 'yes';
    document.getElementsByTagName('head')[0].appendChild(meta_nwds);

	var alertsUrl = "/core/alerts/alerts.js";
	if (typeof ncbiBaseUrl !== 'undefined') {
		alertsUrl = ncbiBaseUrl + alertsUrl;
	}
  </script>



  
    <!-- JavaScript -->
    <script src="/pmc/static/CACHE/js/output.0f72d6a64937.js"></script>
  
  
    <script src="https://code.jquery.com/jquery-3.5.0.min.js"
          integrity="sha256-xNzN2a4ltkB44Mc/Jz3pT4iU1cmeR0FkXs4pru/JxaQ="
          crossorigin="anonymous">
    </script>
    <script>
        var fallbackJquery = "/pmc/static/base/js/jquery-3.5.0.min.js";
        window.jQuery || document.write("<script src=" + fallbackJquery + ">\x3C/script>")
    </script>
  

  <script src="/pmc/static/CACHE/js/output.a212a9fcf845.js"></script>
<script src="/pmc/static/CACHE/js/output.7999321d1aac.js"></script>
<script src="/pmc/static/CACHE/js/output.7ca436b2ea51.js"></script>
<script src="/pmc/static/CACHE/js/output.f8422046fbe0.js"></script>
<script src="/pmc/static/CACHE/js/output.ff40c7d85ff8.js"></script>
<script src="/pmc/static/CACHE/js/output.a6a84a0ad361.js"></script>

<script type="text/javascript" src="/pmc/static/bundles/base/base.038d36e4e31104b40a19.js" ></script>

    <script type="text/javascript">
        if(typeof jQuery !=='undefined') {
            jQuery.migrateMute = true;
        }
    </script>
    <script type="text/javascript" src="https://code.jquery.com/jquery-migrate-1.4.1.js"></script>
    <script type="text/javascript" src="/core/jig/1.15.2/js/jig.nojquery.min.js">//</script><script type="text/javascript" src="/corehtml/pmc/js/common.min.js?_=3.18">//</script><script type="text/javascript" src="/corehtml/pmc/js/NcbiTagServer.min.js?_=3.18">//</script><script type="text/javascript" src="/corehtml/pmc/js/crb.min.js?_=3.18">//</script><script type="text/javascript" src="/corehtml/pmc/js/jactions.min.js?_=3.18">//</script><script type="text/javascript">window.name="mainwindow";</script>

    <script type="text/javascript">var exports = {};</script>
    <script src="/pmc/static/CACHE/js/output.340a3b9cce7f.js"></script>
<script src="/pmc/static/CACHE/js/output.228f96f3298e.js"></script>
    <script type="text/javascript" src="/pmc/static/bundles/article/article.b7dd20e527283dd68f45.js" ></script>
    <script type="text/javascript">
        window.ncbi.pmc.articlePage.init({ pageURL: '/pmc/articles/PMC9657243/', citeCookieName: 'pmc-cf'});
    </script>


  
  
  <script  type="text/javascript" src="https://www.ncbi.nlm.nih.gov/core/pinger/pinger.js"> </script>


  
      
  

</body>
</html>
